

10/053,345

Page 1

=> d ibib ab hitstr 1-34


L7 ANSWER 1 OF 34 USPATFULL
 ACCESSION NUMBER: 2002:297298 USPATFULL
 TITLE: Composition for the topical treatment of poison ivy and other forms of contact dermatitis
 INVENTOR(S): McCadden, Michael E., 121 Whitebridge Meadows La., St. Louis, MO, United States 63141

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6479058	B1	20021112
APPLICATION INFO.:	US 2000-652811		20000831 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-152068P	19990902 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dees, Jose' C.	
ASSISTANT EXAMINER:	Haghighatian, M.	
LEGAL REPRESENTATIVE:	Senniger, Powers, Leavitt & Roedel	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER-OF-DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	957	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Composition for topical administration comprising (a) a corticosteroid, and (b) a drying agent.
 IT 73771-04-7, Prednicarbate
 (topical compns. contg. corticosteroids and drying agents and anti-itching agents for treatment of contact dermatitis)
 RN 73771-04-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 2 OF 34 USPATFULL
 ACCESSION NUMBER: 2002:185247 USPATFULL
 TITLE: Methods and apparatus for medicating the nasal sinuses
 INVENTOR(S): Dyer, Gordon Wayne, Northwood, NH, UNITED STATES


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098154	A1	20020725
APPLICATION INFO.:	US 2001-765894	A1	20010120 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Gordon Wayne Dyer, 12 Murray Lane, Northwood, NH, 03261		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	245		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method and accompanying apparatus for supplying medications, particularly antibiotics, to the deeper parts areas of the sinuses. The pressure of application from use of the Valsalva maneuver and the use of medications that are both water and fat-soluble aids the medications in penetrating deep into the sinuses. When the medication is an antibiotic, this has the benefit of delivering a high level of antibiotics using a line of antibiotics that the likely bacteria will not be as resistant to because they have not had as much prior exposure to this antibiotic. The lighter-than-air propellant aids in delivering the medication to those sinus areas superior to the nose. If the infection extends to the eardrums, making the Valsalva maneuver painful, or if the patient is simply unusually sensitive, then earplugs to reduce the stress on the eardrums may be worn while the patient performs the Valsalva maneuver.
 IT 82034-46-6, Loteprednol etabonate

(methods and app. for applying medication of nasal sinuses)
 RN 82034-46-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 3 OF 34 USPATFULL
 ACCESSION NUMBER: 2002:140834 USPATFULL
 TITLE: Antipsoriatic nail polish
 INVENTOR(S): Bohn, Manfred, Hofheim, GERMANY, FEDERAL REPUBLIC OF
 Kraemer, Karl Theodor, Langen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002071815	A1	20020613
APPLICATION INFO.:	US 2001-13728	A1	20011213 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-135657, filed on 18 Aug 1998, 'PATENTED'		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19736112	19970821
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	378	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to a nail polish comprising one or more glucocorticoids useful in treating nails which show changes due to the syndrome of psoriasis.
 IT 73771-04-7, Prednicarbate
 (antipsoriatic nail polishes contg. glucocorticoids and film-forming polymers)
 RN 73771-04-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 4 OF 34 USPATFULL
 ACCESSION NUMBER: 2001:105006 USPATFULL
 TITLE: ANTIPSORIATIC NAIL POLISH
 INVENTOR(S): BOHN, MANFRED, HOFHEIM, Germany, Federal Republic of
 KRAEMER, KARL THEODOR, LANGEN, Germany, Federal Republic of

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001006625	A1	20010705
APPLICATION INFO.:	US 6352686	B2	20020305
RELATED APPLN. INFO.:	US 1998-135657	A1	19980818 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19736112	19970821
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN HENDERSON FARABOW, GARRETT & DUNNER, 1300 I STREET NW, WASHINGTON, DC, 200053315	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	384	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to a nail polish comprising one or more glucocorticoids useful in treating nails which show changes due to the syndrome of psoriasis.
 IT 73771-04-7, Prednicarbate
 (antipsoriatic nail polishes contg. glucocorticoids and film-forming polymers)
 RN 73771-04-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 5 OF 34 USPTATFULL
 ACCESSION NUMBER: 2000:109326 USPTATFULL
 TITLE: Methods of treating headache and functional extraocular and intraocular myotendinitis
 INVENTOR(S): Sucher, David F., 10 Casa Vieja, Orinda, CA, United States 94563

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6106819		20000822
APPLICATION INFO.:	US 1997-999782		19971205 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-34103P	19961231 (60)
	US 1997-38085P	19970218 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Azpuru, Carlos
 LEGAL REPRESENTATIVE: Zimmerman, Harris
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
 LINE COUNT: 523

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Methods of treating headache and functional extraocular and intraocular myotendinitis by applying to the eyes of a patient being treated a compound selected from the group consisting of hydrocortisone, medrysone, prednisolone, dexamethasone, fluoromethasone, rimexolone, and loteprednol ebonate, and combinations of these compounds with other constituents.

IT 82034-46-6, Loteprednol etabonate
 (treatment of headache and functional extraocular and intraocular myotendinitis)


RN 82034-46-6 USPTATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 34 USPTATFULL (Continued)



L7 ANSWER 6 OF 34 USPTATFULL
 ACCESSION NUMBER: 2000:88675 USPTATFULL
 TITLE: Method and apparatus for configuring a semiconductor device for compatibility with multiple logic interfaces
 INVENTOR(S): Kim, Chi-wook, Suwon, Korea, Republic of
 PATENT ASSIGNEE(S): Kang, Kyung-woo, Kyungki-do, Korea, Republic of
 Samsung Electronics, Co., Ltd., Suwon, Korea, Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6087851		20000711
APPLICATION INFO.:	US 1998-70894		19980430 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	KR 1997-16807	19970430

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Tokar, Michael
 ASSISTANT EXAMINER: Tran, Anh
 LEGAL REPRESENTATIVE: Marger Johnson & McCollom, P.C.
 NUMBER OF CLAIMS: 29
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 19-Drawing-Figure(s); 12-Drawing-Page(s)
 LINE COUNT: 1018

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A semiconductor device can be configured for compatibility with different system level interfaces, e.g., LVTTL or SSTL, after assembly, thereby eliminating the need for bonding options and reducing the cost of manufacturing the device. The device includes an interface dependent circuit that operates with a selected interface in response to one or more interface enable signals. Several alternative embodiments include interface control circuits and mode register circuits for generating the interface enable signals responsive to a row address and control signals such as RAS, CAS, WE, and CS. Some embodiments also include a switching network that allows an input buffer to use an internally generated reference voltage for one interface and an externally applied reference voltage for a second interface.

IT 82034-46-6, Loteprednol etabonate
 (systemic inflammation marker level in evaluation of cardiovascular disorder risk redn. by)

RN 82034-46-6 USPTATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 7 OF 34 USPTATFULL
 ACCESSION NUMBER: 2000:34393 USPTATFULL
 TITLE: Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
 INVENTOR(S): Ridker, Paul, Chestnut Hill, MA, United States
 PATENT ASSIGNEE(S): Hennekens, Charles H., South Natick, MA, United States
 The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6040147		20000321
APPLICATION INFO.:	US 1998-54212		19980402 (9)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Saunders, David
 LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, PC
 NUMBER OF CLAIMS: 47
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 7 Drawing Figure(s); 5 Drawing Page(s)
 LINE COUNT: 1501

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.

IT 82034-46-6, Loteprednol etabonate
 (systemic inflammation marker level in evaluation of cardiovascular disorder risk redn. by)

RN 82034-46-6 USPTATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 8 OF 34 USPTATFULL
 ACCESSION NUMBER: 1999:132219 USPTATFULL
 TITLE: Method of treating allergic rhinitis by delivering medication via the nasal vestibules
 INVENTOR(S): Lin, Matthew M., 100 Pace Dr. S., West Islip, NY, United States 11795
 Lin, Audrey H., 100 Pace Dr. S., West Islip, NY, United States 11795

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972327		19991026
APPLICATION INFO.:	US 1997-955963		19971022 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bawa, Raj		
LEGAL REPRESENTATIVE:	McAulay Nissen Goldberg Kiel & Hand, LLP		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	174		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating allergic rhinitis in a patient is disclosed which comprises applying an anti-allergic rhinitis effective amount of a steroid in ointment or cream carrier to the lining of the vestibules of the patient.

IT 73771-04-7, Prednicarbate
 (steroidal allergy medication delivery via nasal vestibules)

RN 73771-04-7 USPTATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 9 OF 34 USPTATFULL
 ACCESSION NUMBER: 1999:72245 USPTATFULL
 TITLE: Aqueous suspension of loteprednol etabonate
 INVENTOR(S): Inada, Katsuhiko, Kobe, Japan
 Terayama, Hideo, Itami, Japan
 PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5916550		19990629
APPLICATION INFO.:	US 1998-35094		19980305 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-82207	19970314
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Azpuru, Carlos A.	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack, L.L.	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	307	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The conventional aqueous suspension of loteprednol etabonate is not easily amenable to production pH control and entails a pH depression on long-term storage, thus irritating the eye or the nasal mucosa on instillation.

When a C-2 aliphatic amino acid is added to an aqueous suspension of loteprednol etabonate for topical ophthalmic use, the suspension does not undergo pH depression even on prolonged storage, with the result that no irritable response is elicited in the eye or nasal mucosa.

IT 82034-46-6, Loteprednol etabonate
 (aq. suspension of loteprednol etabonate with stable pH)

RN 82034-46-6 USPTATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 10 OF 34 USPTATFULL
 ACCESSION NUMBER: 1998:47989 USPTATFULL
 TITLE: Suspension of loteprednol etabonate for ear, eye, or nose treatment
 INVENTOR(S): Amzelem, Shimon, Rehovot, Israel
 Friedman, Doron, Carmel Yosef, Israel
 PATENT ASSIGNEE(S): Pharmos Corporation, Alachua, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5747061		19980505
APPLICATION INFO.:	US 1996-688157		19960729 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-142743, filed on 25 Oct 1993, now patented, Pat. No. US 5540930		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Webman, Edward J.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
LINE COUNT:	769		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel compositions of matter for delivering water-insoluble steroid drugs suitable for therapeutic use. The invention also provides stable aqueous suspensions of water-insoluble steroid drugs of particle sizes of 100-300 nm which remain in such a state so as to allow for immediate suspension, when desired, even after extended periods of settling.

IT 82034-46-6, Loteprednol etabonate
 (suspension of corticosteroids for ear and eye and nose treatment)

RN 82034-46-6 USPTATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 11 OF 34 USPTATFULL
 ACCESSION NUMBER: 97:18317 USPTATFULL
 TITLE: Corticosteroid 17-alkyl carbonate 21-(O)-carboxylic and carbonic esters, and pharmaceuticals containing these compounds
 INVENTOR(S): Stache, Ulrich, Hofheim, Germany, Federal Republic of
 Alpermann, Hans-Georg, K onigstein, Germany, Federal Republic of
 D urckheimer, Walter, Hattersheim, Germany, Federal Republic of
 Bohn, Manfred, Hofheim, Germany, Federal Republic of
 Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5608093		19970304
APPLICATION INFO.:	US 1994-294804		19940825 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1993-4328819	19930827
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wu, Shean C.	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1804	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Corticoid 17-alkyl carbonate 21-carboxylic and carbonic esters of the formula I ##STR1## are described in which A is CHOH and CHCl, CH.sub.2, C.dbd.O or 9(11) double bonds; Y is H, F or Cl; Z is H, F or CH.sub.3; R(1) is aryl or heteraryl; n and m are zero or 1; R(2) is alkyl or --(CH.sub.2).sub.2--OCH.sub.3; R(3) is H or methyl. They are obtained by reacting a compound of the formula II, ##STR2## in which R(5) is OH, with an activated carboxylic acid of the formula III,

R(6)--CO--(O).sub.n --(X)--R(1) III.

The compounds I have a very strong local and topical antiinflammatory action and exhibit a very good ratio of local to systemic antiinflammatory effects, which ratio is often markedly superior to that of analogous corticoid 17-alkyl carbonate 21-esters which do not carry any aryl or heteraryl group in the 21-ester radical.

IT 163846-14-8P 163846-15-8P 163846-16-8P
 163846-17-1P 163846-18-2P 163846-19-3P
 163846-20-6P 163846-21-7P 163846-22-8P
 163846-23-9P 163846-24-0P 163846-25-1P
 163846-26-2P 163846-27-3P 163846-28-4P
 163846-29-5P 163846-30-8P 163846-31-9P
 163846-32-0P 163846-33-1P 163846-34-2P
 163846-35-3P 163846-36-4P 163846-37-5P
 163846-38-6P 163846-40-0P 163846-41-1P
 163846-44-4P 163846-45-5P 163846-46-6P
 163846-47-7P 163846-48-8P 163846-49-9P
 163846-50-2P 163846-51-3P 163846-52-4P
 163846-53-5P 163846-54-6P 163846-55-7P
 163846-56-8P 163846-57-9P 163846-58-0P
 163846-59-1P 163846-60-4P 163846-61-5P
 163846-62-6P 163846-63-7P 163846-64-8P

L7 ANSWER 11 OF 34 USPATFULL (Continued)


163846-65-9P 163846-66-0P 163846-67-1P
 163846-68-2P 163846-69-3P 163846-70-6P
 163846-71-7P 163846-72-8P 163846-73-9P
 163846-74-0P 163846-75-1P 163846-76-2P
 163846-77-3P 163846-78-4P 163846-79-5P
 163846-80-8P 163846-81-9P 163846-82-0P
 163846-83-1P 163846-84-2P 163846-85-3P
 163846-86-4P 163846-87-5P 163846-88-6P
 163846-89-7P 163846-90-0P 163846-91-1P
 163846-92-2P 163846-93-3P 163846-94-4P
 163846-95-5P 163846-96-6P 163846-97-7P
 163846-98-8P 163846-99-9P 163847-00-5P
 163847-01-6P 163847-02-7P 163847-03-8P
 163847-04-9P 163847-05-0P 163847-06-1P
 163847-07-2P 163847-08-3P 163847-09-4P
 163847-10-7P 163847-11-8P 163847-12-9P
 163847-13-0P 163847-14-1P 163847-15-2P
 163958-62-1P

(prepn. of corticosteroid 17-alkylcarbonate-21-esters as
 antiinflammatories)

RN 163846-14-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(benzoyloxy)-17-[(ethoxycarbonyl)oxy]-11-
 hydroxy-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-15-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-
 [(phenylacetyl)oxy]-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-18-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-
 oxo-3-phenyl-2-propenyl)oxy]-, (11.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 163846-19-3 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-
 methoxybenzoyl)oxy]-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-20-6 USPATFULL


L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-16-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxo-
 3-phenylpropoxy)-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-17-1 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-
 [(phenylacetyl)oxy]-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-
 thienylacetyl)oxy]-, (11.β.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-21-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-
 thienylacetyl)oxy]-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-22-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-
 oxo-3-(2-thienyl)-2-propenyl)oxy]-, (11.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.


L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-23-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[(2-furanylcarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-25-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(1-oxo-3-phenylpropoxy)-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-24-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[(3-(2-furanyl)-1-oxo-2-propenyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 163846-26-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(1-methylethoxycarbonyl)oxy]-21-[(phenoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-27-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

L7 ANSWER 11 OF 34 USPATFULL (Continued)


RN 163846-29-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methoxyethoxycarbonyl)oxy]-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 163846-30-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(phenylacetyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-28-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-17-[(pentyloxy)carbonyl]oxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 163846-31-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(1-methylethoxycarbonyl)oxy]-21-[(phenylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-32-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-11-hydroxy-21-[(phenylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-33-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-21-[(4-methylphenyl)acetyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-36-4 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 163846-37-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-34-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(1-oxo-3-phenylpropoxy)-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-35-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(phenoxyacetyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)

RN 163846-38-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-21-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-40-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-41-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-6,16-dimethyl-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-44-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-chloro-17-[(ethoxycarbonyl)oxy]-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-45-5 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(2-thienylacetyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-46-6 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-21-[(1H-indol-3-ylacetyl)oxy]-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-47-7 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-48-8 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1H-indol-3-ylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-49-9 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 17-[(ethoxycarbonyl)oxy]-21-[(phenylacetyl)oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-50-2 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-51-3 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 34 USPATFULL (Continued)
 RN 163846-52-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-53-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-6-methyl-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-54-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-57-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methoxyethoxy)carbonyl]oxy]-21-[(phenylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-58-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(4-{[bis(2-chloroethyl)amino]phenyl}-1-oxobutoxy)]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-55-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-21-[(phenylacetyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-56-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methylpropoxy)carbonyl]oxy]-21-[(phenylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-59-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(1,3-benzodioxol-5-ylcarbonyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-60-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(phenoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-61-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[[9H-fluoren-9-ylmethoxy]carbonyl]oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-62-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-, (11.beta.,21(E))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-65-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-6-methyl-, (6.alpha.,11.beta.,21(E))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 163846-66-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-16-methyl-, (11.beta.,16.alpha.,21(E))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-63-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.,21(E))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 163846-64-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-17-[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,21(E))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-67-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-16-methyl-, (11.beta.,16.beta.,21(E))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 163846-68-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,21(E))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-69-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-, (11.beta.,21(E))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-71-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[1-(methylethoxy)carbonyl]oxy]-21-[[1-(oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 163846-70-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[[1-(oxo-3-phenyl-2-propenyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

RN 163846-72-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-21-[[1-(oxo-3-phenyl-2-propenyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-73-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[[1-(oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-75-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[[3-[(1,1'-biphenyl)-4-yl]-1-oxo-2-propenyl]oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 163846-74-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[2-(methylpropoxy)carbonyl]oxy]-21-[[1-(oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

RN 163846-76-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[[3-[(1,3-benzodioxol-5-yl)-1-oxo-2-propenyl]oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.,21(E))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-77-3 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-phenyl-2-propynyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-79-5 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorobenzoyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-78-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-nitrobenzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 163846-80-8 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-nitrobenzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-81-9 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(4-(acetylthio)benzoyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)


RN 163846-83-1 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-(methylthio)benzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-84-2 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-(methylthio)benzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-82-0 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(2-(acetoxy)benzoyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-85-3 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-phenylthio)benzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-86-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-pyridinylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-87-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21,21'-[2,6-pyridinediylbis(carbonyloxy)]bis[17-[(ethoxycarbonyl)oxy]-11-hydroxy]-, (11.beta.)-(11'.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-90-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(3-methylbenzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-91-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(3-methylbenzoyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-88-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-methylbenzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-89-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-methylbenzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)


RN 163846-92-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(3-pyridinylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-93-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-(3-pyridinyl)-2-propenyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 163846-94-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(3-thienylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-95-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(3-thienylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163846-97-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(5-chloro-2-thienyl)carbonyl]oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-96-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[1-oxo-3-(2-thienyl)propoxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-98-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[(3-furanylcarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163846-99-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(3-furanylcarbonyl)oxy]-11-hydroxy-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163847-01-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[3-(2-furanyl)-1-oxopropoxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163847-00-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-21-[(3-furanylcarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163847-02-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(5-methyl-2-furanyl)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 34 USPATFULL (Continued)

RN 163847-03-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-[(1H-pyrrol-2-ylcarbonyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163847-04-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-[(4-thiazolylcarbonyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-05-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-21-[(2-furanylmethoxycarbonyloxy)-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163847-08-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-[(1-methyl-1H-indol-2-ylcarbonyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-09-4 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(4-benzoylbzoyloxy)-17-[(ethoxycarbonyloxy)-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163847-06-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-[(1H-indol-3-ylcarbonyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 163847-07-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-[(2-methyl-1H-indol-3-ylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163847-10-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-[(5-methoxy-1H-indol-3-ylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-11-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-[(2-naphthalenylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163847-12-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-quinoxalinylnylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163847-13-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-isoquinolinylnylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163958-62-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.,21.E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



IT 52619-15-5 70283-33-9 70283-58-8
 70283-61-3 73291-83-5 73291-85-7
 73292-19-0 73764-79-1 104286-02-4
 140454-67-7 140454-68-8 140454-69-9
 140454-70-2 140454-71-3 163847-16-3
 163847-17-4 163847-20-9 163847-21-0
 163847-22-1 163847-23-2 163847-25-4
 163847-26-5 163847-27-6 163847-28-7
 (prepn. of corticosteroid 17-alkylcarbonate-21-esters as
 antiinflammatories)
 RN 52619-15-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 163847-14-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1H-indol-3-yl)-1-oxo-2-propenyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 163847-15-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-(dimethylamino)benzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 70283-33-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70283-58-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6-fluoro-11,21-dihydroxy-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70283-61-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11,21-dihydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 11 OF 34 USPATFULL (Continued)



RN 73291-83-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-iodo-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73291-85-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73292-19-0 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-

L7 ANSWER 11 OF 34 USPATFULL (Continued)

RN 140454-67-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-17-[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-68-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-69-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-70-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-17-[(2-methoxyethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 11 OF 34 USPATFULL (Continued)

[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73764-79-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 104286-02-4 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 11 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 140454-71-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163847-16-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-11,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-17-4 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-17-[(pentyloxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163847-20-9 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 17-[(ethoxycarbonyl)oxy]-21-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-21-0 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11,21-dihydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-22-1 USPATFULL

L7 ANSWER 11 OF 34 USPATFULL (Continued)




RN 163847-26-5 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11,21-dihydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163847-27-6 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-28-7 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11,21-dihydroxy-16-methyl-, (6.alpha.,11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163847-23-2 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11,21-dihydroxy-6,16-dimethyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163847-25-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-chloro-17-[(ethoxycarbonyl)oxy]-11,21-dihydroxy-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 11 OF 34 USPATFULL (Continued)



L7 ANSWER 12 OF 34 USPATFULL
 ACCESSION NUMBER: 96:10643 USPATFULL
 TITLE: Cyclodextrins as suspending agents for pharmaceutical suspensions
 INVENTOR(S): Guy, Yaacov J., Rehovot, Israel
 PATENT ASSIGNEE(S): Pharmos Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5576311		19961119
APPLICATION INFO.:	US 1994-346954		19941130 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jordan, Kimberly		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	548		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to stable aqueous suspension of drugs suitable for therapeutic administration without requiring solubilization or complexation of those drugs. The suspensions are stabilized with cyclodextrin type suspending agents. Stabilized suspensions of corticosteroids which employ these suspending agents are useful for therapeutic treatment of the eye, ear, or nose.

IT 82034-46-6, Loteprednol etabonate
 (cyclodextrins as suspending agents for pharmaceutical suspensions)

RN 82034-46-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 14 OF 34 USPATFULL
 ACCESSION NUMBER: 96:51023 USPATFULL
 TITLE: Brain-specific drug delivery
 INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
 PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5525727		19960611
APPLICATION INFO.:	US 1992-967979		19921028 (7)
RELATED APPL. INFO.:	Division of Ser. No. US 1991-639283, filed on 10 Jan 1991, now patented, Pat. No. US 5187158 which is a division of Ser. No. US 1989-295938, filed on 11 Jan 1989, now patented, Pat. No. US 5008257 which is a division of Ser. No. US 1984-665940, filed on 29 Oct 1984, now patented, Pat. No. US 4824850 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 Ser. No. Ser. No. US 1983-461543, filed on 27 Jan 1983, now abandoned Ser. No. Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 And Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1983-US725	19830519
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ivy, C. Warren	
ASSISTANT EXAMINER:	Mach, D. Margaret M.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	6632	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are:

(a) compounds of the formula

(D-DHC) (1)

wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine. reversion. pyridinium salt redox carrier, with the proviso that when [DHC] is β -STR100 wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic-stimulant, steroid sex hormone or long chain alkanol; and

(b) non-toxic pharmaceutically acceptable salts of compounds of formula (1). The corresponding ionic pyridinium salt type drug/carrier entities [D-OC] sup.+ X sup.- are also disclosed.

IT 82034-30-8P 82034-31-9P 82034-32-0P
 82034-34-2P 82034-36-4P 82034-38-6P

L7 ANSWER 13 OF 34 USPATFULL
 ACCESSION NUMBER: 96:67754 USPATFULL
 TITLE: Suspension of loteprednol etabonate for ear, eye, or nose treatment
 INVENTOR(S): Guy, Yaacov J., Rehovot, Israel
 Friedman, Doron I., Carmel Yosef, Israel
 PATENT ASSIGNEE(S): Pharmos Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5540930		19960730
APPLICATION INFO.:	US 1993-142743		19931025 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Webman, Edward J.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	599		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel compositions of matter containing water-insoluble steroid drugs suitable for therapeutic use. The invention provides stable aqueous suspensions of water-insoluble steroid drugs of particle sizes of .ltoreq.15 .mu.m which remain in such a state so as to allow for immediate suspension, when desired, even after extended periods of settling.

IT 82034-46-6, Loteprednol etabonate
 (suspension compns. for anti-inflammatory corticosteroid drugs)

RN 82034-46-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 14 OF 34 USPATFULL (Continued)

82034-39-7P 82034-40-0P 82034-41-1P
 82034-44-4P 82034-45-5P 82034-46-6P
 82034-47-7P 82034-48-8P 82034-49-9P
 82034-50-2P 82034-54-6P 82034-61-5P
 82034-62-6P 82034-63-7P 82034-64-8P
 82034-65-9P 82034-67-1P 82034-68-2P
 82034-69-3P 82034-71-7P 82034-72-8P
 82034-73-9P 82048-82-6P


RN 82034-30-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-31-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-32-0 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 14 OF 34 USPATFULL (Continued)



RN 82034-34-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-36-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-38-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 14 OF 34 USPATFULL (Continued)

17-[(phenoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-44-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-45-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-46-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 14 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82034-39-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyloxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-40-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-41-1 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-

L7 ANSWER 14 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82034-47-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-48-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-49-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 14 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82034-50-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-54-6 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 14 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82034-65-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-67-1 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyl]oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 14 OF 34 USPATFULL (Continued)

RN 82034-61-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1R)-1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-62-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1S)-1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-63-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3,11-dioxo-, chloromethyl ester, (16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 14 OF 34 USPATFULL (Continued)

Absolute stereochemistry.




RN 82034-68-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

RN 82034-69-3 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 82034-71-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 14 OF 34 USPATFULL (Continued)
 difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 82034-72-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-
 11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 82034-73-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-
 11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)-
 (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L7 ANSWER 14 OF 34 USPATFULL (Continued)



RN 82048-82-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyl]oxy]-
 9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



L7 ANSWER 15 OF 34 USPATFULL
 95:33913 USPATFULL
 TITLE: Method of treating inflammatory conditions of the mouth
 using steroid containing mouthwash which may contain
 antifungal agents
 INVENTOR(S): Eisen, Dore, 6720 Beechlands Dr., Cincinnati, OH,
 United States 45237

NUMBER	KIND	DATE
US 5407663		19950418
US 1994-222277		19940404 (8)
20110510		

 PATENT INFORMATION: Continuation-in-part of Ser. No. US 1993-6287, filed on
 15 Jan 1993, now patented, Pat. No. US 5310545 which is
 a continuation-in-part of Ser. No. US 1992-963485,
 filed on 21 Oct 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 1991-802646, filed
 on 9 Dec 1991, now abandoned which is a
 continuation-in-part of Ser. No. US 1991-683380, filed
 on 11 Apr 1991, now abandoned
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Mars, Howard T.
 ASSISTANT EXAMINER: Cook, Rebecca
 LEGAL REPRESENTATIVE: Hendricks, Glenna, Gates, Stephen
 NUMBER OF CLAIMS: 12
 EXEMPLARY CLAIM: 1
 LINE COUNT: 422
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Patients may effectively be treated for inflammatory conditions of the
 mouth using aqueous anti-inflammatory steroids in solutions that can be
 swished and expectorated as a mouthwash. Such therapy would allow direct
 contact of the medication with the diseased mucous membranes and would
 contact areas of the oral cavity that would not usually be reached with
 application of creams, gels, or ointments. Compositions containing
 antifungal agents in addition to steroids are particularly useful.

Swishing for three to five minutes, then expectorating the aqueous
 anti-inflammatory-containing, results in maintenance of contact of the
 active agents with the oral cavity surfaces for a longer time than would
 application of gels containing those agents. The mode of application is
 simple and is not repugnant to the patient as is the application of
 creams, gels, or ointments.

IT 73771-04-7, Prednicarbate
 (mouthwashes contg. steroids and antifungal agents for treatment of
 inflammatory conditions of the mouth)
 RN 73771-04-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-
 oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 15 OF 34 USPATFULL (Continued)



L7 ANSWER 16 OF 34 USPATFULL
 ACCESSION NUMBER: 95:13856 USPATFULL
 TITLE: Redox carriers for brain-specific drug delivery
 INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
 PATENT ASSIGNEE(S): University Of Florida, Gainesville, FL, United States
 (U.S. corporation)

NUMBER	KIND	DATE
US 5389623		19950214
US 1991-766528		19910927 (7)
Division of Ser. No. US 1989-295663, filed on 11 Jan 1989, now patented, Pat. No. US 5087618 which is a division of Ser. No. US 1984-666210, filed on 29 Oct 1984, now patented, Pat. No. US 4829070 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 And Ser. No. US 1983-461543, filed on 27 Jan 1983, now abandoned And Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 And a continuation-in-part of Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564		

NUMBER	DATE
WO 1983-725	19830512
CA 1983-428192	19830516

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Rollins, John W.
 ASSISTANT EXAMINER: Wilson, James D.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis
 NUMBER OF CLAIMS: 28
 EXEMPLARY CLAIM: 1,14
 LINE COUNT: 2585

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Compounds of the formula #STR1# and the nontoxic pharmaceutically acceptable salt thereof, wherein D is the residue of a centrally acting drug containing at least one reactive functional group selected from the group consisting of amino, hydroxyl, mercapto, carboxyl, amide and imide, said residue being characterized by the absence of a hydrogen atom from at least one of said reactive functional groups in said drug; n is a positive integer equal to the number of said functional groups from which a hydrogen atom is absent; and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine. pyridinium salt redox carrier, said carrier comprising a bivalent radical of the formula #STR2# wherein the alkylene group can be straight or branched and can contain 1 to 3 carbon atoms; R.sub.o is a radical identical to the corresponding portion of a natural amino acid; and p is 1 or 2, provided that, when p is 2, then the alkylene groups can be the same or different and the R.sub.o radicals can be the same or different; said bivalent radical being so positioned that the terminal carbonyl function of the bivalent radical is linked to the drug residue while the terminal amino function of the bivalent radical is linked to the remaining portion of the carrier moiety; are adapted for the site-specific/sustained delivery of centrally acting drugs to the brain. The corresponding pyridinium salt

L7 ANSWER 16 OF 34 USPATFULL (Continued)
 type drug/carrier entities D --QC.sup.+].sub.n qY.sup.-t are also disclosed.

IT 82034-30-6P 82034-31-9P 82034-32-0P
 82034-34-2P 82034-36-4P 82034-38-6P
 82034-39-7P 82034-40-0P 82034-41-1P
 82034-44-4P 82034-45-5P 82034-46-6P
 82034-47-7P 82034-48-8P 82034-49-9P
 82034-50-2P 82034-54-6P 82034-61-5P
 82034-62-6P 82034-63-7P 82034-64-8P
 82034-65-9P 82034-67-1P 82034-68-2P
 82034-69-3P 82034-71-7P 82034-72-8P
 82034-73-9P 82048-82-6P
 (prepn. of)


RN 82034-30-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-31-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-32-0 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 16 OF 34 USPATFULL (Continued)
 Absolute stereochemistry.




RN 82034-34-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-36-4 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-38-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 16 OF 34 USPATFULL (Continued)




RN 82034-39-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[[1-methylethoxy]carbonyl]oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-40-0 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-41-1 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 16 OF 34 USPATFULL (Continued)




RN 82034-44-4 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-45-5 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-46-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 16 OF 34 USPATFULL (Continued)


CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-50-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-54-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-61-5 USPATFULL


L7 ANSWER 16 OF 34 USPATFULL (Continued)

Absolute stereochemistry.




RN 82034-47-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-48-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-49-9 USPATFULL

L7 ANSWER 16 OF 34 USPATFULL (Continued)


CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1R)-1-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-62-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1S)-1-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-63-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3,11-dioxo-, chloromethyl ester, (16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 16 OF 34 USPATFULL (Continued)




RN 82034-64-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-65-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-67-1 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-


L7 ANSWER 16 OF 34 USPATFULL (Continued)
 17-[(pentyloxy)carbonyl]oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-68-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-69-3 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 16 OF 34 USPATFULL (Continued)




RN 82034-71-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-72-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-73-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


L7 ANSWER 16 OF 34 USPATFULL (Continued)

Absolute stereochemistry.



RN 82048-82-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 17 OF 34 USPATFULL
 94:97560 USPATFULL
 ACCESSION NUMBER:
 TITLE: Corticoid-17-alkyl-carbonates substituted in the 17-position, process for their preparation and pharmaceuticals containing them
 INVENTOR(S): Stache, Ulrich, Hofheim am Taunus, Germany, Federal Republic of
 Durckheimer, Walter, Hattersheim am Main, Germany, Federal Republic of
 Alpermann, Hans G., Königstein/Taunus, Germany, Federal Republic of
 Petri, Walter, Wiesbaden, Germany, Federal Republic of
 PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5362721		19941108
APPLICATION INFO.:	US 1993-15041		19930208 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-742334, filed on 8 Aug 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1990-4025342	19900810
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Richter, Johann	
ASSISTANT EXAMINER:	Kestler, Kimberly J.	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1599	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The disclosed invention includes corticoid-17-alkylcarbonates substituted in the 17-position, a process for their preparation and pharmaceuticals containing them. These corticoid-17-alkylcarbonates have the following formula I #STR1# where A is CHOH in any desired steric arrangement, C.dbd.O or CH.sub.2 ; Y is H, F, or Cl. 2 is H, F or CH.sub.3 ; R(1) is O-acyl, carbonylalkyl, alkylsulfonate or arylsulfonate;


R(2) is branched alkyl or (CH.sub.2).sub.2-4 --OCH.sub.3 and

R(3) is H or methyl. They have excellent local and topical antiinflammatory action. They are distinguished by a particularly good ratio of local to systemic antiinflammatory activity and in some cases also show stronger local antiinflammatory activities than their isomeric corticoid-17-alkylcarbonates having a linear alkyl group in the 17-alkylcarbonate moiety.

IT 140454-67-7P 140454-68-8P 140454-69-9P
 140454-70-2P 140454-71-3P 140454-72-4P
 140454-73-5P 140454-74-6P 140454-76-8P
 140454-77-9P 140475-97-4P 140475-98-5P
 140475-99-6P
 (prepn. and acylation of, in prepn. of local antiinflammatory)
 RN 140454-67-7 USPATFULL


L7 ANSWER 17 OF 34 USPATFULL (Continued)
 RN 140454-70-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-71-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-72-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-73-5 USPATFULL

L7 ANSWER 17 OF 34 USPATFULL (Continued)
 CN Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 140454-68-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-69-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-11,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 17 OF 34 USPATFULL (Continued)
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-74-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-76-8 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 21-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-77-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-17-[[[(2-


L7 ANSWER 17 OF 34 USPATFULL (Continued)
methylpropoxy)carbonyloxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140475-97-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-6-methyl-17-[(2-methylpropoxy)carbonyloxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-98-5 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyloxy]-11,21-dihydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140475-99-6 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 140452-34-2P 140452-35-3P 140452-36-4P
140452-37-5P 140452-38-6P 140452-39-7P
140452-40-0P 140452-41-1P 140452-42-2P
140452-43-3P 140452-44-4P 140452-45-5P
140452-46-6P 140452-47-7P 140452-48-8P
140452-49-9P 140452-50-2P 140452-51-3P
140452-52-4P 140452-53-5P 140452-54-6P
140452-55-7P 140452-56-8P 140452-57-9P
140452-58-0P 140452-59-1P 140452-60-4P
140452-61-5P 140452-62-6P 140452-63-7P
140452-64-8P 140452-65-9P 140452-66-0P
140452-67-1P 140452-68-2P 140452-69-3P
140452-70-6P 140452-71-7P 140452-72-8P
140452-73-9P 140452-74-0P 140452-75-1P
140452-76-2P 140452-77-3P 140452-78-4P
140452-79-5P 140452-80-6P 140452-81-9P
140452-82-0P 140452-83-1P 140452-84-2P
140452-85-3P 140452-86-4P 140452-87-5P

L7 ANSWER 17 OF 34 USPATFULL (Continued)


140452-88-6P 140452-89-7P 140452-90-0P
140452-91-1P 140452-92-2P 140452-93-3P
140452-94-4P 140452-95-5P 140452-96-6P
140452-97-7P 140452-98-8P 140452-99-9P
140453-00-5P 140453-01-6P 140453-02-7P
140453-03-8P 140453-04-9P 140453-05-0P
140453-06-1P 140453-07-2P 140453-08-3P
140453-09-4P 140453-10-7P 140453-11-8P
140453-12-9P 140453-13-0P 140453-14-1P
140453-15-2P 140453-16-3P 140453-17-4P
140453-18-5P 140453-19-6P 140453-20-9P
140453-21-0P 140453-22-1P 140453-23-2P
140453-24-3P 140453-25-4P 140453-26-5P
140453-27-6P 140453-28-7P 140453-29-8P
140453-30-1P 140453-31-2P 140453-32-3P
140453-33-4P 140453-34-5P 140453-35-6P
140453-36-7P 140453-37-8P 140453-38-9P
140453-39-0P 140453-40-3P 140453-41-4P
140453-42-5P 140453-43-6P 140453-44-7P
140453-45-8P 140453-46-9P 140453-47-0P
140453-48-1P 140453-49-2P 140453-50-5P
140453-51-6P 140453-52-7P 140453-53-8P
140453-54-9P 140453-55-0P 140453-56-1P
140453-57-2P 140453-58-3P 140453-59-4P
140453-60-7P 140453-61-8P 140453-62-9P
140453-63-0P 140453-64-1P 140453-65-2P
140453-66-3P 140453-67-4P 140453-68-5P
140453-69-6P 140453-70-9P 140453-71-0P
140453-72-1P 140453-73-2P 140453-74-3P
140453-75-4P 140453-76-5P 140453-77-6P
140453-78-7P 140453-79-8P 140453-80-1P
140454-09-7P 140454-10-0P 140454-11-1P
140454-12-2P 140454-13-3P 140454-14-4P
140454-15-5P 140454-16-6P 140454-17-7P
140454-18-8P 140454-19-9P 140454-20-2P
140454-21-3P 140454-22-4P 140454-23-5P
140454-24-6P 140454-25-7P 140454-26-8P
140454-27-9P 140454-28-0P 140454-29-1P
140454-30-4P 140454-31-5P 140454-32-6P
140454-33-7P 140454-34-8P 140454-35-9P
140454-36-0P 140454-37-1P 140454-38-2P
140452-57-3P 140475-76-9P 140475-77-0P
140475-78-1P 140475-79-2P 140475-80-5P
140475-81-6P 140475-82-7P 140475-83-8P
140475-84-9P 140475-85-0P 140475-86-1P
140475-87-2P 140475-88-3P 140475-89-4P
140475-90-7P 140475-91-8P 140475-92-9P
140475-93-0P

(prepn. of, as local antiinflammatory for treatment of dermatosis)

RN 140452-34-2 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-[(2-methylpropoxy)carbonyloxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140452-35-3 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methylpropoxy)carbonyloxy]-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-36-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(1-methylethoxy)carbonyloxy]-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-37-5 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyloxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 17 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 140452-38-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-(((2-methoxyethoxy)carbonyl)oxy)-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-39-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-(((1-methylethoxy)carbonyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 140452-43-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-(((1-methylethoxy)carbonyl)oxy)-21-((1-oxopentyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 140452-44-4 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-(((1-methylethoxy)carbonyl)oxy)-21-((1-oxohexyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-40-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-17-(((2,2-dimethylpropoxy)carbonyl)oxy)-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-41-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-(((2-methoxyethoxy)carbonyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-42-2 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-(((1-methylethoxy)carbonyl)oxy)-21-(1-oxobutoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 17 OF 34 USPATFULL (Continued)

RN 140452-45-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-(((1-methylethoxy)carbonyl)oxy)-21-(2-methyl-1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-46-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-11-hydroxy-17-(((1-methylethoxy)carbonyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-47-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(((cyclopropylcarbonyl)oxy)-11-hydroxy-17-(((1-methylethoxy)carbonyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-48-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(3-cyclopentyl-1-oxopropoxy)-11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140452-50-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-49-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(methoxycarbonyl)oxy]-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-51-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-52-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140452-55-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[[[(4-methylphenyl)sulfonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-53-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(phenylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-56-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-[(1-oxobutoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-54-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)



RN 140452-57-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-[(1-oxobutoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


L7 ANSWER 17 OF 34 USPATFULL (Continued)
methylpropoxy)carbonyloxy]-21-[(1-oxopentyl)oxy]-, (11.beta.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 140452-58-0 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methylpropoxy)carbonyloxy]-21-[(1-oxohexyl)oxy]-, (11.beta.)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 140452-59-1 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-(2-methyl-1-oxopropoxy)-17-[(2-methylpropoxy)carbonyloxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140452-62-6 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11-hydroxy-17-[(2-methylpropoxy)carbonyloxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-63-7 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(methoxycarbonyloxy)-17-[(2-methylpropoxy)carbonyloxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-64-8 USPATFULL

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-60-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-11-hydroxy-17-[(2-methylpropoxy)carbonyloxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-61-5 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methylpropoxy)carbonyloxy]-21-[(cyclopropylcarbonyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methylpropoxy)carbonyloxy]-21-[(propoxycarbonyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-65-9 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methylpropoxy)carbonyloxy]-21-[(methylsulfonyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-66-0 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methylpropoxy)carbonyloxy]-21-[(phenylsulfonyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-67-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-11-hydroxy-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-68-2 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(4-methylphenyl)sulfonyl]oxy]-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-69-3 USPATFULL


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-72-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-73-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-74-0 USPATFULL

L7 ANSWER 17 OF 34 USPATFULL (Continued)

CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-21-(1-oxobutoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-70-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-21-[(1-oxopentyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-71-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-21-[(1-oxohexyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 17 OF 34 USPATFULL (Continued)

CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-75-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-21-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-76-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-77-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyloxy]-17-[(2,2-dimethylpropoxy)carbonyloxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-78-4 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-21-(1-oxobutoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-81-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyloxy)-11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-82-0 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyloxy)-11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-83-1 USPATFULL


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-79-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-21-[(1-oxopentyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-80-8 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-21-(2-methyl-1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-21-[(methylsulfonyloxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-84-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-85-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-21-(1-oxobutoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-86-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(1-oxopentyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-87-5 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-(2-methyl-1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-88-6 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-89-7 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140452-90-0 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-21-[(methoxycarbonyl)oxy]-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-91-1 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 17 OF 34 USPATFULL (Continued)


RN 140452-92-2 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-93-3 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(methylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-94-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-95-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[[[4-methylphenyl)sulfonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-96-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140452-99-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-[[[1-oxopentyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-00-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-[[[1-oxohexyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140452-97-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-98-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxobutoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)


RN 140453-01-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-21-(2-methyl-1-oxopropoxy)-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-02-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-03-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[[[cyclopropylcarbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-04-9 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(3-cyclopentyl-1-oxopropoxy)-9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-05-0 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-21-[(methoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-08-3 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-21-[(methylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-09-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-21-[(phenylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-10-7 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenylsulfonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-06-1 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-07-2 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-21-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)
11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-11-8 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-21-[(4-methylphenylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-12-9 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-17-[(2,2-dimethylpropoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-13-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-21-(1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-14-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-21-(1-oxobutoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-17-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-21-[(ethoxycarbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-18-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(methylsulfonyl]oxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-19-6 USPATFULL

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-15-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-21-(2-methyl-1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-16-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(cyclopropylcarbonyl]oxy]-17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)


CN Pregna-1,4-diene-3,20-dione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-20-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-21-(1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-21-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-21-(1-oxobutoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-22-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-21-(2-methyl-1-oxopropoxy)-, (11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-24-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-9-fluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-, (11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 140453-23-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-, (11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 140453-25-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-, (11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-26-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-(1-oxobutoxy)-, (6.alpha.,11.beta.)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 140453-27-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-(1-oxopropoxy)-, (6.alpha.,11.beta.)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




L7 ANSWER 17 OF 34 USPATFULL (Continued)

RN 140453-28-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-(1-oxobutoxy)-, (6.alpha.,11.beta.)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 140453-29-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-(2-methyl-1-oxopropoxy)-, (6.alpha.,11.beta.)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 140453-30-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-31-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-33-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(methylsulfonyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-32-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-34-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-35-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-37-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxobutoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-36-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-38-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-[(1-oxopentyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-39-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-21-[(2-methyl-1-oxopropoxy)carbonyloxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-41-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyloxy)-11-hydroxy-6-methyl-17-[(2-methylpropoxy)carbonyloxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-40-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropoxy)-11-hydroxy-6-methyl-17-[(2-methylpropoxy)carbonyloxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-42-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(3-cyclopentyl-1-oxopropoxy)-11-hydroxy-6-methyl-17-[(2-methylpropoxy)carbonyloxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-43-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyloxy)-11-hydroxy-6-methyl-17-[(2-methylpropoxy)carbonyloxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-45-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[(2-methylpropoxy)carbonyloxy]-21-[(methylsulfonyloxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-44-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[(2-methylpropoxy)carbonyloxy]-21-[(propoxycarbonyloxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-46-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenylsulfonyloxy)-11-hydroxy-6-methyl-17-[(2-methylpropoxy)carbonyloxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-47-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-21-[(4-methylphenyl)sulfonyl]oxy]-17-[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-49-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-21-(2-methyl-1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-48-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-21-(1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-50-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-51-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-53-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-21-[(methylsulfonyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-52-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-21-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-54-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-55-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-56-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy-6-methyl-21-(1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-59-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-60-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy-6-methyl-21-[[methylsulfonyl]oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-57-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy-6-methyl-21-[(1-oxobutoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-58-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-61-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy-21-[(1-oxopropoxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-62-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy-21-[(1-oxobutoxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-63-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-(2-methyl-1-oxopropoxy)-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-65-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-64-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-66-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-67-4 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-69-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxobutoxy)-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-68-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxopropoxy)-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-70-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-[(1-oxopentyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-71-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-21-((2-methyl-1-oxopropoxy)carbonyloxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-73-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-(((2-methylpropoxy)carbonyloxy)-21-((methylsulfonyl)oxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-72-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-((cyclopropylcarbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-17-(((2-methylpropoxy)carbonyloxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-74-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-17-(((2,2-dimethylpropoxy)carbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140453-75-4 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-(((2,2-dimethylpropoxy)carbonyloxy)-21-((ethoxycarbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-77-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-17-(((2-methoxyethoxy)carbonyloxy)-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-76-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-(((4-chlorophenyl)sulfonyloxy)-17-(((2,2-dimethylpropoxy)carbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-78-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-17-(((2-methoxyethoxy)carbonyloxy)-16-methyl-21-((1-oxopropoxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140453-79-8 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-21-(1-oxobutoxy)-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-80-1 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-6,9-difluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)


RN 140454-11-1 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxobutoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-12-2 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 17-[[[(2-methylpropoxy)carbonyl]oxy]-21-[[[(1-oxopentyl)oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-13-3 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-(2-methyl-1-oxopropoxy)-17-[[[(2-methylpropoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140454-09-7 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-(acetyloxy)-17-[[[(2-methylpropoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-10-0 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxopropoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 17 OF 34 USPATFULL (Continued)


RN 140454-14-4 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-(2,2-dimethyl-1-oxopropoxy)-17-[[[(2-methylpropoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-15-5 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-[(cyclopropylcarbonyl)oxy]-17-[[[(2-methylpropoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-16-6 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-(3-cyclopentyl-1-oxopropoxy)-17-[[[(2-methylpropoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


L7 ANSWER 17 OF 34 USPATFULL (Continued)
methylpropoxy)carbonyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-17-7 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-[(ethoxycarbonyloxy)-17-[(2-methylpropoxy)carbonyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-18-8 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-[(4-chlorophenylsulfonyloxy)-17-[(2-methylpropoxy)carbonyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 17 OF 34 USPATFULL (Continued)
CN Pregna-1,4-diene-3,11,20-trione, 17-[(1-methylethoxy)carbonyloxy]-21-(1-oxobutoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-22-4 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 17-[(1-methylethoxy)carbonyloxy]-21-(2-methyl-1-oxopropoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-23-5 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-[(cyclopropylcarbonyloxy)-17-[(1-methylethoxy)carbonyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140454-19-9 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-(acetyloxy)-17-[(1-methylethoxy)carbonyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-20-2 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 17-[(1-methylethoxy)carbonyloxy]-21-(1-oxopropoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-21-3 USPATFULL

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140454-24-6 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-(3-cyclopentyl-1-oxopropoxy)-17-[(1-methylethoxy)carbonyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-25-7 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-[(ethoxycarbonyloxy)-17-[(1-methylethoxy)carbonyloxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-26-8 USPATFULL
CN Pregna-1,4-diene-3,11,20-trione, 21-[(4-chlorophenylsulfonyloxy)-17-[(1-methylethoxy)carbonyloxy]- (9CI) (CA INDEX NAME)


L7 ANSWER 17 OF 34 USPATFULL (Continued)
 [(1-methylethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-27-9 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 21-(acetyloxy)-17-[(2,2-dimethylpropoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-28-0 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-21-(1-oxopropoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140454-29-1 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 21-[(cyclopropylcarbonyl)oxy]-17-[(2,2-dimethylpropoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-30-4 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-21-[(ethoxycarbonyl)oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140454-31-5 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 21-[(4-chlorophenyl)sulfonyl]oxy]-17-[(2,2-dimethylpropoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-32-6 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 21-(acetyloxy)-17-[(2-methoxyethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 17 OF 34 USPATFULL (Continued)


RN 140454-33-7 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 17-[(2-methoxyethoxy)carbonyl]oxy]-21-(1-oxopropoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-34-8 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 21-[(cyclopropylcarbonyl)oxy]-17-[(2-methoxyethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-35-9 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 21-[(4-chlorophenyl)sulfonyl]oxy]-17-[(2-methoxyethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140454-36-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-chloro-11-hydroxy-17-(((2-methylpropoxy)carbonyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-37-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-bromo-11-hydroxy-17-(((2-methylpropoxy)carbonyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)


CN Pregna-1,4-diene-3,20-dione, 21-((ethoxycarbonyl)oxy)-11-hydroxy-17-(((2-methylpropoxy)carbonyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140475-77-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(((4-chlorophenyl)sulfonyl)oxy)-11-hydroxy-17-(((2-methoxyethoxy)carbonyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-78-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-(((1-methylethoxy)carbonyl)oxy)-21-(1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140454-38-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-iodo-17-(((2-methylpropoxy)carbonyl)oxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140462-57-3 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-(((1-methylethoxy)carbonyl)oxy)-21-((1-oxohexyl)oxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140475-76-9 USPATFULL

L7 ANSWER 17 OF 34 USPATFULL (Continued)




RN 140475-79-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-9-fluoro-11-hydroxy-16-methyl-17-(((1-methylethoxy)carbonyl)oxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140475-80-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-17-(((2-methoxyethoxy)carbonyl)oxy)-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-81-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-(((2-methoxyethoxy)carbonyl)oxy)-16-methyl-, (11.beta.,16.alpha.)- (9CI)


L7 ANSWER 17 OF 34 USPATFULL (Continued)
methoxyethoxy)carbonyloxy]-16-methyl-21-[(methylsulfonyl)oxy]-,
(11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140475-82-7 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-9-fluoro-11-hydroxy-17-[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-83-8 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140475-84-9 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-11-hydroxy-17-[(2-methoxyethoxy)carbonyl]oxy]-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-85-0 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140475-86-1 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-21-[(1-oxopentyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-87-2 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-21-[(methylsulfonyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140475-88-3 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-89-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140475-90-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 140475-91-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-6,9-difluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 34 USPATFULL (Continued)




L7 ANSWER 17 OF 34 USPATFULL (Continued)



RN 140475-92-9 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 21-[(2,2-dimethyl-1-oxopropoxy)-17-[[[(1-methylethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140475-93-0 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 21-[(2,2-dimethyl-1-oxopropoxy)-17-[[[(1-methylethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 18 OF 34 USPATFULL

93:12516 USPATFULL
 TITLE: Brain-specific drug delivery
 INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
 PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

NUMBER	KIND	DATE
5187158		19930216
1991-639283		19910110 (7)
PATENT INFORMATION: US 5187158		
APPLICATION INFO.: US 1991-639283		
RELATED APPLN. INFO.: Division of Ser. No. US 1989-295938, filed on 11 Jan 1989, now patented, Pat. No. US 5008257 which is a division of Ser. No. US 1984-665940, filed on 29 Oct 1984, now patented, Pat. No. US 4824850 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 And a continuation-in-part of Ser. No. US 1983-461543, filed on 27 Jan 1983, now abandoned And a continuation-in-part of Ser. No. US 1985-733463, filed on 13 May 1985, now patented, Pat. No. US 4727079 And a continuation-in-part of Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 And a continuation-in-part of Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564		

NUMBER	DATE
CA 1983-428192	19830516
PRIORITY INFORMATION:	
DOCUMENT TYPE: Utility	
FILE SEGMENT: Granted	
PRIMARY EXAMINER: Ivy, C. Warren	
ASSISTANT EXAMINER: Turnipseed, James H.	
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis	
NUMBER OF CLAIMS: 11	
EXEMPLARY CLAIM: 1	
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT: 6314	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are:

(a) compounds of the formula

[D-DHC]

(I)

wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier, with the proviso that when [DHC] is $\text{HSTR1}\text{H}$ wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and

(b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier. The

L7 ANSWER 18 OF 34 USPATFULL (Continued)
corresponding ionic pyridinium salt type drug/carrier entities
[D-OC].sup. + [D-sup. are also disclosed.


IT 82034-30-8P 82034-31-8P 82034-32-0P
82034-34-2P 82034-36-4P 82034-38-6P
82034-39-7P 82034-40-0P 82034-41-1P
82034-44-4P 82034-45-5P 82034-46-6P
82034-47-7P 82034-48-8P 82034-49-9P
82034-50-2P 82034-54-6P 82034-61-5P
82034-62-6P 82034-63-7P 82034-64-8P
82034-65-9P 82034-67-1P 82034-68-2P
82034-69-3P 82034-71-7P 82034-72-8P
82034-73-9P 82048-82-6P

(prepn. of)

RN 82034-30-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-31-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-32-0 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 18 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82034-39-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[[[(pentyloxy)carbonyl]oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-40-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-41-1 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 18 OF 34 USPATFULL (Continued)
Absolute stereochemistry.



RN 82034-34-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-36-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[[[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-38-6 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[[[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 18 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82034-44-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-45-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-46-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 18 OF 34 USPATFULL (Continued)



RN 82034-47-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-48-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-49-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

L7 ANSWER 18 OF 34 USPATFULL (Continued)

RN 82034-61-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, (1R)-1-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-62-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, (1S)-1-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-63-7 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3,11-dioxo-, chloromethyl ester, (16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 18 OF 34 USPATFULL (Continued)

(11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-50-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-54-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 18 OF 34 USPATFULL (Continued)

RN 82034-64-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-65-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyloxy)-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-67-1 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 18 OF 34 USPATFULL (Continued)



RN 82034-68-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-69-3 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 18 OF 34 USPATFULL (Continued)


RN 82034-73-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82048-82-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 18 OF 34 USPATFULL (Continued)




RN 82034-71-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-72-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 19 OF 34 USPATFULL

93:8311 USPATFULL
 TITLE: Bone acting agents
 INVENTOR(S): Saari, Walfred S., Lansdale, PA, United States
 Rodan, Gideon A., Bryn Mawr, PA, United States
 Fisher, Thorsten E., Lansdale, PA, United States
 Anderson, Paul S., Lansdale, PA, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5183815		19930202
APPLICATION INFO.:	US 1992-839741		19920219 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-644178, filed on 22 Jan 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Marr, Howard T.		
ASSISTANT EXAMINER:	Kestler, Kimberly J.		
LEGAL REPRESENTATIVE:	North, Robert J., Caruso, Charles M.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIMS:	1		
LINE COUNT:	713		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Described are new agents for treating bone disorders associated with a reduction in bone mass and abnormalities in bone resorption or bone formation including osteoporosis, Paget's disease, bone metastases and malignant hypercalcemia. The agents are hydroxyl containing steroidal hormones, having bone resorption antagonist or bone formation stimulatory activity, covalently linked through the hydroxyl group via a bond hydrolyzable in the human body, e.g. carbamate or carbonate, which is further covalently linked to an amino, or hydroxy substituted alkylidene-1,1-bisphosphonate, through the respective amino or hydroxy group. The alkyl bisphosphonate moiety confers bone affinity. The agent acts by delivering the steroidal hormone directly to the bone target site where it is released for bone resorption antagonist or bone formation stimulatory action by hydrolysis of the hydrolyzable covalent bond.

IT 73771-04-TDP, derivs. linked to bisphosphonate moieties (prepn. of, for treatment of bone disease)

RN 73771-04-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 19 OF 34 USPATFULL (Continued)

L7 ANSWER 20 OF 34 USPATFULL
 ACCESSION NUMBER: 92:10862 USPATFULL
 TITLE: Redox carriers for brain-specific drug delivery
 INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
 PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States
 (U.S. corporation)

NUMBER	KIND	DATE
US 5087618		19920211
US 1989-295663		19890111 (7)
APPLICATION INFO.: Division of Ser. No. US 1984-666210, filed on 29 Oct 1984, now patented, Pat. No. US 4829070 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 And a continuation-in-part of Ser. No. US 1983-461543, filed on 27 Jan 1983, now abandoned And a continuation-in-part of Ser. No. US 1985-733463, filed on 13 May 1985, now patented, Pat. No. US 4727079 And a continuation-in-part of Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 And a continuation-in-part of Ser. No. US 1983-516392, filed on 22 Jul 1983, now patented, Pat. No. US 4540564		

NUMBER	DATE
CA 1983-428192	19830516
PRIORITY INFORMATION:	
DOCUMENT TYPE: Utility	
FILE SEGMENT: Granted	
PRIMARY EXAMINER: Rollins, John W.	
ASSISTANT EXAMINER: Wilson, James O.	
LEGAL REPRESENTATIVE: Baumeister, Mary Katherine	
NUMBER OF CLAIMS: 50	
EXEMPLARY CLAIM: 27	
LINE COUNT: 2614	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

AB The invention provides compounds of the formula

D--DHC].sub.n (1)

and the nontoxic pharmaceutically acceptable salt thereof, wherein D is the residue of a centrally acting drug containing at least one reactive functional group selected from the group consisting of amino, hydroxyl, mercapto, carbonyl, amide and imide, said residue being characterized by the absence of a hydrogen atom from at least one of said reactive functional groups in said drug; n is a positive integer equal to the number of said functional groups from which a hydrogen atom is absent; and [DHC] is the reduced, biooxidizable, bloodbrain barrier penetrating lipoidal form of a dihydropyridine, revreaction-pyridinium salt redox carrier, said carrier comprising a bivalent radical of the formula ##STR1## wherein the alkylene group can be straight or branched and can contain 1 to 3 carbon atoms; R.sub.o is a radical identical to the corresponding portion of a natural amino acid; and p is 1 or 2, provided that, when p is 2, then the alkylene groups can be the same or different; and the R.sub.o radicals can be the same or different; said bivalent radical being so positioned that the terminal carbonyl function of the bivalent radical is linked to the drug residue while the terminal amino

L7 ANSWER 20 OF 34 USPATFULL (Continued)

function of the bivalent radical is linked to the remaining portion of the carrier moiety. The subject compounds are adapted for the site-specific/sustained delivery of centrally acting drugs to the brain. The corresponding pyridinium salt type drug/carrier entities D--QC.sup.+].sub.n qY.sup.-t are also disclosed.


IT 82034-30-8P 82034-31-9P 82034-32-0P

82034-34-2P 82034-36-4P 82034-38-6P
 82034-39-7P 82034-40-0P 82034-41-1P
 82034-44-4P 82034-45-5P 82034-46-6P
 82034-47-7P 82034-48-8P 82034-49-9P
 82034-50-2P 82034-54-6P 82034-61-5P
 82034-62-6P 82034-63-7P 82034-64-8P
 82034-65-9P 82034-67-1P 82034-68-2P
 82034-69-3P 82034-71-7P 82034-72-8P
 82034-73-9P 82048-82-6P

RN 82034-30-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-31-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-32-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 20 OF 34 USPATFULL (Continued)



RN 82034-34-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-36-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-38-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 20 OF 34 USPATFULL (Continued)



RN 82034-39-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyloxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-40-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-41-1 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyloxy)-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 20 OF 34 USPATFULL (Continued)

RN 82034-46-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-47-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-48-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-49-9 USPATFULL

L7 ANSWER 20 OF 34 USPATFULL (Continued)
INDEX NAME)


Absolute stereochemistry.



RN 82034-44-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-45-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 20 OF 34 USPATFULL (Continued)

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-50-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-54-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyloxy)-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 82034-61-5 USPATFULL


L7 ANSWER 20 OF 34 USPATFULL (Continued)
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
 [(1-methylethoxy)carbonyloxy]-3-oxo-, (1R)-1-chloroethyl ester,
 (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-62-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
 [(1-methylethoxy)carbonyloxy]-3-oxo-, (1S)-1-chloroethyl ester,
 (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-63-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3,11-dioxo-, chloromethyl ester,
 (16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 20 OF 34 USPATFULL (Continued)
 17-[(pentyloxy)carbonyloxy]-, chloromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-68-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyloxy)-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-69-3 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 20 OF 34 USPATFULL (Continued)




RN 82034-64-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-65-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-
 [(methoxycarbonyloxy)-16-methyl-3-oxo-, chloromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-67-1 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-

L7 ANSWER 20 OF 34 USPATFULL (Continued)




RN 82034-71-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-72-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-73-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 20 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82048-82-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyl]oxy-
9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester,
(11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 21 OF 34 USPATFULL

ACCESSION NUMBER: 91:30479 USPATFULL
 TITLE: Brain-specific drug delivery
 INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
 PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States
 (U.S. corporation)

NUMBER	KIND	DATE
US 5008257		19910416
US 1989-295938		19890111 (7)
Division of Ser. No. US 1984-665940, filed on 29 Oct 1984, now patented, Pat. No. US 4824850 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 Ser. No. Ser. No. US 1983-461543, filed on 27 Jan 1983, now abandoned Ser. No. Ser. No. US 1985-733463, filed on 13 May 1985, now patented, Pat. No. US 4622218 Ser. No. Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 And Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564		

NUMBER	DATE
CA-1983-428192	19830516
PRIORITY INFORMATION:	
DOCUMENT TYPE: Utility	
FILE SEGMENT: Granted	
PRIMARY EXAMINER: Scoll, Robert L.	
ASSISTANT EXAMINER: Covert, John M.	
LEGAL REPRESENTATIVE: Baumeister, Mary Katherine	
NUMBER OF CLAIMS: 28	
EXEMPLARY CLAIM: 1	
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT: 6383	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are:

(a) compounds of the formula.

[D-DHC]

(I)

wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine, pyridinium salt redox carrier, with the proviso that when [DHC] is #STR1# wherein R is a lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and

(b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of

L7 ANSWER 21 OF 34 USPATFULL (Continued)


a dihydropyridine, pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entities [D-QC].sup.+ X.sup.- are also disclosed.

IT 82034-30-8P 82034-31-9P 82034-32-0P
 82034-34-2P 82034-36-4P 82034-38-6P
 82034-39-7P 82034-40-0P 82034-41-1P
 82034-44-4P 82034-45-5P 82034-46-6P
 82034-47-7P 82034-48-8P 82034-49-9P
 82034-50-2P 82034-54-6P 82034-61-5P
 82034-62-6P 82034-63-7P 82034-64-8P
 82034-65-9P 82034-67-1P 82034-68-2P
 82034-69-3P 82034-71-7P 82034-72-8P
 82034-73-9P 82048-82-6P
 (prepn. of)

RN 82034-30-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-
11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 82034-31-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-
11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 82034-32-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 21 OF 34 USPATFULL (Continued)



RN 82034-34-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-36-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-
17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 82034-38-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 21 OF 34 USPATFULL (Continued)




RN 82034-39-7 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyl]oxy-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-40-0 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-41-1 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 21 OF 34 USPATFULL (Continued)


RN 82034-46-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-47-7 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-48-8 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-49-9 USPATFULL


L7 ANSWER 21 OF 34 USPATFULL (Continued)

Absolute stereochemistry.




RN 82034-44-4 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-45-5 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 21 OF 34 USPATFULL (Continued)


RN 82034-50-2 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-50-2 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-54-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 82034-61-5 USPATFULL


L7 ANSWER 21 OF 34 USPATFULL (Continued)
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
 [[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1R)-1-chloroethyl ester,
 (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-62-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
 [[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1S)-1-chloroethyl ester,
 (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-63-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[[(1-methylethoxy)carbonyl]oxy]-3,11-dioxo-, chloromethyl ester,
 (16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 21 OF 34 USPATFULL (Continued)
 17-[[(pentyloxy)carbonyl]oxy]-, chloromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-68-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-69-3 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 21 OF 34 USPATFULL (Continued)




RN 82034-64-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-65-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-
 [(methoxycarbonyl)oxy]-16-methyl-3-oxo-, chloromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-67-1 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-

L7 ANSWER 21 OF 34 USPATFULL (Continued)




RN 82034-71-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-72-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-73-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 21 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82048-82-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyloxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 22 OF 34 USPATFULL (Continued)

RN 82034-30-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-31-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-32-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-34-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-

L7 ANSWER 22 OF 34 USPATFULL

ACCESSION NUMBER: 91:17242 USPATFULL

TITLE: Soft steroids having anti-inflammatory activity
INVENTOR(S): Bodor, Nicholas S., 7211 SW. 97th La., Gainesville, FL, United States 32608
PATENT ASSIGNEE(S): Bodor, Nicholas S., Gainesville, FL, United States (U.S. individual)

NUMBER	KIND	DATE
US 4996335		19910226
US 1985-807034		19851209 (6)
PATENT INFORMATION: US 4996335 19910226		
APPLICATION INFO.: US 1985-807034 19851209 (6)		
RELATED APPLN. INFO.: Continuation of Ser. No. US 1984-626535, filed on 29 Jun 1984, now abandoned which is a continuation of Ser. No. US 1982-418458, filed on 15 Sep 1982, now abandoned which is a continuation-in-part of Ser. No. US 1981-265785, filed on 21 May 1981, now abandoned which is a continuation-in-part of Ser. No. US 1980-168453, filed on 10 Jul 1980, now abandoned		
DOCUMENT TYPE: Utility		
FILE SEGMENT: Granted		
PRIMARY EXAMINER: Friedman, Stanley J.		
ASSISTANT EXAMINER: Criares, Theodore J.		
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis		
NUMBER OF CLAIMS: 113		
EXEMPLARY CLAIM: 1		
LINE COUNT: 3465		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The invention provides novel soft steroidal anti-inflammatory agents, pharmaceutical compositions containing said agents, and methods of administering same to mammals in the treatment of inflammation. Preferred compounds of the invention include haloalkyl 17.alpha.-alkoxycarbonyloxy-11.beta.-hydroxyandrosta-4-en-3-one-17.beta.-carboxylates and the corresponding DELTA.sup.1,4 compounds, optionally bearing 6.alpha.- and/or 9.alpha.-fluorine and 16.alpha.- or 16.beta.-methyl substituents. Especially preferred compounds include haloalkyl 17.alpha.-alkoxycarbonyloxy-9.alpha.-fluoro-11.beta.-hydroxy-16-methylandrosta-1,4-dien-3-one-17.beta.-carboxylates.


IT 82034-30-8P 82034-31-9P 82034-32-0P
82034-34-2P 82034-36-4P 82034-38-6P
82034-39-7P 82034-40-0P 82034-41-1P
82034-44-4P 82034-46-6P 82034-47-7P
82034-48-8P 82034-49-9P 82034-50-2P
82034-54-6P 82034-61-5P 82034-62-6P
82034-63-7P 82034-64-8P 82034-65-9P
82034-67-1P 82034-68-2P 82034-69-3P
82034-71-7P 82034-73-9P 82034-73-9P
82048-82-6P 133991-63-6P 265651-67-0P
265651-69-2P 265651-70-5P 265651-72-7P
265651-73-8P 265651-74-9P 265651-75-0P
265651-76-1P 265651-77-2P 265651-78-3P
265651-79-4P 265651-81-8P 265651-82-9P
265651-83-0P 265651-84-1P 265651-85-2P
265651-86-3P 265651-87-4P 265651-88-5P
265651-89-6P 265651-90-9P 265651-91-0P
265651-92-1P 265652-01-9P

(prepn. of androstenone carboxylic acid derivs. with anti-inflammatory

L7 ANSWER 22 OF 34 USPATFULL (Continued)

[[[(1-methylethoxy)carbonyloxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-36-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyloxy)-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-38-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(ethoxycarbonyloxy)-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-39-7 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyloxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 34 USPATFULL (Continued)
Absolute stereochemistry.




RN 82034-40-0 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-41-1 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-44-4 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-

L7 ANSWER 22 OF 34 USPATFULL (Continued)


RN 82034-48-8 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-49-9 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-50-2 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 22 OF 34 USPATFULL (Continued)
11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-46-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-47-7 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[[[1-methylethoxy]carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 22 OF 34 USPATFULL (Continued)


RN 82034-54-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-61-5 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (1R)-1-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-62-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (1S)-1-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 22 OF 34 USPATFULL (Continued)




RN 82034-63-7 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[[1-methylethoxy]carbonyloxy]-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-64-8 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 22 OF 34 USPATFULL (Continued)




RN 82034-69-3 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-71-7 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 22 OF 34 USPATFULL (Continued)


RN 82034-65-9 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[[methoxycarbonyloxy]-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-67-1 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[[pentyloxy]carbonyloxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-68-2 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyloxy)-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 22 OF 34 USPATFULL (Continued)


RN 82034-72-8 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-73-9 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82048-82-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyloxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 22 OF 34 USPATFULL (Continued)
Absolute stereochemistry.



RN 265651-79-4 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 22 OF 34 USPATFULL (Continued)




RN 265651-82-9 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 265651-81-8 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 6,9-difluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265651-83-0 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 22 OF 34 USPATFULL (Continued)




RN 265651-84-1 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, 2-chloroethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 22 OF 34 USPATFULL (Continued)
17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-87-4 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 6-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-85-2 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-88-5 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-86-3 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 6-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(1-methylethoxy)carbonyl]oxy]-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 34 USPATFULL (Continued)




RN 265651-89-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(methoxycarbonyl)oxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-90-9 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 6-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 22 OF 34 USPATFULL (Continued)



IT 82034-45-5P
(prepn. of androstenone carboxylic acid derivs. with anti-inflammatory activity)

RN 82034-45-5 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 22 OF 34 USPATFULL (Continued)


RN 265651-91-0 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 265651-92-1 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 265652-05-9 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-3-oxo-, 1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 23 OF 34 USPATFULL

ACCESSION NUMBER: 90:11422 USPATFULL
TITLE: Brain-specific drug delivery of steroid sex hormones cleaved from pyridinium carboxylates and dihydro-pyridine carboxylate precursors
INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

NUMBER	KIND	DATE
US 4900837		19900213
US 1987-76191		19870721 (7)
20020910		
PATENT INFORMATION:	US 4900837	19900213
APPLICATION INFO.:	US 1987-76191	19870721 (7)
DISCLAIMER DATE:	20020910	
RELATED APPLN. INFO.:	Division of Ser. No. US 1984-665940, filed on 29 Oct 1984, now patented, Pat. No. US 4824850 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 And a continuation-in-part of Ser. No. US 1983-461543, filed on 27 Jun 1983 now abandoned And a continuation-in-part of Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 And a continuation-in-part of Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564	

NUMBER	DATE
JP 1982-101940	19820614
CA 1983-428192	19830516
IE 1983-1149	19830517
ZA 1983-3521	19830517
ES 1983-522489	19830517
IT 1983-48327	19830518

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan R.
LEGAL REPRESENTATIVE: Baumeister, Mary Katherine, Clarke, Dennis P.
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1, 27
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 6389

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are:

(a) compounds of the formula

[D--DHC]

(I)

wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine.reversion.pyridinium salt redox carrier, with the proviso that when [DHC] is ##STR1## wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH function group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and

(b) non-toxic pharmaceutically acceptable salts of compounds of formula

L7 ANSWER 23 OF 34 USPATFULL (Continued)


(1) wherein (D) is a centrally acting drug species and [DHC] is the reduced, bioreducible, blood-brain barrier penetrating lipoidal form of a dihydropyridine, pyridinium salt type drug/carrier entities [D-OC].sup.+ X.sup.- are also disclosed.

IT 82034-30-8P 82034-31-9P 82034-32-0P
82034-34-2P 82034-36-4P 82034-38-6P
82034-39-7P 82034-40-0P 82034-41-1P
82034-44-4P 82034-45-5P 82034-46-6P
82034-47-7P 82034-48-8P 82034-49-9P
82034-50-2P 82034-54-6P 82034-61-5P
82034-62-6P 82034-63-7P 82034-64-8P
82034-65-9P 82034-67-1P 82034-68-2P
82034-69-3P 82034-71-7P 82034-72-8P
82034-73-9P 82048-82-6P

RN 82034-30-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-31-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-32-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-

L7 ANSWER 23 OF 34 USPATFULL (Continued)

[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-34-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-36-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-38-6 USPATFULL

L7 ANSWER 23 OF 34 USPATFULL (Continued)

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-39-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyl]oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-40-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-41-1 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-

L7 ANSWER 23 OF 34 USPATFULL (Continued)

17-[(phenoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-44-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-45-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-46-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82034-47-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 82034-48-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 23 OF 34 USPATFULL (Continued)



RN 82034-61-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, (1R)-1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-62-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, (1S)-1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 23 OF 34 USPATFULL (Continued)

RN 82034-49-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-50-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-54-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyloxy)-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 23 OF 34 USPATFULL (Continued)



RN 82034-63-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-64-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-65-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyloxy)-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82034-67-1 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyloxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-68-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyloxy)-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 23 OF 34 USPATFULL (Continued)



RN 82034-69-3 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-71-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 23 OF 34 USPATFULL (Continued)



RN 82034-72-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-73-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82048-82-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyloxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 34 USPATFULL (Continued)

Absolute stereochemistry.



L7 ANSWER 24 OF 34 USPATFULL
 ACCESSION NUMBER: 89:92627 USPATFULL
 TITLE: Brain-specific drug delivery
 INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
 PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States
 (U.S. corporation)

NUMBER	KIND	DATE
US 4880921		19891114
US 1987-75830		19870720 (7)
20020910		

RELATIONSHIP INFO.: Division of Ser. No. US 1984-665940, filed on 29 Oct 1984, now patented, Pat. No. US 4824850 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932 And a continuation-in-part of Ser. No. US 1983-461543, filed on 27 Jan 1983, now abandoned And a continuation-in-part of Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 And a continuation-in-part of Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564

NUMBER	DATE
JP 1982-101940	19820614
CA 1983-428192	19830516
IE 1983-1149	19830517
ZA 1983-3521	19830517
ES 1983-522489	19830517
IT 1983-48327	19830518

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Robinson, Douglas W.
 ASSISTANT EXAMINER: Lipovsky, Joseph A.
 LEGAL REPRESENTATIVE: Baumeister, Mary Katherine, Clarke, Dennis P.
 NUMBER OF CLAIMS: 54
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
 LINE COUNT: 6386
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are:

(a) compounds of the formula

[D--DHC]


(1)

wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier, with the proviso that when [DHC] is ~~##STR1##~~ wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain

L7 ANSWER 24 OF 34 USPATFULL (Continued)


RN 82034-32-0 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-34-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-36-4 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyloxy)-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-38-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-


L7 ANSWER 24 OF 34 USPATFULL (Continued)
 alkanol; and

(b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entities [D--QC].sup.+ X.sup.- are also disclosed.

IT 82034-30-8P 82034-31-9P 82034-32-0P
 82034-34-2P 82034-36-4P 82034-38-6P
 82034-39-7P 82034-40-0P 82034-41-1P
 82034-44-4P 82034-45-5P 82034-46-5P
 82034-47-7P 82034-48-8P 82034-49-9P
 82034-50-2P 82034-54-6P 82034-61-5P
 82034-62-6P 82034-63-7P 82034-64-8P
 82034-65-9P 82034-67-1P 82034-68-2P
 82034-69-3P 82034-71-7P 82034-72-8P
 82034-73-9P 82040-82-6P

(prepn. of)
 RN 82034-30-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-31-9 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 24 OF 34 USPATFULL (Continued)
 [(methoxycarbonyloxy)-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-39-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyl-oxycarbonyloxy)-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-40-0 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-41-1 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyloxy)-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


L7 ANSWER 24 OF 34 USPATFULL (Continued)
INDEX NAME)

Absolute stereochemistry.




RN 82034-44-4 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-45-5 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 24 OF 34 USPATFULL (Continued)




RN 82034-49-9 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-50-2 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-54-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 24 OF 34 USPATFULL (Continued)
RN 82034-46-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-47-7 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-48-8 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L7 ANSWER 24 OF 34 USPATFULL (Continued)



RN 82034-61-5 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1R)-1-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-62-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1S)-1-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 24 OF 34 USPTAFULL (Continued)




RN 82034-63-7 USPTAFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-64-8 USPTAFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 24 OF 34 USPTAFULL (Continued)




RN 82034-69-3 USPTAFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-71-7 USPTAFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 24 OF 34 USPTAFULL (Continued)

RN 82034-65-9 USPTAFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyloxy)-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-67-1 USPTAFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyloxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-68-2 USPTAFULL

CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 24 OF 34 USPTAFULL (Continued)

RN 82034-72-8 USPTAFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-73-9 USPTAFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82048-82-6 USPTAFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyloxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 24 OF 34 USPATFULL (Continued)

L7 ANSWER 25 OF 34 USPATFULL

ACCESSION NUMBER: 89:92522 USPATFULL
 TITLE: Brain-specific delivery of dopamine utilizing dihydropyridine/pyridinium salt-type redox carriers
 INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
 PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

NUMBER	KIND	DATE
US 4880816		19891114
US 1987-116583		19871104 (7)
20020910		

PATENT INFORMATION: Division of Ser. No. US 1985-733463, filed on 13 May 1985, now patented, Pat. No. US 4727079 which is a continuation-in-part of Ser. No. US 1984-665940, filed on 29 Oct 1984 Ser. No. US 1983-516382, filed on 22 Jul 1983, now patented, Pat. No. US 4540564 And Ser. No. US 1983-461543, filed on 27 Jan 1983 which is a continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932, said Ser. No. 665940 And Ser. No. 516382, each which is a continuation-in-part of Ser. No. US 1983-475493, filed on 15 Mar 1983, now patented, Pat. No. US 4622218 Ser. No. 461543 And Ser. No. 379316, said Ser. No. 665940 which is a continuation-in-part of Ser. No. 516382

NUMBER	DATE
CA 1983-428192	19830516

PRIORITY INFORMATION: CA 1983-428192 19830516
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Rotman, Alan L.
 LEGAL REPRESENTATIVE: Baumeister, Mary Katherine, Clarke, Dennis P.
 NUMBER OF CLAIMS: 21
 EXEMPLARY CLAIM: 1, 18
 NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
 LINE COUNT: 2099

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A brain-specific dopaminergic response is elicited in a patient in need of such treatment, e.g., a patient afflicted with Parkinson's disease of hyperprolactinemia, by administering thereto a therapeutically effective amount of preferably catechol protected dopamine tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.reyeaction.pyridinium salt type redox carrier, e.g., 1,4-dihydrotrigonelline. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type dopamine/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained brain-specific dopaminergic activity.

IT 82034-30-8P 82034-31-9P 82034-32-0P
 82034-34-2P 82034-36-4P 82034-38-6P
 82034-39-7P 82034-40-0P 82034-41-1P
 82034-44-4P 82034-45-5P 82034-46-6P
 82034-47-7P 82034-48-8P 82034-49-9P

L7 ANSWER 25 OF 34 USPATFULL (Continued)


82034-50-2P 82034-54-6P 82034-61-5P
 82034-62-6P 82034-63-7P 82034-64-8P
 82034-65-9P 82034-67-1P 82034-68-2P
 82034-69-3P 82034-71-7P 82034-72-8P
 82034-73-9P 82048-82-6P

(prepn. of)

RN 82034-30-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-31-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-32-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 25 OF 34 USPATFULL (Continued)



RN 82034-34-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-36-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 82034-38-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 25 OF 34 USPATFULL (Continued)




RN 82034-39-7 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyloxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-40-0 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-41-1 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyloxy)-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 25 OF 34 USPATFULL (Continued)


RN 82034-46-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-47-7 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[[1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-48-8 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-49-9 USPATFULL


L7 ANSWER 25 OF 34 USPATFULL (Continued)
INDEX NAME)

Absolute stereochemistry.




RN 82034-44-4 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-45-5 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 25 OF 34 USPATFULL (Continued)


RN 82034-50-2 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-50-2 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-54-6 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[[propoxycarbonyloxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-61-5 USPATFULL


L7 ANSWER 25 OF 34 USPATFULL (Continued)
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
 [(1-methylethoxy)carbonyloxy]-3-oxo-, (1R)-1-chloroethyl ester,
 (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-62-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
 [(1-methylethoxy)carbonyloxy]-3-oxo-, (1S)-1-chloroethyl ester,
 (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-63-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3,11-dioxo-, chloromethyl ester,
 (16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-68-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyloxy)]-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-69-3 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 25 OF 34 USPATFULL (Continued)




RN 82034-64-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)]-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-65-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyloxy)]-16-methyl-3-oxo-, chloromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-67-1 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-

L7 ANSWER 25 OF 34 USPATFULL (Continued)




RN 82034-71-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-72-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-73-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 25 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82048-82-6 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyl]oxy-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 26 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82034-31-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-32-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-34-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 26 OF 34 USPATFULL

ACCESSION NUMBER: 86:63379 USPATFULL

TITLE: Testicular-specific drug delivery

INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States

PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4622218		19861111
APPLICATION INFO.:	US 1983-475493		19830315 (6)
DISCLAIMER DATE:	20011030		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4479932		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1982-101940	19820614
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wiseman, Thomas G.	
ASSISTANT EXAMINER:	Teskin, Robin Lyn	
LEGAL REPRESENTATIVE:	Kerkam, Stowell, Kondracki & Clarke	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	969	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Testicular acting drug species are site-specifically/sustainedly delivered to the testes by administering to a male in need of such treatment a pharmacologically effective amount of the target drug species [D] tethered to a reduced, blood-testis barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.reversion.pyridinium salt type redox carrier, e.g. 1,4-dihydropyridine. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type drug/carrier entity [D-QC].sup.+ prevents elimination thereof from the testes, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained testicular-specific drug activity, whether ascribable to the cleavage of the [D-QC].sup.+ entity and sustained release of the drug [D] in the testes and/or to [D-QC].sup.+ itself.

IT 82034-30-8P 82034-31-9P 82034-32-0P

82034-34-2P 82034-36-4P 82034-38-6P

82034-39-7P 82034-40-0P 82034-41-1P

82034-44-4P 82034-45-5P 82034-46-6P

82034-47-7P 82034-48-8P 82034-49-9P

82034-50-2P 82034-54-6P 82034-51-3P

82034-52-6P 82034-63-7P 82034-64-8P

82034-65-9P 82034-67-1P 82034-68-2P

82034-69-3P 82034-71-7P 82034-72-8P


82034-73-9P 82048-82-6P

(prepn. of)

RN 82034-30-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


L7 ANSWER 26 OF 34 USPATFULL (Continued)



RN 82034-36-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-38-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-39-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyl]oxy-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 26 OF 34 USPATFULL (Continued)



RN 82034-40-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-41-1 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-44-4 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester.

L7 ANSWER 26 OF 34 USPATFULL (Continued)

RN 82034-47-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[[[1-methylethoxy]carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-48-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-49-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 26 OF 34 USPATFULL (Continued)

(11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-45-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-46-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 26 OF 34 USPATFULL (Continued)

RN 82034-50-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-54-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[[[1-methylethoxy]carbonyl]oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 82034-61-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (1R)-1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 26 OF 34 USPATFULL (Continued)





RN 82034-63-7 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 26 OF 34 USPATFULL (Continued)
17-[[[(pentyloxy)carbonyl]oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 82034-69-3 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 26 OF 34 USPATFULL (Continued)




RN 82034-65-9 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[[methoxycarbonyl]oxy]-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-67-1 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-

L7 ANSWER 26 OF 34 USPATFULL (Continued)




RN 82034-71-7 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-72-8 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-73-9 USPATFULL
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 26 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82048-82-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyloxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 27 OF 34 USPATFULL (Continued)

RN 98008-79-8 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 21-chloro-17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 98008-83-4 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 21-chloro-6-fluoro-11-hydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 98008-87-8 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 21-chloro-9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 27 OF 34 USPATFULL

ACCESSION NUMBER: 86:41127 USPATFULL

TITLE: Corticoid derivatives and process for production thereof

INVENTOR(S): Nitta, Issei, Machida, Japan
 Maruyama, Akira, Yokohama, Japan
 Nakao, Kenichiro, Tokyo, Japan
 Miyake, Motoyoshi, Tokyo, Japan
 Ueno, Hiroaki, Yokohama, Japan

PATENT ASSIGNEE(S): Mitsubishi Chemical Industries, Ltd., Tokyo, Japan
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4602009		19860722
APPLICATION INFO.:	US 1984-645100		19840828 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1984-120439	19840612
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Obion, Fisher, Spivak, McClelland & Maier	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1,14	
LINE COUNT:	823	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel corticoid 17.alpha.-alkoxycarbonyl carboxylate derivatives are disclosed. These derivatives have strong topical anti-inflammatory activity and extremely weak systemic adverse reactions and are useful for the treatment of acute and chronic eczema, eczema seborrhoicum, contact dermatitis, atopic dermatitis, asthma, etc.


IT 98008-75-4P 98008-79-8P 98008-83-4P

98008-87-8P 98008-91-4P
 (prepn. and antiinflammatory activity of)

RN 98008-75-4 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 21-chloro-9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 27 OF 34 USPATFULL (Continued)

RN 98008-91-4 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 21-chloro-9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 98008-74-3P 98008-78-7P 98008-82-3P

98008-86-7P 98040-70-1P


(prepn. and chlorination of)

RN 98008-74-3 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-21-[(trifluoromethyl)sulfonyl]oxy-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 27 OF 34 USPATFULL (Continued)



RN 98008-78-7 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[[trifluoromethyl)sulfonyl]oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 27 OF 34 USPATFULL (Continued)




RN 98008-86-7 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-21-[[trifluoromethyl)sulfonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 98008-82-3 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11-hydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-21-[[trifluoromethyl)sulfonyl]oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 98040-70-1 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-21-[[trifluoromethyl)sulfonyl]oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 27 OF 34 USPATFULL (Continued)




IT 98008-73-2P 98008-77-6P 98008-81-2P
 98008-85-6P
 (prepn. and trifluoromethylsulfonylation of)
 RN 98008-73-2 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11,21-dihydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 98008-77-6 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 27 OF 34 USPATFULL (Continued)


RN 98008-81-2 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 98008-85-6 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11,21-dihydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 98008-90-3
 (trifluoromethylsulfonylation of)
 RN 98008-90-3 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11,21-dihydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 27 OF 34 USPATFULL (Continued)



L7 ANSWER 28 OF 34 USPATFULL

ACCESSION NUMBER: 86:25007 USPATFULL
 TITLE: 6-oxygenated corticoid 17.alpha.-carbonates and process for production thereof
 INVENTOR(S): Nitta, Issei, Machida, Japan
 Nakao, Kenichiro, Tokyo, Japan
 Miyake, Motoyoshi, Tokyo, Japan
 Maruyama, Akira, Yokohama, Japan
 Takashima, Junko, Kawasaki, Japan
 PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4585766		19860429
APPLICATION INFO.:	US 1984-645099		19840828 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1983-164772	19830907
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Obion, Fisher, Spivak, McClelland & Maier	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1,11	
LINE COUNT:	644	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel 6-oxygenated corticoid 17.alpha.-carbonates are disclosed. These compounds have strong topical anti-inflammatory activity which are accompanied by extremely weak systemic adverse reaction. The present compounds are useful for the treatment of acute and chronic eczema, eczema seborrhoicorum, contact dermatitis, atopic dermatitis, asthma, etc.

IT 98008-75-4P 98008-79-8P 98008-83-4P
 98008-87-8P 98008-91-4P


(prepn. and antiinflammatory activity of)

RN 98008-75-4 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 21-chloro-9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 28 OF 34 USPATFULL (Continued)



RN 98008-79-8 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 21-chloro-17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 98008-83-4 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 21-chloro-6-fluoro-11-hydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 98008-87-8 USPATFULL

L7 ANSWER 28 OF 34 USPATFULL (Continued)

CN Pregna-1,4-diene-3,6,20-trione, 21-chloro-9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 98008-91-4 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 21-chloro-9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 98008-74-3P 98008-78-7P 98008-82-3P

98008-86-7P 98040-70-1P


(prepn. and chlorination of)

RN 98008-74-3 USPATFULL

CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-21-[[[trifluoromethyl]sulfonyl]oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 28 OF 34 USPATFULL (Continued)



RN 98008-78-7 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[[[(trifluoromethyl)sulfonyl]oxy]-, (11.beta.,16.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 28 OF 34 USPATFULL (Continued)




RN 98008-86-7 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-21-[[[(trifluoromethyl)sulfonyl]oxy]-, (11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 98008-82-3 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11-hydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-21-[[[(trifluoromethyl)sulfonyl]oxy]-, (11.beta.,16.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 98040-70-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-21-[[[(trifluoromethyl)sulfonyl]oxy]-, (11.beta.,16.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 28 OF 34 USPATFULL (Continued)




IT 98008-73-2P 98008-77-6P 98008-81-2P
 98008-85-6P
 (prepn. and trifluoromethylsulfonylation of)
 RN 98008-73-2 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11,21-dihydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 98008-77-6 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 28 OF 34 USPATFULL (Continued)


RN 98008-81-2 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 98008-85-6 USPATFULL
 CN Pregna-1,4-diene-3,6,20-trione, 9-fluoro-11,21-dihydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 98008-90-3
 (trifluoromethylsulfonylation of)
 RN 98008-90-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 28 OF 34 USPATFULL (Continued)



L7 ANSWER 29 OF 34 USPATFULL

85:53658 USPATFULL
 TITLE: Brain-specific drug delivery
 INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States
 PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States
 (U.S. corporation)

NUMBER	KIND	DATE
US 4540564		19850910
US 1983-516382		19830722 (6)
APPLICATION INFO.: Continuation-in-part of Ser. No. US 1982-379316, filed on 18 May 1982, now patented, Pat. No. US 4478932 Ser. No. Ser. No. US 1983-461543, filed on 27 Jan 1983 And Ser. No. US 1983-475493, filed on 15 Mar 1983, said Ser. No. 461543 And Ser. No. 475493, each which is a continuation-in-part of Ser. No. 379316		

NUMBER	DATE
WO 1983-40725	19830512
CA 1983-428192	19830516
DOCUMENT TYPE: Utility	
FILE SEGMENT: Granted	
PRIMARY EXAMINER: Nucker, Christine M.	
LEGAL REPRESENTATIVE: Clarke, Dennis P.	
NUMBER OF CLAIMS: 86	
EXEMPLARY CLAIM: 1, 12	
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT: 4240	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are:

(a) compounds of the formula

[D-DHC] (I)

wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier, with the proviso that when [DHC] is ~~##STR1##~~ wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alcohol; and

(b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entities [D-OC].sup.+ Y.sup.- are also disclosed.


IT 82034-30-8P 82034-31-8P 82034-32-8P
 82034-34-2P 82034-36-4P 82034-38-6P

L7 ANSWER 29 OF 34 USPATFULL (Continued)

82034-39-7P 82034-40-8P 82034-41-1P
 82034-44-4P 82034-45-5P 82034-46-6P
 82034-47-7P 82034-48-8P 82034-49-9P
 82034-50-2P 82034-54-6P 82034-61-5P
 82034-62-6P 82034-63-7P 82034-64-8P
 82034-65-9P 82034-67-1P 82034-68-2P
 82034-69-3P 82034-71-7P 82034-72-8P
 82034-73-9P 82048-82-6P
 (prepn. of)


RN 82034-30-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-31-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-32-0 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 29 OF 34 USPATFULL (Continued)




RN 82034-34-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-36-4 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-38-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 29 OF 34 USPATFULL (Continued)



RN 82034-39-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyloxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-40-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-41-1 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyloxy)-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 29 OF 34 USPATFULL (Continued)

RN 82034-46-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-47-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-48-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-49-9 USPATFULL

L7 ANSWER 29 OF 34 USPATFULL (Continued)
INDEX NAME)


Absolute stereochemistry.



RN 82034-44-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-45-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 29 OF 34 USPATFULL (Continued)

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-50-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyloxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-54-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyloxy)-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 82034-61-5 USPATFULL


L7 ANSWER 29 OF 34 USPATFULL (Continued)
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
 [[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1R)-1-chloroethyl ester,
 (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-62-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-
 [[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1S)-1-chloroethyl ester,
 (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-63-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3,11-dioxo-, chloromethyl ester,
 (16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 29 OF 34 USPATFULL (Continued)
 17-[[[(pentylthoxy)carbonyl]oxy]-, chloromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-68-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-69-3 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 29 OF 34 USPATFULL (Continued)




RN 82034-64-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-65-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-
 [(methoxycarbonyl)oxy]-16-methyl-3-oxo-, chloromethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-67-1 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-

L7 ANSWER 29 OF 34 USPATFULL (Continued)




RN 82034-71-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester,
 (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-72-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester,
 (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-73-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 29 OF 34 USPATFULL (Continued)


Absolute stereochemistry.




RN 82048-82-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 30 OF 34 USPATFULL (Continued)



RN 82034-31-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-32-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-34-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 30 OF 34 USPATFULL

ACCESSION NUMBER: 84:60884 USPATFULL

TITLE: Brain-specific drug delivery

INVENTOR(S): Bodor, Nicholas S., Gainesville, FL, United States

PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4479932		19841030
APPLICATION INFO.:	US 1982-379316		19820518 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nucker, Christine M.		
LEGAL REPRESENTATIVE:	Clarke, Dennis P.		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	8,23		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1732		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Centrally acting drug species are site-specifically/sustainedly delivered to the brain by administering to a patient in need of such treatment a therapeutically effective amount of the target drug species [D] tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.reveaction.pyridinium salt type redox carrier. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type drug/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, and subsequent cleavage of the quaternary carrier/drug species results in sustained delivery of the drug [D] in the brain and facile elimination of the carrier moiety [QC].sup.+.

IT 82034-30-8P 82034-31-9P 82034-32-0P

82034-34-2P 82034-36-4P 82034-38-6P

82034-39-7P 82034-40-0P 82034-41-1P

82034-44-4P 82034-45-5P 82034-46-6P

82034-47-7P 82034-48-8P 82034-49-9P

82034-50-2P 82034-54-6P 82034-61-5P

82034-62-6P 82034-63-7P 82034-64-8P

82034-65-9P 82034-67-1P 82034-68-2P

82034-69-3P 82034-71-7P 82034-72-8P

82034-73-9P 82048-82-6P


(prepn. of)

RN 82034-30-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 30 OF 34 USPATFULL (Continued)



RN 82034-36-4 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-38-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-39-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(pentyloxy)carbonyl]oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 30 OF 34 USPATFULL (Continued)



RN 82034-40-0 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-41-1 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-44-4 USPATFULL


CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester.

L7 ANSWER 30 OF 34 USPATFULL (Continued)

RN 82034-47-7 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-48-8 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-49-9 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 30 OF 34 USPATFULL (Continued)

(11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-45-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-46-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 30 OF 34 USPATFULL (Continued)

RN 82034-50-2 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-54-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-61-5 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1R)-1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 30 OF 34 USPATFULL (Continued)



RN 82034-62-6 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-3,11-dioxo-, (15)-1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-63-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-3,11-dioxo-, chloromethyl ester, (16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 30 OF 34 USPATFULL (Continued)
 17-[[[pentyloxy]carbonyl]oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-68-2 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[[[ethoxycarbonyl]oxy]-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-69-3 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[[[ethoxycarbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 30 OF 34 USPATFULL (Continued)




RN 82034-64-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[[[ethoxycarbonyl]oxy]-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-65-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[[[methoxycarbonyl]oxy]-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-67-1 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-

L7 ANSWER 30 OF 34 USPATFULL (Continued)




RN 82034-71-7 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[[[ethoxycarbonyl]oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-72-8 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[[[ethoxycarbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-73-9 USPATFULL
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[[[ethoxycarbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 30 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 82048-82-6 USPATFULL

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyloxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 31 OF 34 USPATFULL (Continued)

IT 70283-37-3P 73291-81-3P 73291-82-4P

73291-83-5P 73291-84-6P 73291-85-7P

73291-86-8P 73291-87-9P 73291-88-0P

73291-89-1P 73291-90-4P 73291-91-5P

73291-92-6P 73291-93-7P 73291-94-8P

73291-95-9P 73291-96-0P 73291-97-1P

73291-98-2P 73291-99-3P 73292-00-9P

73292-01-0P 73292-02-1P 73292-03-2P

73292-04-3P 73292-05-4P 73292-06-5P

73292-07-6P 73292-08-7P 73292-09-8P

73292-10-1P 73292-11-2P 73292-12-3P

73292-13-4P 73292-14-5P 73292-15-6P


73292-16-7P 73292-17-8P 73292-18-9P

73292-19-0P (preph. of)

RN 70283-37-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyloxy)-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73291-81-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-chloro-17-[(ethoxycarbonyloxy)-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73291-82-4 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-bromo-17-[(ethoxycarbonyloxy)-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 34 USPATFULL

ACCESSION NUMBER: 83:11243 USPATFULL

TITLE: Corticoid-17-(alkyl carbonates) and process for their manufacture

INVENTOR(S): Stache, Ulrich, Hofheim am Taunus, Germany, Federal Republic of
Fritsch, Werner, Bad Soden am Taunus, Germany, Federal Republic of
Alpermann, Hans G., Konigstein, Germany, Federal Republic of
Sandow, Jurgen K., Konigstein, Germany, Federal Republic of
Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

PATENT ASSIGNEE(S):

NUMBER	KIND	DATE
US 4377575		198030322
US 1980-216258		19801215 (6)
Continuation of Ser. No. US 1979-31845, filed on 20 Apr 1979, now abandoned		

NUMBER	DATE
DE 1978-2817988	19780425

PRIORITY INFORMATION: DE 1978-2817988 19780425

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Roberts, Elbert L.

LEGAL REPRESENTATIVE: Curtis, Morris & Safford

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1,12

LINE COUNT: 982

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB What is disclosed are steroid-21-halogeno-17-(alkyl carbonates), useful as medicaments for the treatment of inflammatory dermatoses, and a method for making them.


IT 73292-19-0

(chlorination of)


RN 73292-19-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 31 OF 34 USPATFULL (Continued)



RN 73291-83-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-iodo-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73291-84-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-21-fluoro-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 73291-85-7 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyloxy]-17-[(ethoxycarbonyloxy)-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 34 USPATFULL (Continued)




RN 73291-86-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-chloro-11-hydroxy-17-
 [(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73291-87-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-bromo-11-hydroxy-17-[(propoxycarbonyl)oxy]-
 , (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 73291-88-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-fluoro-11-hydroxy-17-
 [(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 34 USPATFULL (Continued)


CN Pregna-1,4-diene-3,20-dione, 21-bromo-17-[(butoxycarbonyl)oxy]-11-hydroxy-
 , (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 73291-92-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-11-hydroxy-21-iodo-,
 (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73291-93-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-21-fluoro-11-hydroxy-
 , (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73291-94-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-11-hydroxy-,
 (11.beta.)- (9CI) (CA INDEX NAME)


L7 ANSWER 31 OF 34 USPATFULL (Continued)

Absolute stereochemistry.




RN 73291-89-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-11-hydroxy-
 17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73291-90-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-21-chloro-11-hydroxy-
 , (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73291-91-5 USPATFULL


L7 ANSWER 31 OF 34 USPATFULL (Continued)

Absolute stereochemistry.




RN 73291-95-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-bromo-11-hydroxy-17-
 [(pentyloxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73291-96-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-iodo-17-
 [(pentyloxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73291-97-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-fluoro-11-hydroxy-17-
 [(pentyloxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 31 OF 34 USPATFULL (Continued)




RN 73291-98-2 USPATFULL.
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(4-methylphenyl)sulfonyl]oxy-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 73291-99-3 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-bromo-17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 73292-00-9 USPATFULL

L7 ANSWER 31 OF 34 USPATFULL (Continued)




RN 73292-03-2 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11-hydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73292-04-3 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-21-[(methylsulfonyl)oxy]-17-[(propoxycarbonyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 73292-05-4 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-chloro-11-hydroxy-6-methyl-17-[(propoxycarbonyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 34 USPATFULL (Continued)


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-21-iodo-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73292-01-0 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 73292-02-1 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-21-[(methylsulfonyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 31 OF 34 USPATFULL (Continued)

Absolute stereochemistry.




RN 73292-06-5 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-chloro-11-hydroxy-16-methyl-21-[(methylsulfonyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73292-07-6 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-chloro-11,21-dihydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73292-08-7 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 21-chloro-11-hydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 31 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 73292-09-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-bromo-17-[(butoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73292-10-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-9-fluoro-11-hydroxy-21-iodo-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73292-11-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-21-chloro-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


L7 ANSWER 31 OF 34 USPATFULL (Continued)



RN 73292-14-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-21-iodo-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73292-15-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73292-16-7 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9,21-difluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 34 USPATFULL (Continued)

11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73292-12-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-17-[(pentyloxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 73292-13-4 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-bromo-9-fluoro-11-hydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 31 OF 34 USPATFULL (Continued)



RN 73292-17-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-chloro-17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 73292-18-9 USPATFULL

CN Pregna-1,4-diene-3,11,20-trione, 21-chloro-17-[(ethoxycarbonyl)oxy]-9-fluoro-16-methyl-, (16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 73297-52-6 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-iodo-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 34 USPATFULL (Continued)



L7 ANSWER 32 OF 34 USPATFULL

ACCESSION NUMBER: 80:65788 USPATFULL

TITLE: Corticoid 17-(alkyl carbonates) and processes for their preparation

INVENTOR(S): Stache, Ulrich, Hofheim am Taunus, Germany, Federal Republic of
Fritsch, Werner, Bad Soden am Taunus, Germany, Federal Republic of
Alpermann, Hans G., Königstein all of, Germany, Federal Republic of
Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4242334		19801230
APPLICATION INFO.:	US 1978-930194		19780802 (S)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1977-2735110	19770804
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Curtis, Morris & Safford	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1, 14	
LINE COUNT:	3731	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB What is disclosed is corticoid 17-(alkyl carbonates) of the formula ##STR1## as defined in the specification, which compounds can be used in veterinary therapy and human therapy, in the form of suspensions, ointments, creams, sprays and the like, for the treatment of inflammatory dermatoses of very diverse cause.


IT 70283-35-1

(acylation of, by Me chloroformate)

RN 70283-35-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 70283-58-8P


(prepn. and acylation by propanoyl chloride)

L7 ANSWER 32 OF 34 USPATFULL (Continued)

RN 70283-58-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6-fluoro-11,21-dihydroxy-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 70283-33-9P

(prepn. and acylation of)

RN 70283-33-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 70283-61-3P


(prepn. and acylation of, by Me chloroformate)

RN 70283-61-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11,21-dihydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)




IT 70283-40-8P

(prepn. and oxidn. of)

RN 70283-40-8 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17,21-bis[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 70283-60-2P


(prepn. and reaction of, with morpholine)

RN 70283-60-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(chloroacetyl)oxy]-17-[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)




IT 70283-33-9P

(prepn. and reactions of)

RN 70283-33-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 70283-34-0P 70283-35-1P 70283-37-3P

70283-39-5P 70283-41-9P 70283-42-0P

70283-43-1P 70283-44-2P 70283-45-3P

70283-46-4P 70283-47-5P 70283-48-6P

70283-49-7P 70283-50-0P 70283-51-1P

70283-52-2P 70283-53-3P 70283-54-4P

70283-55-5P 70283-56-6P 70283-59-9P

70283-62-4P 70283-63-5P 70283-64-6P

70283-65-7P 70283-66-8P 70283-67-9P

70283-70-4P 70283-71-5P 70292-88-5P

(prepn. of)


RN 70283-34-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-17-[[methoxycarbonyl]oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)


Absolute stereochemistry.



RN 70283-41-9 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-21-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 70283-42-0 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 32 OF 34 USPATFULL (Continued)



RN 70283-35-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70283-37-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70283-39-5 USPATFULL


CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[[pentyloxy]carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

L7 ANSWER 32 OF 34 USPATFULL (Continued)

RN 70283-43-1 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 21-[(butoxycarbonyl)oxy]-17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70283-44-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 70283-45-3 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(methylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)



RN 70283-46-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropyloxy)carbonyl]oxy]-17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70283-47-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-(1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)




RN 70283-50-0 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(1-oxopentyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 70283-51-1 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 32 OF 34 USPATFULL (Continued)



RN 70283-48-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 70283-49-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-(1-oxobutoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)


RN 70283-52-2 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17,21-bis[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70283-53-3 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70283-54-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-21-[(methylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)



RN 70283-55-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopentylcarbonyl)oxy]-9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70283-56-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-21-(1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)



RN 70283-59-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-21-(1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70283-62-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17,21-bis[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)



RN 70283-63-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(methoxycarbonyl)oxy]-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70283-64-6 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-21-(1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)



RN 70283-65-7 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70283-66-8 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-21-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)



RN 70283-67-9 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopentylcarbonyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 70283-70-4 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 21-[(chloroacetyl)oxy]-17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 32 OF 34 USPATFULL (Continued)




● HCl

L7 ANSWER 32 OF 34 USPATFULL (Continued)



RN 70283-71-5 USPATFULL
 CN Pregna-1,4-diene-3,11,20-trione, 17,21-bis[(ethoxycarbonyl)oxy]-9-fluoro-16-methyl-, (16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 70292-88-5 USPATFULL
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-21-[(4-morpholinylacetyl)oxy]-, hydrochloride, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 33 OF 34 USPATFULL

ACCESSION NUMBER: 80:55196 USPATFULL
 TITLE: Novel .DELTA..sup.4 -androstenes
 INVENTOR(S): Teutsch, Jean G., Pantin, France
 Deraedt, Roger, Les Pavillons-sous-Bois, France
 PATENT ASSIGNEE(S): Roussel Uclaf, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4232015		19801104
APPLICATION INFO.:	US 1979-63939		19790806 (6)
DISCLAIMER DATE:	19960918		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1978-23851	19780816
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Hammond & Littell, Weissenberger and Musserlian	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1,21	
LINE COUNT:	631	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel .DELTA..sup.4 -androstenes of the formula ##STR1## wherein R.sub.1 is alkyl of 1 to 3 carbon atoms, R' is an acyl of an organic carboxylic acid or carbonic acid of 1 to 18 carbon atoms, R.sub.2 is selected from the group consisting of alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12 carbon atoms, --CF.sub.3, aryl of 6 to 12 carbon atoms and aralkyl of 7 to 12 carbon atoms, Y is selected from the group consisting of hydrogen, fluorine and methyl, X is selected from the group consisting of hydrogen, chlorine, bromine and fluorine and the dotted lines in the A and B rings indicate one or 2 double bonds in 1(2) and 6(7) positions with the proviso when R.sub.1 is methyl and the B ring is saturated, X is hydrogen when Y is hydrogen and X is not hydrogen when Y is fluorine having a remarkable anti-inflammatory activity and their preparation.


IT 75220-02-9P

(prepn. of)

RN 75220-02-9 USPATFULL

CN Androsta-1,4,6-trien-3-one, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-17-(1-propynyl)-, (11.beta.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



44-56
 1, 4, 6, 8, 9, 10, 11
 7, 12-17
 24-25, 28
 30-41

L7 ANSWER 34 OF 34 USPATFULL
ACCESSION NUMBER: 75:33330 USPATFULL
TITLE: Process for preparing 17.alpha.-monoesters of
17.alpha., 21-dihydroxy-20-oxo steroids
INVENTOR(S): Philipps, Gordon Hanley, Wembley, England
Bain, Brian MacDonald, Chalfont St. Peter, England
Durrant, Graham, London, England
PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3891631		19750624
APPLICATION INFO.:	US 1973-387487		19730810 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1972-37655	19720811
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1406	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The specification describes a process for preparing 17.alpha.-carboxylate or neutral phosphate or carbonate esters of 17.alpha.,21-dihydroxy-20-oxo steroids wherein a 21-carboxylate or neutral phosphate or carbonate ester of a 17.alpha.,21-dihydroxy-20-oxo steroid is treated with a non-hydroxylic base in an anhydrous aprotic medium to remove a proton selectively from the 17.alpha.-hydroxyl grouping, and the reaction mixture neutralised or acidified whereby the intermediate product is protonated. The base used in the process can be for example a carbanionoid e.g. alkali metal alkyl, or metal amide, e.g. alkali metal amide, base. The process is applicable to the preparation of a wide variety of 17-esters of the above-mentioned type. The process can also be used to prepare certain enol-aldehydes corresponding to the above-described 17-ester, a particular class of these enol-aldehydes being described in the specification as novel compounds.

IT 52619-15-5P


(prepn. of)

RN 52619-15-5 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11,21-dihydroxy-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 34 OF 34 USPATFULL (Continued)



=> d ibib ab hitstr 1-2

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1983:438694 CAPLUS

DOCUMENT NUMBER: 99:38694

T/TITLE: Structural and configurational dependence of the sensory process in steroids

AUTHOR(S): Ohloff, Guenther; Maurer, Bruno; Winter, Beat; Giersch, Wolfgang

CORPORATE SOURCE: Firmenich S. A., Res. Lab., Geneva, CH-1211, Switz.

SOURCE: Helvetica Chimica Acta (1983), 66(1), 192-217

CODEN: HCACAV; ISSN: 0018-019X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Sixty androstanes and estranes were prepd. as structurally modified testosterone and 19-nortestosterone and their mol. structure-steroid-type odor perception relationship was studied. Odor perception with O-contg. compds. was regioselective with C-3 osmophoric groups being the most active. The steroid-type scent was also diastereoselective with axial 2-hydroxy and 3-hydroxy steroids having greater odor intensity than that of their equatorial epimers. Normal ring junctions and configurations were odorants whereas cis-junctions were practically inactive. Steroid odorant perception was also enantioselective with C19-steroids of normal configuration having odor perception thresholds at very low concns., whereas their unnatural enantiomers were odorless.

IT 86306-64-1P


RL: RCT_(Reactant);_SPN_(Synthetic preparation);_PREP_(Preparation);_RACT_(Reactant or reagent)

(prepn. and elimination reaction of)

RN 86306-64-1 CAPLUS

CN Androst-1-en-3-one, 17-[(methoxycarbonyl)oxy]-, (5.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



4, 5, 24, 25
1, 4, 5, 28, 29-32, 45

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1972:448697 CAPLUS

DOCUMENT NUMBER: 77:48697

TITLE: Steroids. XXX. Synthesis of esters of 3-keto steroid 2-carboxylic acids. II

AUTHOR(S): De Ruggieri, Pietro; Gandolfi, Carmelo; Guzzi, Umberto; Lab. Ric. Ormonoter. Richter, Gruppo Lepetit S.p.A., Milan, Italy

CORPORATE SOURCE: Annali di Chimica (Rome, Italy) (1972), 62(1), 71-85

CODEN: ANCRAL; ISSN: 0003-4592

DOCUMENT TYPE: Journal

LANGUAGE: Italian

AB The 5.alpha.-androst-3-ones (I) and (II) are carboxylated with dialkyl carbonates to give the 3-oxoandrostane-2.alpha.-carboxylate esters (III) and (IV). Similarly prepd. is Me 3-oxocholest-4-ene-2.alpha.-carboxylate. IV is treated with PC15 at 0.degree. to give the 3-chloroandrost-2-ene (V) which is heated with NaOEt in EtOH to give the 3-ethoxy ester (VI).


IT 37722-33-1P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)

RN 37722-33-1 CAPLUS

CN Androst-1-ene-2-carboxylic acid, 17-[(methoxycarbonyl)oxy]-3-oxo-, methyl ester, (5.alpha.,17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




102
1, 4, 5

=> d ibib ab hitstr 1-63

L9 ANSWER 1 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:864325 CAPLUS
 DOCUMENT NUMBER: 137:346196
 TITLE: Composition for the topical treatment of poison ivy and other forms of contact dermatitis
 INVENTOR(S): McCadden, Michael E.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 9 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6479058	B1	20021112	US 2000-652811	20000831
PRIORITY APPLN. INFO.: US 1999-152068 P 19990902				
AB	Compn. for topical administration, preferably a solid-in-liq. suspension, comprises (a) a corticosteroid and (b) a drying agent, such as calamine and zinc oxide. For example, for contact dermatitis a compn. contg. hydrocortisone 1 %, calamine 8 %, zinc oxide 8 %, glycerin 2 %, bentonite magma 25 % and calcium hydroxide q.s., in sterile water to 100% is preferably administered two to four times a day for from one day to a week or more until healing occurs.			
IT	73771-04-7, Prednicarbate RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compns. contg. corticosteroids and drying agents and anti-itching agents for treatment of contact dermatitis)			
RN	73771-04-7 CAPLUS			
CN	Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:832575 CAPLUS
 DOCUMENT NUMBER: 137:346196
 TITLE: Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent
 INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed
 PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 872 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085308	A2	20021031	WO 2002-US13135	20020423
WO 2002085308	A3	20021219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-KR13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-KR13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-KR13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

L9 ANSWER 2 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: WO 2002-0513135 A 20020423


OTHER SOURCE(S):

AB This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addn., they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. Treatment with antisense oligonucleotides in combination with anti-inflammatory steroid and/or ubiquinones is also provided. These agents and the compn. and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

IT 82034-46-6 Loteprednol etabonate
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cotreatment with antisense oligo and treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 2 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




L9 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:689375 CAPLUS
 DOCUMENT NUMBER: 137:380195
 TITLE: Effect of crystal form on in vivo topical anti-inflammatory activity of corticosteroids
 AUTHOR(S): Sohn, Young-Taek; Kim, Sun-Young
 CORPORATE SOURCE: College of Pharmacy, Duksung Womens University, Seoul, 132-714, S. Korea
 SOURCE: Archives of Pharmacol Research (2002), 25(4), 556-559
 CODEN: APHRDQ; ISSN: 0253-6269
 PUBLISHER: Pharmaceutical Society of Korea
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The aim of this study was to gain information on the effects of the crystal form of corticosteroids on the topical anti-inflammatory activity. Two different crystal forms, Form A and Form B1 of the drugs of prednicarbate, hydrocortisone, betamethasone 17-valerate, prednisolone, and methylprednisolone were prep. and their topical anti-inflammatory activities were measured using arachidonic acid induced ear edema assay in mice. Two crystal forms of the drugs showed differences in anti-inflammatory activity. Among the drugs examd., Form B of prednicarbate and betamethasone 17-valerate showed significantly more potent anti-inflammatory activities as compared to their Form A.

IT 73771-04-7, Prednicarbate
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (crystal form effect on in vivo topical anti-inflammatory activity of corticosteroids in mice)

RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:591117 CAPLUS
 DOCUMENT NUMBER: 137:149955
 TITLE: Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model
 AUTHOR(S): Berdy, Gregg J.; Stoppel, Juan O.; Epstein, Arthur B.
 CORPORATE SOURCE: Department of Ophthalmology, Washington University School of Medicine, St. Louis, USA
 SOURCE: Clinical Therapeutics (2002), 24(6), 918-929
 CODEN: CLTHDG; ISSN: 0149-2918
 PUBLISHER: Elsevier Science, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Olopatadine hydrochloride 0.1% ophthalmic soln. and loteprednol etabonate 0.2% ophthalmic suspension are topical antiallergic agents indicated for treatment of the signs and symptoms of allergic conjunctivitis and seasonal allergic conjunctivitis (SAC), resp. The purpose of this study was to compare the efficacy and tolerability of olopatadine, loteprednol, and placebo in inhibiting the early-phase allergic reaction (within 30 min) after conjunctival allergen challenge (CAC). This was a single-center, randomized, double-masked, parallel-controlled CAC study. It consisted of 3 visits, with CAC performed at visit 1, confirmation and randomization at visit 2, and evaluation of the treatments at visit 3. Subjects with a history of allergic conjunctivitis were randomized to receive olopatadine, loteprednol, or placebo in a 2:2:1 ratio. Because loteprednol requires a loading period to achieve max. efficacy, subjects assigned to this treatment received loteprednol QID bilaterally for a 14-day period; the olopatadine and placebo groups received placebo QID bilaterally during this period. At the evaluation visit, subjects received 1 drop of the assigned treatment in each eye. Fifteen minutes later, they were challenged with allergen. Subjects evaluated itching at 3, 5, and 10 min after challenge using a standardized 5-point scale; the investigator evaluated redness at 10, 15, and 20 min after challenge. Intraocular pressure (IOP) was measured at baseline and after the 14-day loading period. Nonparametric analyses were performed on the change from visit 2 to visit 3 in mean itching and redness scores for each time point, and on the change in mean IOP from visit 1 to visit 3. Fifty subjects (86% white; 42% male, 58% female; age range, 21-71 yr) were enrolled and completed the study (20 olopatadine, 20 loteprednol, 10 placebo). The allergens to which subjects reacted were ragweed pollen (40%), cat hair or dander (30%), grass pollen (24%), and tree pollen (6%). The difference in inhibition of itching and redness was clin. significant (.gtoreq.1 unit difference) and statistically significant (P < 0.05) in favor of olopatadine compared with loteprednol at all 3 time points. The loteprednol group had a statistically significant increase in IOP after 2 wk of treatment (P < 0.001). In the population studied, olopatadine was more efficacious than loteprednol in reducing the acute signs and symptoms of SAC during the early phase of the ocular allergic reaction and appeared to be better tolerated.

IT 82034-46-6, Loteprednol etabonate
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (olopatadine hydrochloride 0.1% ophthalmic soln. vs. loteprednol etabonate 0.2% ophthalmic suspension in conjunctival allergen challenge model)

L9 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:385539 CAPLUS
 DOCUMENT NUMBER: 137:346268
 TITLE: Design and development of a soft corticosteroid, loteprednol etabonate
 AUTHOR(S): Bodor, Nicholas; Buchwald, Peter
 CORPORATE SOURCE: University of Florida, Gainesville, FL, USA
 SOURCE: Lung Biology in Health and Disease (2002), 163(Inhaled Steroids in Asthma), 541-564
 CODEN: LBHDD7; ISSN: 0362-3181
 PUBLISHER: Marcel Dekker, Inc.
 DOCUMENT TYPE: Journal, General Review
 LANGUAGE: English

AB A review. Topical application of active corticosteroids that undergo nonoxidative, extrahepatic metab. can provide improved, safer treatments of allergic diseases by minimizing the risk of systemic absorption and, therefore, the occurrence of side effects. Loteprednol etabonate, a soft corticosteroid that contains 17.alpha.-carbonate and 17.beta. ester side chains and that was designed by using an inactive metabolite-based approach, lacks serious side effects and already received FDA approval for use in all inflammatory and allergy-related ophthalmic disorders. Since exptl. evidence indicates that it also produces strong and long-lasting antiinflammatory effect after intranasal or intrapulmonary administration, currently it is being developed for the treatment of allergic conditions, such as rhinitis and asthma.

IT 82034-46-6, Loteprednol etabonate
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (design and development of soft corticosteroid loteprednol etabonate)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 89 THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 6 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:150128 CAPLUS
 DOCUMENT NUMBER: 13744865
 TITLE: Different Skin Thinning Potential of Equipotent Medium-Strength Glucocorticoids
 AUTHOR(S): Korting, Hans Christian; Unholzer, Angela; Schaefer-Korting, Monika; Tausch, Irene; Gassmueller, Johannes; Nietsch, Karl-Heinz
 CORPORATE SOURCE: Klinik und Poliklinik fuer Dermatologie und Allergologie, Ludwig-Maximilians-Universitaet, Munich, Germany
 SOURCE: Skin Pharmacology and Applied Skin Physiology (2002), 15(2), 85-91
 CODEN: SPAPFF; ISSN: 1422-2868
 PUBLISHER: S. Karger AG
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB In this study, we investigated the effect of prednicarbate, mometasone furoate and betamethasone 17-valerate on total skin thickness over a treatment period of 6 wk. The study was conducted as a double-blind, placebo-controlled randomized clin. trial with a confirmatory approach. The influence of these drugs on healthy human skin under non-occlusive conditions was assessed by measuring total skin thickness and epidermal thickness using 20 and 50 MHz sonog., resp. Epidermal surface structure was evaluated using profilometry. Visual assessment addressed signs of atrophy and formation of telangiectasia. The redn. of total skin thickness induced by prednicarbate was clearly less than that caused by betamethasone 17-valerate and mometasone furoate. Prednicarbate led to a higher degree of skin thinning than vehicle. For tech. reasons, epidermal thickness could not be reliably evaluated with 50 MHz sonog. Profilometry did not demonstrate any differences between treatments. Visible signs of atrophy or telangiectasia were detected in two subjects each upon betamethasone 17-valerate and mometasone furoate, but not upon prednicarbate or its vehicle. Prednicarbate is a topical glucocorticoid with an improved benefit/risk ratio, as it causes less skin atrophy than the equipotent betamethasone 17-valerate.

IT 73771-04-7, Prednicarbate
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (different skin thinning potential of equipotent medium-strength glucocorticoids in humans)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 6 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:935594 CAPLUS
 DOCUMENT NUMBER: 136:69730
 TITLE: Preparation of 1,3-bis-(substituted-phenyl)-2-propen-1-ones as VCAM-1 inhibitors for treatment of inflammatory disorders
 INVENTOR(S): Meng, Charles Q.; Ni, Liming; Sikorski, James A.; Hoong, Lee K.
 PATENT ASSIGNEE(S): Atherogenics, Inc., USA
 SOURCE: PCT Int. Appl., 220 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098291	A2	20011227	WO 2001-US19720	20010620
WO 2001098291	A3	20020516		

V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, ST, TH, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.:
 US 2000-212769P P 20000620
 US 2000-255934P P 20001215

OTHER SOURCE(S): MARPAT 136:69730
 AB Title compds. I [wherein R2a, R3a, R4a, R5a, R6a, R2b, R3b, R4b, R5b, and R6b = independently H, (cyclo)alkyl, (hetero)aryl, carbocyclyl, (halo)alkylthio, (un)substituted alkoxy or amino, (halo)acyl, amido, (halo)alkylsulfonyl, aminocarbonyl, alkenyl, alkynyl, halo, OH, SH, CN, NO2, SO3H, sulf(on)amido, PO3H2, alditol, carbohydrate, amino acid, etc.; R22 and R23 = independently H or alkyl; or R22 or R23 and R6a can join together to form a bridged carbocycle, (hetero)aryl, or heterocycle; R2a and R3a, R3a and R4a, R4a and R5a, R5a and R6a, R2b and R3b, R3b and R4b, R4b and R5b, or R5b and R6b and independently join to form a bridged (un)substituted carbocycle, cycloalkenyl, cycloalk(en)ylcarbonyl, (hetero)aryl, heterocycle, or alkylenedioxy; and the E or Z isomers thereof] were prepd. to inhibit the expression of VCAM-1. For example, 3',5'-dimethoxy-4'-hydroxyacetophenone was treated with Et glycolate, PPh3, and di-Et azodicarboxylate in THF to give 4'-ethoxycarbonylmethoxy-3',5'-dimethoxyacetophenone (904). Coupling the acetophenone and 5-(benzo[b]thien-2-yl)-2,4-dimethoxybenzaldehyde (prepn. given) in the presence of NaOH in abs. EtOH afforded the 1,3-diphenyl-2-propen-1-one II (391), which stimulated cultured human aortic smooth muscle cell activity with IC50 of 0.45 .mu.M. I are useful for the treatment of inflammatory disorders that are mediated by VCAM-1, including arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

IT 73771-04-7, Prednicarbate
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

L9 ANSWER 7 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (Biological study); USES (Uses)
 (co-administration of bis(substituted phenyl)propenone VCAM-1 inhibitors with corticosteroids)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 8 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:903789 CAPLUS
 DOCUMENT NUMBER: 136194202
 TITLE: Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: A multicenter study
 AUTHOR(S): Berardesca, E.; Barbaresechi, M.; Veraldi, S.; Pimpinelli, N.
 CORPORATE SOURCE: Department of Dermatology, IRCCS Policlinico S. Matteo, Pavia, Italy
 SOURCE: Contact Dermatitis (2001), 45(5), 280-285
 CODEN: CODEDG; ISSN: 0105-1873
 PUBLISHER: Munksgaard International Publishers Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Disturbances of skin barrier function occur in several skin diseases, e.g., atopic dermatitis (AD), irritant/allergic contact dermatitis (ICD, ACD). Skin barrier damage triggers the prodn. of cytokines that stimulate lipogenesis which may also cause inflammatory processes. The aim of this study was to evaluate the efficacy of a topical skin lipid mixt. in the treatment of ICD, ACD and AD. 580 Consecutive patients suffering from ICD, ACD or AD were treated with a skin lipid mixt. contg. ceramide-3 and patented nanoparticles. Patients received the lipid mixt. alone or in combination with topical corticosteroids until clearance or for 8 wk. Both treatment groups statistically improved all parameters considered at week 4 and 8 as compared to baseline. Between the 2 treatment groups, there was a statistically significant difference in favor of combined therapy for (ICD, ACD, AD, resp.): erythema, pruritus and overall disease severity; erythema and pruritus; erythema, pruritus, fissuring and overall disease severity. No statistically significant difference was found for (ICD, ACD, AD, resp.): dryness, scaling and fissuring; scaling, fissuring and overall disease severity; dryness and scaling. Between the 2 ACD treatment groups, there was a statistically significant difference in favor of the skin lipid mixt. for dryness. In conclusion, the study shows that balanced lipid mixts. are effective in improving barrier properties and the clin. condition of the skin in contact dermatitis.

IT 73771-04-7, Prednicarbate
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (evaluation of efficacy of skin lipid mixt. in humans with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 8 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:850977 CAPLUS
 DOCUMENT NUMBER: 135:376779
 TITLE: Pharmaceutical and cosmetic compositions containing organosiloxanes and phospholipids
 INVENTOR(S): Piotrowski, Ralf; Seigfried, Bernd G.
 PATENT ASSIGNEE(S): Mika Pharma Gesellschaft fuer die Entwicklung und Vermarktung Pharmazeutischer Produkte m.b.H., Germany
 SOURCE: FCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087344	A1	20011122	WO 2001-DE1483	20010414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10024413	A1	20011206	DE 2000-10024413	20000519
EP 1282446	A1	20030212	EP 2001-940156	20010414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: DE 2000-10024413 A 20000519
 WO 2001-DE1483 W 20010414


AB The invention relates to a pharmaceutical and/or cosmetic compn. for use in humans, animals or plants. The compn. contains at least one pharmaceutical and/or cosmetic active ingredient, at least one silicon org. compd. based on an oligomer and/or polymer diorganosiloxane, and at least one phospholipid. Thus a compn. contained (wt./wt.): clotrimazole 1; propanol-2 8; hexamethyldisiloxane 78.8; phospholipid (75% phosphatidylcholine, 25% ethanol) 10; peppermint oil 0.2; 1,2-propanediol 2.

IT 73771-04-7, Prednicarbate
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (pharmaceutical and cosmetic compns. contg. organosiloxanes and phospholipids)

RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 9 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 10 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:846198 CAPLUS
 DOCUMENT NUMBER: 136:128480
 TITLE: Retrometabolic drug design - novel aspects, future directions
 AUTHOR(S): Bodor, N.
 CORPORATE SOURCE: IVAX Corporation, Miami, FL, USA
 SOURCE: Pharmazie (2001), 56(Suppl. 1), 567-574
 CODEN: PHARAT; ISSN: 0031-7144
 PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. A brief overview of the general, retrometabolic drug design principles, including soft drug and chem. delivery system design, is presented. Selected recent developments within these fields are also summarized, including results related to the design of soft bufuralol and amiodarone analogs, to the airway activity of luteprednol etabonate, a soft corticosteroid, and to the brain targeted delivery of some neuropeptides.

IT 82034-46-6, Luteprednol etabonate
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (retrometabolic drug design)

RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:729696 CAPLUS
 DOCUMENT NUMBER: 135:277746
 TITLE: Controlled delivery system of antifungal and keratolytic agents for treatment of infections of the nail
 INVENTOR(S): Friedman, Michael; Licht, Danielle; Cohen, Rachel; Yacobi, Avraham; Golaner, Yechiel; Moros, Dan; Levitt, Barrie
 PATENT ASSIGNEE(S): Taro Pharmaceutical Industries Ltd., Israel
 SOURCE: Eur. Pat. Appl., 17 pp.
 CODEN: EPAXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1138314	A2	20011004	EP 2001-650031	20010326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, IT, LV, FI, RO				
CA 2341814	AA	20010927	CA 2001-2341814	20010322
JP 2001316247	A2	20011113	JP 2001-91489	20010327
CN 1324607	A	20011205	CN 2001-119020	20010327

PRIORITY APPLN. INFO.: US 2000-534960 A 20000327


AB A topical sustained release system for the delivery of antifungal agents to the finger or toenails achieves high penetration through the nails by combining the drug with a keratolytic agent and a humectant. The sustained-release topical prep. is provided in a varnish or spray form for treating the nail and surrounding tissues. The compn. may further comprise antibacterial, antiviral, n antipsoriatic agents, or combinations. Thus, a nail varnish formulation contained urea 0.7, miconazole nitrate 0.8, Eudragit S 7.3, water 4.0, acetone 61.3, iso-ProH 20.4, PEG-400 0.4, and glycerol 4.9% by wt.

IT 73771-04-7, Prednicarbate
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (controlled delivery system of antifungal and keratolytic agents for treatment of infections of nail)

RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 11 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:661489 CAPLUS
 DOCUMENT NUMBER: 135:225864
 TITLE: Method for preparing antibodies to macrophage migration inhibitory factor
 INVENTOR(S): Kloetzer, William S.; Hanna, Nabil
 PATENT ASSIGNEE(S): Idec Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064749	A2	20010907	WO 2001-US5933	20010226
WO 2001064749	A3	20020502		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-185390 P 20000228
 US 2000-233625 P 20000518


AB The authors disclose the prepn. of high-affinity antibodies to macrophage migration inhibitory factor (MIF) by utilizing animals in which the MIF gene was deleted by homologous recombination. In one example, a plasmid vector expressing the MIF gene was digested with AgeI which disrupts exon 2, intron 2, and exon 3. A neo cassette was inserted at the digestion site and the vector used to prep. embryonic stem cells and knockout (MIF^{-/-}) mice. Monoclonal antibodies were prepd. from knockout mice and shown to inhibit the phenylpyruvate tautomerase activity of MIF. In a second example, anti-MIF monoclonal antibodies were shown to inhibit lethality in an endotoxic shock model.

IT 73771-04-7, Prednicarbate 82034-46-6, Luteprednol etabonate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in combination therapy with antibodies to macrophage migration inhibitory factor)

RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 13 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 Absolute stereochemistry.



L9 ANSWER 13 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:247172 CAPLUS
 DOCUMENT NUMBER: 134:256899
 TITLE: Combination of luteoprednol and .beta.2-adrenoceptor agonists for the treatment of allergies and respiratory tract diseases
 INVENTOR(S): Szelenyi, Istvan; Poppe, Hildegard; Heer, Sabine; Engel, Juergen
 PATENT ASSIGNEE(S): Asta Medica Ag, Germany
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022956	A2	20010405	WO 2000-EP9392	20000926
WO 2001022956	A3	20011011		
W:	AU, BG, BR, BY, CA, CN, CZ, DZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			

DE 19947235	A1	20010405	DE 1999-19947235	19990930
BR 2000014374	A	20020625	BR 2000-14374	20000926
EP 1216047	A2	20020626	EP 2000-969304	20000926
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			

PRIORITY APPLN. INFO.: DE 1999-19947235 A 19990930
 WO 2000-EP9392 W 20000926

AB The invention relates to a novel combination of a soft steroid, esp. luteoprednol, and at least one .beta.2-adrenoceptor agonist for treating allergies and/or respiratory tract diseases simultaneously, sequentially or sep.; to drugs contg. said combination, to methods for producing such drugs and to the use of the novel combination for producing drugs for the simultaneous, sequential or sep. treatment of allergies and/or respiratory tract diseases. Thus and aerosol was prepd. that contained 6 .mu.g formoterol fumarate dihydrate and 200 .mu.g luteoprednol per stroke. 2H-heptafluoropropane (1.000 g) propellant was cooled to -55.degree.C and 11.7 g Tagat TO in 11.7 g ethanol was added under stirring, followed by the addn. of 3.34 g micronized luteoprednol etabonate and 0.1 g formoterol fumarate dihydrate. The suspension was dild. with 1,170.0 g 2H-heptafluoropropane, filled in metal containers with valves for dosing 50 .mu.L suspension per stroke.

IT 82034-46-6, Luteoprednol etabonate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
 USES (Uses)

(combination of luteoprednol and .beta.2-adrenoceptor agonists for the treatment of allergies and respiratory tract diseases)

RN 82034-46-6 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

L9 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:247171 CAPLUS
 DOCUMENT NUMBER: 134:256898
 TITLE: Combination of luteoprednol and antihistamines for the local treatment of allergies and respiratory tract diseases
 INVENTOR(S): Szelenyi, Istvan; Marx, Degenhard; Heer, Sabine; Engel, Juergen
 PATENT ASSIGNEE(S): Asta Medica Ag, Germany
 SOURCE: PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022955	A2	20010405	WO 2000-EP9391	20000926
WO 2001022955	A3	20010517		
W:	AU, BG, BR, BY, CA, CN, CZ, DZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			

DE 19947234	A1	20010405	DE 1999-19947234	19990930
BR 2000014312	A	20020521	BR 2000-14312	20000926
EP 1216046	A2	20020626	EP 2000-969303	20000926
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY			

PRIORITY APPLN. INFO.: DE 1999-19947234 A 19990930
 WO 2000-EP9391 W 20000926

AB The invention relates to a novel combination of a soft steroid, esp. luteoprednol, and at least one antihistamine such as e.g., azelastine and/or levocabastine, for simultaneous, sequential or sep. application for the local treatment of allergies and respiratory tract diseases, e.g., allergic rhinitis (rhinoconjunctivitis). Thus a nasal spray contained in g: azelastine hydrochloride 0.1000; luteoprednol etabonate 1.000; Avicel RC 591 1.100; polysorbate 80 0.1000; sorbitol soln. 701 6.000; sodiumedetate 0.0500; benzalkonium chloride 0.0200; water at 100 mL.

IT 82034-46-6, Luteoprednol etabonate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
 USES (Uses)


(combination of luteoprednol and antihistamines for local treatment of allergies and respiratory tract diseases)

RN 82034-46-6 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:167849 CAPLUS
 DOCUMENT NUMBER: 134:217194
 TITLE: Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
 INVENTOR(S): Ridker, Paul; Hennekens, Charles H.
 PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015744	A1	20010308	WO 2000-US24251	20000831
WO 2001015744	C2	20020926		
V: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1212101	A1	20020612	EP 2000-959851	20000831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003508453	T2	20030304	JP 2001-520155	20000831
PRIORITY APPLN. INFO.: US 1999-387028 A 19990831				
WO 2000-US24251 W 20000831				
AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder such as atherosclerosis, stroke, and myocardial infarction by assessing the level of systemic inflammation marker (such as sICAM or C-reactive protein) in an individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorders; and of drug combinations (anti-inflammatory agents, lipid-reducing agents, angiotensin system inhibitors, calcium channel blockers, .beta.-adrenergic receptor blockers) suitable for prevention future cardiovascular disease.				
IT 82034-46-6, luteoprednol etabonate				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(use of agents and systemic inflammatory markers to predict and inhibit cardiovascular disorders in humans)				
RN 82034-46-6 CAPLUS				
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

L9 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:139514 CAPLUS
 DOCUMENT NUMBER: 135:175639
 TITLE: Fluticasone propionate: a rare contact sensitizer
 AUTHOR(S): Goossens, An; Huygens, Sarah; Matura, M.; Degreef, Hugo
 CORPORATE SOURCE: Department of Dermatology, University Hospital, Louvain, Belg.
 SOURCE: European Journal of Dermatology (2001), 11(1), 29-34
 CODEN: EJDDE4; ISSN: 1167-1122
 PUBLISHER: John Libbey Eurotext
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Fluticasone propionate is the first of a new generation of fluorinated corticosteroids that have been synthesized with a view to sepg. local activity from undesirable side effects. In recent years, contact allergy to the newer topical corticosteroids has received increasing attention. The results of patch testing with fluticasone propionate, even in patients with a known contact allergy to corticosteroids, argue for a low sensitization and cross-sensitization potential.
 IT 73771-04-7, Prednicarbate
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (fluticasone propionate, contact allergy, and cross-sensitization with other corticosteroids and non-active formulation ingredients)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 17 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:627990 CAPLUS

DOCUMENT NUMBER: 133:227792

TITLE:

Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids

INVENTOR(S): Lugo, Sergio Ulloa; Ramos, Jose Villacampa; Arellano, Sergio Morales; Michel, Olivier

PATENT ASSIGNEE(S): Schering Corp., USA

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051605	A1	20000908	WO 1999-US4502	19990301
V: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9930652	A1	20000921	AU 1999-30652	19990301
EP 1049471	A1	20001108	EP 1999-912236	19990301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
BR 9909368	A	20001121	BR 1999-9368	19990301
JP 2001510485	T2	20010731	JP 1999-517143	19990301
ZA 9901908	A	19990923	ZA 1999-1908	19990309
PRIORITY APPLN. INFO.: WO 1999-US4502	A	19990301		

OTHER SOURCE(S): MARPAT 133:227792

AB Disclosed herein are compns. and methods for treating atopic dermatitis, angioedema, urticaria, allergic rhinitis and other such disorders. The compns. comprise therapeutically effective amts. of antihistamines such as, for example, loratadine, and glucocorticoids such as, for example, betamethasone, for such treatment. A tablets contain betamethasone 0.1-0.5, loratadine 2-10, lactose monohydrate 55-290, sodium croscarmellose 0.8-4, and magnesium stearate 0.4-1 mg.


IT 73771-04-7, Prednicarbate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids)

RN 73771-04-7 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 17 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:589886 CAPLUS

DOCUMENT NUMBER: 133:172203

TITLE:

Methods of treating headache and functional extraocular and intraocular myotendinitis

INVENTOR(S): Sucher, David F.

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 8 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6106819	A	20000822	US 1997-999782	19971205
PRIORITY APPLN. INFO.: US 1996-34103P	P	19961231		
			US 1997-38085P	P 19970218
AB Methods of treating headache and functional extraocular and intraocular myotendinitis by applying to the eyes of a patient being treated a compd. selected from the group consisting of hydrocortisone, medrysone, prednisolone, dexamethasone, flumethasone, rimexolone, and loteprednol ebonate, and combinations of these compds. with other constituents.				
IT 82034-46-6, Loteprednol etabonate				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(treatment of headache and functional extraocular and intraocular myotendinitis)				
RN 82034-46-6 CAPLUS				
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 19 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:456837 CAPLUS

DOCUMENT NUMBER: 133:94281

TITLE:

Skin care and protective compositions containing transfer agents and barrier materials

INVENTOR(S): Homola, Andrew M.; Dunton, Ronald K.; Pitts, Gary

PATENT ASSIGNEE(S): Four Star Partners, USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038617	A2	20000706	WO 1999-US30003	19991223
WO 2000038617	A3	20000921		
V: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356840	AA	20000706	CA 1999-2356840	19991223
EP 1139981	A2	20011010	EP 1999-968903	19991223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.: US 1998-113950P	P	19981224		
			US 1999-117283P	P 19990126
			WO 1999-US30003	W 19991223

AB The present invention discloses compns. contg. a one or more transfer agents and one or more barrier materials which form, upon application to a substrate, even a wet substrate or substrate immersed under water, adhesive, protective barriers. The compns. may be modified to provide an appropriate viscosity and other characteristics and may serve as a carrier for active agents.


IT 73771-04-7, Prednicarbate
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (skin care and protective compns. contg. transfer agents and barrier materials)

RN 73771-04-7 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 19 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 20 OF 63 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2000:414694 CAPLUS
 DOCUMENT NUMBER: 133:261550
 TITLE: Luteoprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways
 AUTHOR(S): Szelenyi, Istvan; Hochhaus, Gunther; Heer, Sabine; Kusters, Sabine; Marx, Degenhard; Poppe, Hildegard; Engel, Jurgen
 CORPORATE SOURCE: Pulmonary Pharmacology, Corporate Research & Development, ASTA Medica, Frankfurt and Dresden, Germany
 SOURCE: Drugs of Today (2000), 36(5), 313-320
 CODEN: MDACAP; ISSN: 0025-7656
 PUBLISHER: Prous Science
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review with 58 refs. There are several approaches for developing new antiallergic/asthmatic agents. One of them is the improvement of an existing class of effective drug classes. Due to some undesired effects of intranasal or inhaled corticosteroids, there is a need for better tolerated corticosteroids. Luteoprednol etabonate belongs to the so-called class of soft steroids because it is metabolized by a 1-step reaction (hydrolysis) without using the cytochrome P 450 monooxygenase system. In in vitro investigations in human cells, luteoprednol inhibited the release of proinflammatory cytokines (e.g., TNF- α , GM-CSF, IL-4, IL-5) to an extent according to its relative binding potency to the glucocorticoid receptor. In in vivo animal studies, luteoprednol effectively inhibited allergically induced vascular leakage in the nasal cavity of actively sensitized Brown Norway rats and rhinorrhea in actively sensitized domestic pigs following nasal challenge. In several models of allergic asthma, luteoprednol was able to suppress the allergically induced late-phase eosinophilia in mice, rats and guinea pigs. After intrapulmonary administration of luteoprednol, only a slight, nonsignificant redn. in thymus wt. was obsd. in a dose range far less than the therapeutically relevant doses. Its therapeutic ratio is clearly superior to those of beclomethasone and budesonide. Luteoprednol is a safe steroid with an extremely wide range between therapeutic and side-effect-inducing doses. Its elimination profile, its pronounced binding to plasma protein and erythrocytes and its low oral bioavailability makes this drug highly suitable for nasal or pulmonary use.

IT 82034-46-6, Luteoprednol etabonate
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 RN Luteoprednol etabonate treatment of allergic diseases of the airways
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11 β ,17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 20 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2000:361478 CAPLUS
 DOCUMENT NUMBER: 133:99753
 TITLE: Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids
 AUTHOR(S): Lange, Katharina; Kleuser, Burkhard; Gysler, Anja; Bader, Michael; Maia, Claudia; Scheiderer, Claus; Korting, Hans Christian; Schafer-Korting, Monika
 CORPORATE SOURCE: Institut für Pharmazie der Freien Universität Berlin, Berlin, D-14195, Germany
 SOURCE: Skin Pharmacology and Applied Skin Physiology (2000), 13(2), 93-103
 CODEN: SPAPFF; ISSN: 1422-2868
 PUBLISHER: S. Karger AG
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The nonhalogenated double ester of prednisolone, prednicarbate (PC), is the first topical glucocorticoid with an improved benefit/risk ratio verified clin. and in vitro. To evaluate if this is due to unique characteristics of this steroid, a new compd. created according to an identical concept, prednisolone 17-ethylcarbonate, 21-phenylacetate (PEP), and the new halogenated monoester desoximetasone 21-cinnamate (DCE) were tested and compared to PC, desoximetasone (DM) and betamethasone 17-valerate (BMV). Isolated foreskin keratinocytes served for in vitro investigations of anti-inflammatory processes in the epidermis, fibroblasts of the same origin were used to investigate the atrophogenic potential. Inflammation was induced by TNF- α , resulting in an increased interleukin 1 α (IL-1 α) synthesis. As quantified by ELISA, all drugs significantly reduced IL-1 α prodn. But PC and BMV appeared particularly potent, followed by DM and the two new congeners, which revealed minor anti-inflammatory activity. Glucocorticoid esters including PEP are rapidly degraded in keratinocytes (85% within 12 h). Hence, a RNase protection assay of IL-1 α mRNA was performed allowing short incubation times and thus minimizing biodegrdn. This assay confirmed the anti-inflammatory potency of native PC and BMV. In contrary DCE and PEP did not reduce IL-1 α mRNA to a significant extent. Therefore PEP acts as a prodrug only. In fibroblasts, IL-1 α and IL-6 syntheses indicate proliferation and inflammation, resp. Whereas PC and PEP inhibited IL-1 α and IL-6 prodn. in fibroblasts only to a minor extent, cytokine synthesis was strongly affected by the conventional glucocorticoids BMV and DM, but also by DCE. The minor unwanted effect of PC and PEP on fibroblasts was also reflected by their low influence on cell proliferation as derived from 3H-thymidine incorporation. Again, more pronounced antiproliferative features were seen with the halogenated glucocorticoids. In the following, the correlation between antiproliferative effects in keratinocytes (suppression of IL-1 α) and antiproliferative effects in fibroblasts (suppression of IL-1 α and IL-6; 3H-thymidine incorporation) was analyzed. Here, PC is revealed as the only glucocorticoid with an improved benefit/risk ratio. Native PEP is shown to be almost ineffective and DCE presents exactly the opposite features of PC. It is tempting to speculate if this is due to different glucocorticoid receptor subtypes or different signaling pathways in keratinocytes and fibroblasts.

IT 73771-04-7, Prednicarbate 162846-15-9
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 RN Topical glucocorticoids metab. and differential effects and mode of action on cutaneous inflammation and proliferation in vitro


L9 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)-]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-15-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-(phenylacetyl)-, (11.beta.)-]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:351357 CAPLUS
 DOCUMENT NUMBER: 133:9107
 TITLE: Dry powder for inhalation
 INVENTOR(S): Keller, Manfred; Mueller-Walz, Rudi
 PATENT ASSIGNEE(S): Skyepharma A.-G., Switz.
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: F1XXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000028979	A1	20000525	WO 1999-CH528	19991110
W: AU, CA, CN, CZ, HU, IN, JP, NO, NZ, PL, RO, RU, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9964578	A1	20000605	AU 1999-64578	19991110
EP 1131059	A1	20010912	EP 1999-952212	19991110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
JP 2002529498	T2	20020910	JP 2000-582027	19991110
EP 1283036	A1	20030212	EP 2002-25796	19991110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
NO 2001002346	A	20010626	NO 2001-2346	20010511
PRIORITY APPLN. INFO.:			CH 1998-2286	A 19981113
			EP 1999-952212	A3 19991110
			WO 1999-CH528	W 19991110


AB The moisture resistance of dry powder formulations for inhalation, which contain a pharmaceutically inert carrier of noninhalable particle size and a finely divided pharmaceutical substance of inhalable particle size, is improved and the storage stability of the formulations is increased by adding Mg stearate to minimize the deleterious effect of moisture on fine particle dose and fine particle fraction even under relatively extreme temp. and humidity conditions. Thus, 198.46 g lactose-H₂O (particle size 100% <200 μm, 50% <125 μm, 10% <75 μm) was mixed with 1 g sieved Mg stearate, then with 0.54 g formoterol fumarate-2H₂O, and loaded into a multidose dry powder inhaler.

IT 82034-46-6, Loteprednol etabonate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THW (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dry powder for inhalation)

RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)-]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:313121 CAPLUS
 DOCUMENT NUMBER: 132:308545
 TITLE: Preparation of soft steroids having anti-inflammatory activity
 INVENTOR(S): Bodor, Nicholas S.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 47 pp., Cont. of U.S. Ser. No. 626,535, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4996335	A	19910226	US 1985-807034	19851209
ZA 8104440	A	19821027	ZA 1981-4440	19810630
CA 1174667	A1	19840918	CA 1981-381293	19810708
SU 1318169	A3	19870615	SU 1981-3306552	19810709
JP 58206561	A2	19831201	JP 1982-101940	19820614
JP 2587034	B2	19970305		
AT 8402656	A	19850715	AT 1984-2656	19840820
AT 379817	B	19860310		
WO 8903390	A1	19890420	WO 1987-US2590	19871013
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
EP 334853	A1	19891004	EP 1987-907186	19871013
EP 334853	B1	19930609		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 90355	E	19930615	AT 1987-907186	19871013
PRIORITY APPLN. INFO.:			US 1980-168453	19800710
			US 1981-265785	19810521
			US 1982-418458	19820915
			US 1984-626535	19840629
			AT 1981-3070	19810710
			CA 1982-381293	19820908
			EP 1987-907186	19871013
			WO 1987-US2590	19871013

OTHER SOURCE(S): MARPAT 132:308545
 AB The title steroids [I; R1 = alkyl, hydroxyalkyl, haloalkyl, CH2CO2R6, CH2CONR7R8, CHR9YR11, CHR10O2CR6, (un)substituted Ph, CH2Ph; R2 = (un)substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ph, CH2Ph; R3 = H, alpha- or beta.-OH, -O2CR2, -Me, -CH2; R4 = H, F, Cl; R5 = H, F, Cl, Me; R6 = (un)substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl; R7, R8 = H, alkyl, cycloalkyl, Ph, CH2Ph; NR7R8 = satd. monocyclic amine; R9 = H, alkyl, Ph; R10 = H, alkyl, Ph, halophenyl; R11 = alkyl; R9R11 = alkylene; X = O, S; Y = O, S, SO, SO2] are prepd. as antiinflammatory agents. Thus, oxidn. of hydrocortisone with NaIO4 gave cortienic acid (II, R1 = R2 = H), which was treated with Me chloroformate, converted to the Na salt and esterified using CH2ClI to give II (R1 = CH2Cl, R2 = MeO2C). At 1 mg/cotton pellet II (R1 = CH2Cl, R2 = EtO2C) inhibited granulation tissue in rats by 68%.

IT 82034-30-8P 82034-31-9P 82034-32-0P
 82034-34-2P 82034-36-4P 82034-38-6P
 82034-39-7P 82034-40-0P 82034-41-1P
 82034-44-4P 82034-46-6P 82034-47-7P
 82034-48-8P 82034-49-9P 82034-50-2P
 82034-54-6P 82034-61-5P 82034-62-6P
 82034-63-7P 82034-64-8P 82034-65-9P
 82034-67-1P 82034-68-2P 82034-69-3P

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


82034-71-7P 82034-72-9P 82034-73-9P
 82048-82-6P 133991-63-6P 265651-67-0P
 265651-69-2P 265651-70-5P 265651-72-7P
 265651-73-0P 265651-74-9P 265651-75-0P
 265651-76-1P 265651-77-2P 265651-78-3P
 265651-79-4P 265651-81-8P 265651-82-9P
 265651-83-0P 265651-84-1P 265651-85-2P
 265651-86-3P 265651-87-4P 265651-88-5P
 265651-89-6P 265651-90-9P 265651-91-0P
 265651-92-1P 265652-05-9P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of androstenedione carboxylic acid derivs. with anti-inflammatory activity)

RN 82034-30-8 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-31-9 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-32-0 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)-

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-39-7 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[[1-pentylxy]carbonyl]oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-40-0 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-41-1 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(phenoxycarbonyl)oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-34-2 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy]-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-36-4 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[[1-propoxycarbonyl]oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-38-6 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-44-4 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-46-6 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-47-7 CAPLUS


CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[[1-methylethoxy]carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry.




RN 82034-48-8 CAPLUS
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-49-9 CAPLUS
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-50-2 CAPLUS

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 82034-62-6 CAPLUS
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1S)-1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-63-7 CAPLUS
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3,11-dioxo-, chloromethyl ester, (16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-54-6 CAPLUS
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-61-5 CAPLUS
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (1R)-1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 82034-64-8 CAPLUS
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-16-methyl-3,11-dioxo-, chloromethyl ester, (16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-65-9 CAPLUS
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[[methoxycarbonyl]oxy]-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82034-67-1 CAPLUS
CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[[[pentyl]oxy]carbonyl]oxy]-, chloromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 82034-68-2 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 16,17-bis[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82034-69-3 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 82034-73-9 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 82048-82-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, methyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 133991-63-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-67-0 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(2-chloroethoxy)carbonyl]oxy]-

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 82034-71-7 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 82034-72-8 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-3-oxo-, 2-chloroethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 265651-69-2 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-69-2 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(2-propenyloxy)carbonyl]oxy]-, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 265651-70-5 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265651-72-7 CAPLUS


L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN Androsta-1,4-diene-17-carboxylic acid, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 265651-73-8 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-74-9 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 6-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN Androsta-1,4-diene-17-carboxylic acid, 6-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 265651-78-3 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-79-4 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 265651-75-0 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 6-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-76-1 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(methoxycarbonyl)oxy]-3-oxo-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265651-77-2 CAPLUS




L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 265651-81-8 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-82-9 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 265651-83-0 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, fluoromethyl ester, (11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265651-84-1 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(1-methylethoxycarbonyl)oxy]-3-oxo-, 2-chloroethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 265651-87-4 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 6-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxycarbonyl)oxy]-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-88-5 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 265651-85-2 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265651-86-3 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 6-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(propoxycarbonyl)oxy]-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 265651-89-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 11-hydroxy-17-[(methoxycarbonyl)oxy]-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 265651-90-9 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 6-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, chloromethyl ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265651-91-0 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-17-[(methoxycarbonyl)oxy]-16-methyl-3-oxo-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 265651-92-1 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-3-oxo-17-[(1-methylethoxycarbonyl)oxy]-, chloromethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 265652-05-9 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxycarbonyl)oxy]-3-oxo-, 1-chloroethyl ester, (11.beta.,16.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 24 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:192086 CAPLUS
 DOCUMENT NUMBER: 133:8991
 TITLE: Effect of cyclodextrins on the solubility and stability of a novel soft corticosteroid, loteprednol etabonate
 AUTHOR(S): Bodor, N.; Drustup, J.; Wu, W.
 CORPORATE SOURCE: Center for Drug Discovery, College of Pharmacy, University of Florida, Gainesville, FL, USA
 SOURCE: Pharmazie (2000), 55(3), 206-209
 CODEN: PHARAT; ISSN: 0031-7144
 PUBLISHER: Gova-Verlag Pharmazeutischer Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB To increase the aq. soly. and stability of the soft corticosteroid loteprednol etabonate (LE), drug complexation using various cyclodextrins (CDs), such as .gamma.-cyclodextrin (.gamma.-CD), 2-hydroxypropyl-.beta.-cyclodextrin (HPBCD), maltosyl-.beta.-cyclodextrin (MBCD), mixt. of glucosyl/maltosyl-.alpha.-, .beta.-, and .gamma.-cyclodextrin (GMCD), and heptakis(2,6-di-O-methyl)-.beta.-cyclodextrin (DMCD), were attempted. The solubilizing and stabilizing effects of CD by itself or combined with various co-solvents were also investigated. Micronized (5 .mu.) LE was mixed in various aq. CD or CD with co-solvent solns. After equilibration and filtration at 23.degree.C, the soly. of LE was detd. by HPLC. Subsequently, the stability of LE in the solns. was also detd. by following the LE concn. change in the soln. for an appropriate period. CD complexation significantly increased the aq. soly. and stability of LE. The increase in soly. displayed a concn. dependency on CDs (0-50%). Among the five CDs used, DMCD showed the highest effects on the soly. (4.2-18.3 mg/mL in 10-50% DMCD) and stability (t90 > 4 yr at 4.degree.C, when LE 0.5 mg/mL was dissolved in 10% DMCD soln.) of LE. By adding co-solvents, such as glycerol, propylene glycol (PG), polyvinyl alc. (PVA), and polyvinylpyrrolidone (PVP-10), the soly. of LE in DMCD solns. was further increased. Degradn. of LE to the corresponding metabolites, .DELTA.1-corticenic acid etabonate (AE) and .DELTA.1-corticenic acid (A), in aq. CD solns. appeared to be a predicted, two-step kinetics. Differential Scanning Calorimetry (DSC) was used to assist explaining the solubilizing and stabilizing activity differences between CDs. LE/CD mixt. or lyophilized LE/CD complex was scanned at a rate of 20.degree.C/min. The exothermic peak found in the DSC diagram with LE/DMCD sample, but not with LE/HPBCD samples, suggests a stronger complex formed between LE and DMCD, resulting in higher soly. and stability of LE in DMCD than in HPBCD.

IT RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclodextrins effect on the soly. and stability of loteprednol etabonate)

RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 24 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 25 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:192080 CAPLUS
 DOCUMENT NUMBER: 132:28870
 TITLE: Loteprednol etabonate: a review of ophthalmic clinical studies
 AUTHOR(S): Howes, J. P.
 CORPORATE SOURCE: JFH Inc., Gainesville, FL, USA
 SOURCE: Pharmazie (2000), 55(3), 178-183
 CODEN: PHARAT; ISSN: 0031-7144
 PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
 DOCUMENT TYPE: Journal: General Review
 LANGUAGE: English

AB A review with 25 refs. Loteprednol etabonate (LE) is a corticosteroid designed using the "soft drug" concept of Bodor. LE has been extensively evaluated as a treatment for ophthalmic inflammatory conditions. LE is administered as a sterile eye drop suspension and is com. available as either a 0.5% or a 0.2% suspension. Lotemax (0.5% LE) has been demonstrated as effective in reducing the signs and symptoms of giant papillary conjunctivitis (GPC), acute anterior uveitis and inflammation following cataract extrn. with intraocular lens (IOL) implantation. It is also effective for the prophylaxis of seasonal allergic conjunctivitis (SAC) in patients with a history of that condition. Alrex (0.2% LE) is effective for the treatment of the signs and symptoms of SAC. In comparison with other steroids LE has a superior safety profile which has been attributed to its "soft drug" characteristics.

IT 82034-46-6, Loteprednol etabonate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (loteprednol etabonate: review of ophthalmic clin. studies)

RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:139952 CAPLUS
 DOCUMENT NUMBER: 133:34376
 TITLE: Solid lipid nanoparticles as drug carriers for topical glucocorticoids
 AUTHOR(S): Maia, C. S.; Mehnert, W.; Schafer-Korting, M.
 CORPORATE SOURCE: Department of Pharmacology and Toxicology, Freie Universität Berlin, Berlin, D-14195, Germany
 SOURCE: International Journal of Pharmaceutics (2000), 196(2), 165-167
 CODEN: IJPHDE; ISSN: 0378-5173
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Recent investigations both in vitro and in human subjects proved the benefit/risk ratio of prednicarbate (PC) to exceed those of halogenated topical glucocorticoids about 2-fold. To obtain a further highly desired increase by drug targeting to viable epidermis, PC was incorporated into solid lipid nanoparticles (SLN). Keratinocyte and fibroblast monolayer cultures, reconstructed epidermis and excised human skin served to evaluate SLN toxicity and PC absorption. Well-tolerated preps. (e.g., cellular viability 94.5% following 18 h incubation of reconstructed epidermis) were obtained. PC penetration into human skin increased by 301 as compared to PC cream, permeation of reconstructed epidermis increased even 3-fold. The present study shows the great potential of SLN to improve drug absorption by the skin.

IT 73771-04-7, Prednicarbate 104286-02-4
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (solid lipid nanoparticles as carriers for topical glucocorticoids)

RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 104286-02-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11,21-dihydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:21587 CAPLUS
 DOCUMENT NUMBER: 132:59186
 TITLE: Loteprednol etabonate nasal drops for treatment of olfactory diseases
 INVENTOR(S): Kimura, Seiko; Sato, Kiichi
 PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JXXXXF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000007569	A2	20000111	JP 1998-189751	19980619
PRIORITY APPLN. INFO.: JP 1998-189751 19980619				
AB Nasal drops contg. 0.01-10.0 W/V loteprednol etabonate as suspensions with particles 1-500 .mu.m in diam. are claimed for treatment of olfactory diseases. Loteprednol etabonate promoted olfactory epithelium regeneration. Examples of suspensions were formulated.				
IT 82034-46-6, Loteprednol etabonate				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (loteprednol etabonate nasal drops for treatment of olfactory diseases)				
RN 82034-46-6 CAPLUS				
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L9 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:722298 CAPLUS
 DOCUMENT NUMBER: 132:269970
 TITLE: Local tolerability of solid lipid nanoparticles for dermal use
 AUTHOR(S): Maia, C.; Gysler, A.; Mehnert, W.; Mueller, R. H.; Schaefer-Korting, M.
 CORPORATE SOURCE: Department of Pharmacy (Pharmacology and Toxicology; Pharmaceutical Technology, Biopharmacy and Biotechnology), Freie Universitaet Berlin, Berlin, D-14195, Germany
 SOURCE: Proceedings of the International Symposium on Controlled Release of Bioactive Materials (1999), 26th, 399-400
 CODEN: PCRMFY; ISSN: 1022-0178
 PUBLISHER: Controlled Release Society, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The tolerability of the topical glucocorticoid, prednicarbate, incorporated into solid nanoparticles of various lipids was investigated in monolayer cultures of human skin keratinocytes and fibroblasts in vitro. Prednicarbate did not influence cellular viability. Tolerability declined considerably if irritative detergents were used in lipid nanoparticle formation. Witepsol and Dynasan 114 adversely affected keratinocyte viability, but Lipoid S was well tolerated.
 IT 73771-04-7, Prednicarbate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Local tolerability of solid lipid nanoparticles for dermal use)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:526188 CAPLUS
 DOCUMENT NUMBER: 131:267192
 TITLE: Modulation of irritation-induced increase of E-selectin mRNA in vivo by topically applied corticosteroids
 AUTHOR(S): Kukutsch, Nicole A.; Coors, Esther A.; Gruschwitz, Matthias S.; Von den Driesch, Peter
 CORPORATE SOURCE: Department of Dermatology, University of Erlangen-Nuremberg, Erlangen, Germany
 SOURCE: Journal of Investigative Dermatology (1999), 113(2), 170-174
 CODEN: JIDEAE; ISSN: 0022-202X
 PUBLISHER: Blackwell Science, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB There is a continuous need for methods to evaluate the biol. effects of topically applied drugs in the skin. Irritation of the epidermis with SDS leads to an upregulation of E-selectin on endothelial cells and E-selectin mRNA can be detected in vivo within a short time. This study was aimed to investigate whether this biol. response can be used as a read-out for the anti-inflammatory effect of topically administered corticosteroids. The authors investigated skin of healthy volunteers treated according to the two following exptl. protocols: (i) topical application of different corticosteroids (vs. basic ointments as controls) for 12 h and irritation with SDS 1% for 4 h; (ii) irritation with SDS 1% for 12 h and application of the corticosteroids for 5 h. The biopsy specimens were subjected to RNA extrn. and reverse transcription and competitive reverse transcriptase-polymerase chain reaction was performed using defined concns. of a pre-constructed mimic DNA. As result, the authors found strong pos. signals for wild-type E-selectin mRNA in all biopsies pretreated with basic ointments, whereas in biopsies from areas pretreated with corticosteroids the bands for wild-type E-selectin DNA could be detected at 10-1000 lower levels of mimic DNA concns. The reverse expt., application of corticosteroids after the irritation, again yielded significantly reduced signals for E-selectin mRNA. In both exptl. settings, the different strength of the topical corticosteroids used was reflected by significant differences in the amt. of E-selectin mRNA found in the biopsies. This study demonstrates the pharmacol. effect of topical corticosteroids on the irritation-induced E-selectin mRNA expression on dermal endothelial cells in vivo using very small tissue samples and this approach may be of value for further pharmaceutical studies.
 IT 73771-04-7, Prednicarbate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Corticosteroid topical administration modulation of irritation-induced increase of E-selectin mRNA in vivo by topically applied corticosteroids)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

IT 73771-04-7, Prednicarbate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Corticosteroid topical administration modulation of irritation-induced increase of E-selectin mRNA in vivo by topically applied corticosteroids)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L9 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:522135 CAPLUS
 DOCUMENT NUMBER: 131:134676
 TITLE: Antipsoriatic nail polishes containing glucocorticoids
 INVENTOR(S): Bohn, Manfred; Kraemer, Karl Theodor
 PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland GmbH, Germany
 SOURCE: Can. Pat. Appl., 13 pp.
 CODEN: CPXKEB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2245637	AA	19990221	CA 1998-2245637	19980820
EP 913154	A1	19990506	EP 1998-115049	19980811
EP 913154	B1	20021120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 227993	E	20021215	AT 1998-115049	19980811
US 2001006625	A1	20010705	US 1998-135657	19980818
US 6352686	B2	20020305		
BR 9803756	A	20000328	BR 1998-3756	19980819
NO 9803818	A	19990222	NO 1998-3818	19980820
ZA 9807531	A	19990222	ZA 1998-7531	19980820
CN 1209318	A	19990303	CN 1998-118470	19980820
AU 9880856	A1	19990304	AU 1998-80856	19980820
AU 740615	B2	20011108		
JP 11130679	A2	19990518	JP 1998-233671	19980820
US 2002071815	A1	20020613	US 2001-13728	20011213
PRIORITY APPLN. INFO.:				
			DE 1997-19736112 A	19970821
			US 1998-135657	A1 19980818
AB A nail polish comprises at least one glucocorticoid, at least one physiol. acceptable solvent and at least one water-insol. film-forming agent. The nail polish is suitable for the treatment of nail psoriasis. A nail polish contained clobetasol-17-propionate 8, Me vinyl ether-nobutyl maleate copolymer (in isopropanol) 30, isopropanol 31, and EtOAc 31.4.				
IT 73771-04-7, Prednicarbate RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antipsoriatic nail polishes contg. glucocorticoids and film-forming polymers) RN 73771-04-7 CAPLUS CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME) Absolute stereochemistry.				

L9 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 31 OF 63 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1999:33868 CAPLUS
 DOCUMENT NUMBER: 131:683
 TITLE: Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis
 CORPORATE SOURCE: The Loteprednol Etabonate US Uveitis Study Group, USA
 SOURCE: American Journal of Ophthalmology (1999), 127(5), 537-544
 CODEN: AJOPAA; ISSN: 0002-9394
 PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Aim of this study was to compare the safety and efficacy of loteprednol etabonate 0.5% ophthalmic suspension with prednisolone acetate 1.0% ophthalmic suspension in reducing the ocular signs and symptoms assocd. with acute anterior uveitis. Two prospective studies were conducted in sequence. Both were parallel, randomized, double-masked, active-controlled comparisons conducted at academic or private clinics in the United States. Efficacy was evaluated by the proportion of patients with a score of 0 for key signs and symptoms of uveitis. Intraocular pressure was increased regularly. The first study involved up to 42 days of treatment, starting with a dose of eight times per day. The second study involved up to 28 days of treatment, starting with a dose of 16 times per day. In the first study (N = 70), the proportion of patients achieving resolu. by the final visit was anterior chamber cell (74% loteprednol etabonate, 88% prednisolone acetate, P = .194) and flare (71% loteprednol etabonate, 81% prednisolone acetate, P = .330). In the second study (N = 175), the proportion of patients achieving resolu. by the final visit was anterior chamber cell (72% loteprednol etabonate, 87% prednisolone acetate, P = .015) and flare (66% loteprednol etabonate, 82% prednisolone acetate, P = .017). In both studies, intraocular pressure increase of more than 10 mm Hg was obsd. more frequently in patients receiving prednisolone acetate (seven patients) than those receiving loteprednol etabonate (one patient). Although a clin. meaningful redn. of signs and symptoms was noted in both treatment groups, loteprednol etabonate was less effective than prednisolone acetate in both of these controlled studies. However, the more favorable profile of loteprednol etabonate with respect to intraocular pressure increase may make it useful in many patients.

IT 82034-46-6, Loteprednol etabonate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THW (Therapeutic use); BIOL (Biological study); USES (Uses)
 (loteprednol etabonate and prednisolone acetate effect in reducing the ocular signs and symptoms assocd. with acute anterior uveitis in humans)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 31 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 32 OF 63 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1999:28070 CAPLUS
 DOCUMENT NUMBER: 130:321225
 TITLE: Delivery system for allergy medication via the nasal vestibules
 INVENTOR(S): Lin, Matthew M.; Lin, Audrey H.
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 10 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920248	A1	19990429	WO 1998-US22274	19981021
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5972327	A	19991026	US 1997-955963	19971022
CA 2308030	AA	19990429	CA 1998-2308030	19981021
PRIORITY APPLN. INFO.:			US 1997-955963	A 19971022
			WO 1998-US22274	W 19981021

AB A method for treating allergic rhinitis in a patient is disclosed which comprises applying an anti-allergic rhinitis effective amt. of a steroid in ointment or cream carrier to the lining of the vestibules of the patient.


IT 73771-04-7, Prednicarbate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THW (Therapeutic use); BIOL (Biological study); USES (Uses)
 (steroidal allergy medication delivery via nasal vestibules)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:109599 CAPLUS
 DOCUMENT NUMBER: 130:134390
 TITLE: Loteprednol etabonate, a new soft steroid is effective in a rabbit acute experimental model for arthritis
 AUTHOR(S): Buris, L. F.; Bodor, N.; Buris, Laslo
 CORPORATE SOURCE: First Dep. Surgery, Medical Univ. Debrecen, Debrecen, H-4032, Hung.
 SOURCE: Pharmazie (1999), 54(1), 58-61
 CODEN: PHARAT; ISSN: 0031-7144
 PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Loteprednol etabonate, a new soft steroid designed for use as a local therapeutic, was compared to dexamethasone in rabbit exptl. model for arthritis. Joint inflammation was induced by local injection of antigen into the patellofemoral articulation in sensitized rabbits. Co-administration of either dexamethasone or loteprednol etabonate directly into the joint effectively blocked the inflammatory response. Both the synovial fluid cellular content and synovium histol. were examd. The steroid treatments prevented the adverse inflammatory effects of antigen action. These results, together with previous studies showing decreased systemic activity of the soft steroid, indicate that the loteprednol etabonate could provide a therapeutic advantage over currently used intra-articular steroids for alleviating rheumatoid arthritis.
 IT 82034-46-6, Loteprednol etabonate
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 34 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1998:797332 CAPLUS
 DOCUMENT NUMBER: 130:148866
 TITLE: The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate
 AUTHOR(S): Abelson, Mark; Howes, John; George, Michelle
 CORPORATE SOURCE: Ophthalmic Research Associates, North Andover, MA, USA
 SOURCE: Journal of Ocular Pharmacology and Therapeutics (1998), 14(6), 533-542
 CODEN: JOPTFV; ISSN: 1080-7683
 PUBLISHER: Mary Ann Liebert, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Two studies were conducted using the conjunctival provocation test (CPT) model of ocular allergy. The objective of the first study was to evaluate the sensitivity of the CPT model to a topical corticosteroid. Selected was loteprednol etabonate 0.5%, previously found effective in the treatment of ocular allergy and inflammation. The study was a randomized double-masked, placebo-controlled, paired-comparison of loteprednol etabonate 0.5% (LE), b.i.d. or q.i.d. Sixty subjects who had a min. pre-detd. allergic response received LE in one eye and placebo in the fellow eye for 28 days from Day 7 to Day 35. Antigen challenges were carried out on Days 0, 7 (baseline), 21 and 35. The primary endpoints were interocular differences in itching and mean redness (the av. of ciliary, conjunctival and episcleral vessel beds). LE (either b.i.d. or q.i.d.) was significantly more effective than placebo for reducing mean redness and itching. No clin. or statistically significant changes in intraocular pressure were obsd. Based upon the results of Study 1, we used the CPT model to aid in the selection of a concn. of loteprednol etabonate for subsequent studies in environmental seasonal allergic conjunctivitis. This was a randomized double-masked, placebo-controlled, paired-comparison of loteprednol etabonate 0.1%, 0.2% and 0.3%, q.i.d. in 88 subjects. The dosing and testing regimen was similar to the first portion of the study. Loteprednol etabonate, 0.1%, 0.2% and 0.3%, was numerically superior to the placebo in reducing mean redness and itching. At the 20-min post allergen challenge, the 0.1% concn. was significantly superior (p < 0.05) to the placebo on Visit 4 (2 and 4 h challenge) in reducing the mean redness; however, LE was only numerically superior in relieving itching. The 0.2% concn. was significantly superior (p < 0.05) to the placebo in the redn. of mean redness and itching on Visit 3 (Day 21) and in redn. of mean redness on Visit 4 (4 h challenge). The 0.3% concn. was significantly superior (p < 0.05) to the placebo in the redn. of mean redness on all visits, and statistically significant in the redn. of itching on Visit 4 (4 h challenge). While there were some elevations of IOP with LE 0.2%, they were not clin. significant.
 IT 82034-46-6, Loteprednol etabonate
 RI: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (the conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L9 ANSWER 34 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1998:741802 CAPLUS
 DOCUMENT NUMBER: 130:148726
 TITLE: Loteprednol etabonate: clinical potential in the management of ocular inflammation
 AUTHOR(S): Noble, Stuart; Goa, Karen L.
 CORPORATE SOURCE: Adis International Limited, Auckland, N. Z.
 SOURCE: BioDrugs (1998), 10(4), 329-339
 CODEN: BIODR4; ISSN: 1173-8804
 PUBLISHER: Adis International Ltd.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 33 refs. Loteprednol etabonate is a corticosteroid which is the product of "soft drug" design (synthesis of a compd. that undergoes predictable metab. to inactive metabolites after its therapeutic effects have been expressed at or near the site of application). It has been developed as a topical treatment for ocular inflammation. Loteprednol etabonate is designed to be rapidly converted to inactive and nontoxic metabolites, thus minimizing systemic adverse effects. The concn. of the drug in plasma from 10 healthy volunteers who received ocular loteprednol etabonate at therapeutic or supra-therapeutic dosages was below the limit of detection. In 2 double-masked, placebo-controlled studies, loteprednol etabonate 0.5% 4 times daily (1 drop/eye) for 2 wk was more effective than placebo in relieving moderate to severe postoperative ocular inflammation after cataract surgery. The same regimen was also effective when administered for up to 6 wk in 3 double-masked placebo-controlled studies in patients with moderate or severe contact lens-assoc. giant papillary conjunctivitis. Data from 2 double-masked placebo-controlled studies indicate that loteprednol etabonate 0.2% (1 drop/eye 4 times daily for 2 wk) is effective in patients with moderate to severe seasonal allergic conjunctivitis. Furthermore, a single placebo-controlled trial has shown that loteprednol etabonate 0.5% has prophylactic efficacy in patients with a history of seasonal allergic conjunctivitis. Ocular loteprednol etabonate was well tolerated, both locally and systemically, in clin. trials reported to date. Elevated intraocular pressure (IOP) is possible after ocular administration of the drug but is infrequent overall: only 1.7% of 901 patients or volunteers who received loteprednol 0.2 or 0.5% for .gtoreq.28 days had a clin. significant increase (.gtoreq.10mm Hg) in IOP. Unlike prednisolone acetate, loteprednol etabonate did not significantly increase IOP from baseline in a small randomized crossover study in known steroid responders. There were no serious or unexpected treatment-related ocular adverse events in patients receiving loteprednol etabonate in clin. trials. The potential for cataract formation or glaucoma after long term treatment is unknown. Thus, loteprednol etabonate can reduce ocular inflammation caused by cataract surgery, seasonal allergic conjunctivitis or contact lens wear. The benign tolerability profile of loteprednol etabonate, in particular its low propensity to cause elevated IOP (when used in the short term) is an attractive characteristic. However, the place of loteprednol etabonate in clin. practice cannot be properly assessed until direct efficacy comparisons with other active treatments are available.
 IT 82034-46-6, Loteprednol etabonate
 RI: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ocular inflammation in humans treatment with)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L9 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:682113 CAPLUS

DOCUMENT NUMBER: 129:39893

TITLE: Means of ascertaining an individual's risk profile for atherosclerotic disease based on systemic inflammation marker levels

INVENTOR(S): Ridker, Paul; Hennekens, Charles H.

PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc., USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9843630	A1	19981008	WO 1998-US6613	19980402
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9871008	A1	19981022	AU 1998-71008	19980402
US 6040147	A	20000321	US 1998-54212	19980402
EP-1003501	A1	20000531	EP 1998-917992	19980402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001525058	T2	20011204	JP 1998-542023	19980402
PRIORITY APPLN. INFO.:			US 1997-41950P	P 19970402
			US 1997-43039P	P 19970402
			US 1998-70894P	P 19980109
			WO 1998-US6613	W 19980402

AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder. The primary basis for this invention is evidence from the Physicians' Health Study, a large scale, randomized, double-blind, placebo-controlled trial of aspirin and .beta.-carotene in the primary prevention of cardiovascular disease conducted among 22,000 apparently healthy men. In that trial, baseline level of C-reactive protein, a marker for underlying systemic inflammation, was found to det. the future risk of myocardial infarction and stroke, independent of a large series of lipid and non-lipid risk factors. Baseline C-reactive protein level was not assocd. with venous thrombosis, a vascular event generally not assocd. with atherosclerosis. Further, the data indicate that the magnitude of benefit that apparently healthy individuals can expect from prophylactic aspirin is dependent in large part upon baseline level of C-reactive protein.

IT 82034-46-6, Loteprednol etabonate

RL: BSU (Biological study, unclassified); THU (Therapeutic use);

BIOL (Biological study); USES (Uses)


(systemic inflammation marker level in evaluation of cardiovascular disorder risk redn. by)

RN 82034-46-6 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

L9 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:668086 CAPLUS

DOCUMENT NUMBER: 129:281016

TITLE: Aqueous suspension of loteprednol etabonate with stable pH

INVENTOR(S): Inada, Katsuhiko; Terayama, Hideo

PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 6 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 868919	A2	19981007	EP 1998-104220	19980310
EP 868919	A3	20011219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 5916550	A	19990629	US 1998-35094	19980305
CA 2231977	AA	19980914	CA 1998-2231977	19980312
AU 9858412	A1	19980917	AU 1998-58412	19980312
AU 730196	B2	20010301		
JP 10316572	A2	19981202	JP 1998-83037	19980312
JP 3147076	B2	20010319		

PRIORITY APPLN. INFO.:

AB The conventional aq. suspension of loteprednol etabonate (I) is not easily amenable to prodn. pH control and entails a pH depression on long-term storage, thus irritating the eye or the nasal mucosa on instillation.

When a C2-7 aliph. amino acid is added to an aq. suspension of loteprednol etabonate for topical ophthalmic use, the suspension does not undergo pH depression even on prolonged storage, with the result that no irritable response is elicited in the eye or nasal mucosa. An eye drop contained 1 0.5, concd. glycerin 2.6, .epsilon.-aminocaproic acid Tyloxapol 0.3, PVP 0.6, sodium edetate 0.01 g, benzalkonium chloride 0.05 mL, hydrochloric acid q.s. and water q.s. 100 mL, pH = 5.53. The pH of the soln. after 6 mo of storage at 40.degree. and 75% relative humidity was 5.11.

IT 82034-46-6, Loteprednol etabonate


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aq. suspension of loteprednol etabonate with stable pH)

RN 82034-46-6 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

L9 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:584945 CAPLUS
 DOCUMENT NUMBER: 130:592
 TITLE: A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis
 AUTHOR(S): Dell, Steven J.; Lowry, George M.; Northcutt, James A.; Howes, John; Novack, Gary D.; Hart, Kathryn
 CORPORATE SOURCE: Texan Eye Care, Austin, TX, USA
 SOURCE: Journal of Allergy and Clinical Immunology (1998), 102(2), 251-255
 CODEN: JACIBY; ISSN: 0091-6749
 PUBLISHER: Mosby, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Loteprednol etabonate (0.2% ophthalmic suspension) was more effective than placebo in the treatment of seasonal allergic conjunctivitis. The substance had a safety profile comparable to that of placebo during this 6-wk trial.
 IT 82034-46-6, Loteprednol etabonate
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (allergic-conjunctivitis-of-humans-treatment-with-ophthalmic-suspension-of)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2003 ACS

L9 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

ACCESSION NUMBER: 1998:371047 CAPLUS
 DOCUMENT NUMBER: 129:90492
 TITLE: Prednicarbate: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders
 AUTHOR(S): Spencer, Caroline M.; Wagstaff, Antona J.
 CORPORATE SOURCE: Adis International Limited, Auckland, N. Z.
 SOURCE: BioDrugs (1998), 9(1), 61-86
 CODEN: BIDRPF; ISSN: 1173-8904
 PUBLISHER: Adis International Ltd.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 82 refs. Prednicarbate is a synthetic, nonhalogenated, moderate-to-high-potency corticosteroid. It is rapidly metabolized to prednisolone during skin permeation. Prednicarbate is indicated for relief of inflammation and pruritus assocd. with corticosteroid-responsive dermatol. disorders such as dermatitis (eczema) [including atopic dermatitis] and psoriasis and can be used in children and elderly patients. Large clin. trials conducted in patients with various dermatoses confirm the efficacy of the drug. Smaller trials, conducted in patients with dermatitis, show prednicarbate generally to have activity similar to that of comparable corticosteroids. Data concerning use of prednicarbate in psoriasis are more limited, although again the drug demonstrated efficacy similar to that of the corticosteroids with which it was compared. The tolerability of prednicarbate was generally good, although methods of recording adverse events were not clearly reported in many trials. The atrophogenic potential of prednicarbate appears to be low when no occlusion is used. However, atrophogenic effects increase with occlusion. Therefore, prednicarbate is a useful option for the treatment of corticosteroid-responsive dermatoses and appears to have low atrophogenic potential when used without occlusion.
 IT 73771-04-7, Prednicarbate
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); EPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (skin diseases of humans treatment by)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1998:282324 CAPLUS
 DOCUMENT NUMBER: 128:326537
 TITLE: Suspension of loteprednol etabonate for ear, eye, or nose treatment
 INVENTOR(S): Amselem, Shimon; Friedman, Doron
 PATENT ASSIGNEE(S): Pharmos Corp., USA
 SOURCE: U.S., 8 pp., Cont.-in-part of U.S. 5,540,930.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5747061	A	19980505	US 1996-688157	19960729
US 5540930	A	19960730	US 1993-142743	19931025
CA 2174550	AA	19950504	CA 1994-2174550	19941021
HU 74882	A2	19970228	HU 1996-1081	19941021
IL 111402	A1	20001206	IL 1994-111402	19941025
			US 1993-142743	A2 19931025

PRIORITY APPLN. INFO.:

AB The invention provides novel compns. of matter for delivering water-insol. steroid drugs suitable for therapeutic use. The invention also provides stable aq. suspensions of water-insol. steroid drugs of particle sizes of .1 to eq. 30 .mu.m which remain in such a state so as to allow for immediate suspension, when desired, even after extended periods of settling. An aq. ophthalmic suspension was formulated contg. PVP 0.6, glycerin 2.4, tyloxapol 0.3, edetate disodium 0.01, benzalkonium chloride 0.01, and loteprednol etabonate 0.5%. The suspension was evaluated on patients having giant papillary conjunctivitis, allergic conjunctivitis, and acute anterior uveitis. The compn. was well tolerated in all patients and was significantly more effective than the vehicle itself, which was used as a placebo, with regard to the redn. of signs and symptoms of ocular inflammation.

IT 82034-46-6, Loteprednol etabonate


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (suspension of corticosteroids for ear and eye and nose treatment)

RN 82034-46-6 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 41 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1998:41614 CAPLUS
 DOCUMENT NUMBER: 128:149716
 TITLE: Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro
 AUTHOR(S): Lange, Katharina; Gysler, Anja; Bader, Michael; Kleuser, Burkhard; Korting, Hans Christian; Schafer-Korting, Monika
 CORPORATE SOURCE: Institut für Pharmazie II, Abteilung Pharmakologie und Toxikologie, Freie Universität Berlin, Berlin, D-14195, Germany
 SOURCE: Pharmaceutical Research (1997), 14(12), 1744-1749
 CODEN: PHREEB; ISSN: 0724-8741
 PUBLISHER: Plenum Publishing Corp.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The purpose of the study was pharmacodynamic characterization of topical prednicarbate (PC), its metabolites prednisolone 17-ethylcarbonate (PEC) and prednisolone (PD), betamethasone 17-valerate (BMV), betamethasone (BM) and desoximetasone (DM) by evaluating their effects on epidermal and dermal cells. An addnl. purpose was the synopsis of pharmacokinetic and pharmacodynamic studies, possibly explaining the improved benefit-risk ratio of prednicarbate. Isolated foreskin keratinocytes were used to investigate the influence on epidermal inflammatory processes, dermal fibroblasts of the same origin to study antiproliferative activities of glucocorticoids. Interleukins were measured by ELISA-assay, the influence on II-1.alpha.-prodn. also on mRNA-level by RNase protection assay. Proliferation was assessed by 3H thymidine incorporation and biodegrdn. by HPLC/UV-absorption. Cell viability was controlled by MTT assay. In keratinocytes, inflammation was induced by TNF.alpha., resulting in an increased II-1.alpha. synthesis. This cytokine was particularly suppressed by PC and BMV, whereas PEC, PD, DM and BM were less potent (p .ltoreq. 0.05). Since, however, the double ester PC is rapidly degraded in keratinocytes, an RNase-protection assay of II-1.alpha. mRNA was performed allowing short incubation times and thus minimizing biodegrdn. effects. In agreement with the previous expt., the antiinflammatory potency of native PC was confirmed. In fibroblasts, II-1.alpha. and II-6 synthesis indicate proliferation and inflammation resp. Whereas PC inhibited II-1.alpha. and II-6 prodn. in fibroblasts to a minor extent only, it was strongly reduced by the conventional glucocorticoids and PEC (p .ltoreq. 0.05). The minor unwanted effect of PC on fibroblasts was also reflected by its low influence on cell proliferation as assayed by 3H thymidine incorporation. More pronounced antiproliferative features were obsd. with BM, PEC and esp. BMV. Correlating antiphlogistic effects in keratinocytes (suppression of II-1.alpha.) with antiproliferative effects in fibroblasts (suppression of II-1.alpha. and II-6), the improved benefit-risk ratio of PC compared to conventional glucocorticoids does not result only from distinct drug metab. in the skin but also from a specific influence on the cytokine network.


IT 73771-04-7, Prednicarbate

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (antiinflammatory and antiproliferative effect of prednicarbate and its metabolites in foreskin keratinocytes and dermal fibroblasts)

RN 73771-04-7 CAPLUS


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

L9 ANSWER 41 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 Absolute stereochemistry.



L9 ANSWER 42 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1998:20642 CAPLUS
 DOCUMENT NUMBER: 128:136544
 TITLE: Loteprednol etabonate.
 AUTHOR(S): Graul, A.; Martin, L.; Castaner, J.
 CORPORATE SOURCE: Prous Science Publishers, Barcelona, 08080, Spain
 SOURCE: Drugs of the Future (1997), 22(10), 1086-1090
 CODEN: DRFUD4; ISSN: 0377-8282
 PUBLISHER: J. R. Prous, S.A.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 38 refs. covering the synthesis, pharmacol., pharmacokinetics, metab., and clin. studies of loteprednol etabonate as an ocular antiinflammatory agent.
 IT 82034-46-6P, Loteprednol etabonate
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 43 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:760006 CAPLUS
 DOCUMENT NUMBER: 128:18835
 TITLE: Measurement of antiinflammatory effects of glucocorticoids on human keratinocytes in vitro. Comparison of normal human keratinocytes with the keratinocyte cell line HaCaT
 AUTHOR(S): Stein, Martina; Bernd, August; Ramirez-Bosca, Ana; Kippenberger, Stefan; Holzmann, Hans
 CORPORATE SOURCE: Zentrum Dermatologie Venerologie, Johann Wolfgang Goethe-University, Frankfurt/Main, D-60590, Germany
 SOURCE: Arzneimittel-Forschung (1997), 47(11), 1266-1270
 CODEN: ARZMAD; ISSN: 0004-4172
 PUBLISHER: Editio Cantor Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB There are only few objective in vitro methods available for the testing of antiinflammatory pharmaceutical products. One possibility is in the stimulation of cytokine prodn. in cultivated human keratinocytes by UV light and the subsequent testing of suppressing activities. From the dermatol. aspect the interleukins 6 and 8 are esp. interesting because they are elevated in psoriatic skin. In the present work three glucocorticoids were tested in cultures of normal human keratinocytes and in the permanent keratinocyte cell line HaCaT. Both cell species produced IL-6 and IL-8 spontaneously, albeit in very small amts. After UV irradiation the interleukin prodn. increased in a dose dependent manner. The IL-6 and IL-8 induction could be suppressed by each of the glucocorticoids tested. The thymidine incorporation rate of the cells was not affected by the glucocorticoids indicating that the obsd. suppression of cytokine induction was not the result of a generalized cell damage. The response of both HaCaT keratinocytes and primary human keratinocytes to UV irradiation and glucocorticoid application was similar indicating the possible use of the generally available HaCaT cells for the pharmacol. testing of antiinflammatory activities in vitro.
 IT 73771-04-7, Prednicarbate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 43 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 44 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:533539 CAPLUS
 DOCUMENT NUMBER: 127:210356
 TITLE: Glucocorticoids and zinc compound for the treatment of skin disorders.
 INVENTOR(S): Story, Michael John; Williams, Desmond Berry
 PATENT ASSIGNEE(S): Bellara Medical Products Ltd., Australia; Story, Michael John; Williams, Desmond Berry
 SOURCE: PCT Int. Appl., 21 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727862	A1	19970807	WO 1997-AU48	19970130
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9715365	A1	19970822	AU 1997-15365	19970130
PRIORITY APPLN. INFO.:			AU 1996-7847	19960202
			WO 1997-AU48	19970130
AB	A method for the treatment of skin disorders comprises the application of a formulation consisting of a glucocorticosteroid and a pharmaceutically acceptable zinc compd. The zinc compd. may be zinc monoglycerolate. The efficacy of topical zinc monoglycerolate was equiv. to that of 1% hydrocortisone ointment in the treatment of atopic dermatitis.			
IT	73771-04-7, Prednicarbate RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (glucocorticoids and zinc compd. for treatment of skin disorders)			
RN	73771-04-7 CAPLUS			
CN	Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.




L9 ANSWER 44 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

L9 ANSWER 45 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:432135 CAPLUS
 DOCUMENT NUMBER: 127:90292
 TITLE: A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis
 AUTHOR(S): Dell, Steven J.; Shulman, David G.; Lowry, George M.; Howes, John
 CORPORATE SOURCE: Texan Eye Care and Clinicor, Austin, TX, USA
 SOURCE: American Journal of Ophthalmology (1997), 123(6), 791-797
 CODEN: AJOPAA; ISSN: 0002-9394
 PUBLISHER: Ophthalmic Publishing Co
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB To evaluate the efficacy and safety of loteprednol etabonate 0.5% as prophylactic treatment for the ocular signs and symptoms of seasonal allergic conjunctivitis. In this randomized, double-masked, placebo-controlled, parallel study, 293 adults with history of seasonal allergic conjunctivitis were treated with either loteprednol etabonate or vehicle (placebo) four times daily, beginning before the onset of the allergy season and continuing for 6 wk. The primary efficacy measure was a primary composite score (sum of itching and bulbar conjunctival injection scores). Supportive efficacy measures were the investigator global assessment and a secondary composite score (sum of tearing, erythema, chemosis, and discomfort scores), all calcd. during the 21-day peak pollen season. The proportion of patients who never developed moderate or severe signs and symptoms of allergy during the peak pollen season in the loteprednol etabonate treatment group was greater than that in the placebo group. For the primary composite score, this efficacy criterion was reached by 94% of patients (136/145) in the loteprednol etabonate group and 78% of patients (111/143) in the placebo group ($P = .001$). The magnitude of effect was similar for the investigator global assessment (86% [118/138] vs 64% [87/137]; $P < .001$) and, although not statistically significant, the secondary composite score (77% [112/145] vs 68% [97/143]; $P = .092$). None of the loteprednol etabonate-treated patients had an intraocular pressure increase of 10 mm Hg or more, whereas two placebo patients did. Loteprednol etabonate is generally effective in prophylaxis of seasonal allergic conjunctivitis and has an acceptable safety profile.
 IT 82034-46-6, Loteprednol etabonate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L9 ANSWER 45 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 46 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:428164 CAPLUS
 DOCUMENT NUMBER: 127:145308
 TITLE: Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts
 AUTHOR(S): Gysler, Anja; Lange, Katharina; Korting, Hans Christian; Schaefer-Korting, Monika
 CORPORATE SOURCE: Institut für Pharmazie II, Abteilung für Pharmakologie und Toxikologie, Freie Universität Berlin, Berlin, 14195, Germany
 SOURCE: Pharmaceutical Research (1997), 14(6), 793-797
 CODEN: PHREEB; ISSN: 0724-8741
 PUBLISHER: Plenum
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB This study was conducted for evaluation of skin layer-specific prednicarbate (PC) biotransformation, possibly explaining the improved benefit/risk ratio of this topical corticosteroid in atopic dermatitis. Metab. of PC in keratinocyte and fibroblast monolayers derived from human juvenile foreskin was evaluated. Drug concn. was detd. by HPLC/UV-absorption. Accompanying cell viability tests (MTT-tests) were performed to exclude toxic drug effects. Keratinocytes hydrolyzed the double ester PC (2.5.times.10⁻⁶ M) at position 21 to the monoester prednisolone 17-ethylcarbonate (P17EC) which nonenzymically transformed to prednisolone 21-ethylcarbonate (P21EC). This metabolite was enzymically cleaved to prednisolone (PD), the main biotransformation product at 24 h. Fibroblasts, however, showed a distinctively lower enzyme activity. Both, PC and P17EC (or rather P21EC) were hydrolyzed to a minor extent only. The biotransformation pathway, however, was the same. When P17EC was added sep., it transformed to P21EC and again was cleaved by keratinocytes to a much higher extent. Despite of the rather high glucocorticoid concn. MTT-tests proved a non-disturbed cell viability and proliferation rate. Extrapolating our results to the in-vivo situation, topically applied PC may be metabolized by epidermal cells during skin penetration. A complex mixt. of compds. reaches the dermis, whose fibroblasts are barely able to metabolize the steroids. Since skin atrophy is less pronounced with PC as compared to conventional halogenated glucocorticoids, less potent PC metabolites appear to be the dominant species in the dermis.
 IT 73771-04-7, Prednicarbate
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prednicarbate biotransformation in human skin keratinocytes and fibroblasts in benefit-risk detn. for topical use for atopic dermatitis)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L9 ANSWER 46 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




L9 ANSWER 47 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:377881 CAPLUS
 DOCUMENT NUMBER: 126:347271
 TITLE: Combination of LTD4 receptor antagonists with glucocorticosteroids
 INVENTOR(S): Burchardt, Elmar-Reinhold; Mueller-Peddinghaus, Reiner; Abram, Trevor S.
 PATENT ASSIGNEE(S): Bayer A.-G., Germany; Burchardt, Elmar-Reinhold; Mueller-Peddinghaus, Reiner; Abram, Trevor S.
 SOURCE: PCT Int. Appl., 13 pp.
 CODEN: PIXXD2
 PATENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9715298	A1	19970501	WO 1996-EP4391	19961010
W:	AU, BG, BR, BY, CA, CN, CZ, EE, HU, IS, JP, KE, KP, KR, LT, LV, MK, NO, NZ, PL, RO, RU, SG, SI, SK, UA, US, VN			
RW:	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
AU 9672891	A1	19970515	AU 1996-72891	19961010
PRIORITY APPLN. INFO.:			GB 1995-21696	19951023
			WO 1996-EP4391	19961010

OTHER SOURCE(S): MARPAT 126:347271
 AB The invention relates to a combination of glucocorticosteroids with LTD4 receptor antagonists in medicaments for the treatment of inflammatory disorders, esp. of the airways. Esp. preferred LTD4 receptor antagonists are PhO(CH2)4O(p-C6H4)CH2CH2CHCH[S(p-C6H4)COOR2]CH2CH2COOR1 [R1, R2=H, (branched) C1-6-alkyl, benzyl].
 IT 73771-04-7, Prednicarbate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination of LTD4 receptor antagonists with glucocorticosteroids)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 48 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:282935 CAPLUS
 DOCUMENT NUMBER: 126:325147
 TITLE: A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis
 AUTHOR(S): Friedlaender, Mitchell H.; Howes, John
 CORPORATE SOURCE: Scripps Clinic Medical Group, Inc, La Jolla, CA, 92037, USA
 SOURCE: American Journal of Ophthalmology (1997), 123(4), 455-464
 CODEN: AJOPAA; ISSN: 0002-9394
 PUBLISHER: Ophthalmic Publishing Co
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The objective is to evaluate the safety and effectiveness of loteprednol etabonate 0.5% ophthalmic suspension in reducing the ocular signs and symptoms accompanying contact lens-assocd. giant papillary conjunctivitis. In a randomized, double-masked, placebo-controlled, parallel-group study conducted at 14 academic or private practice clinics, 223 adults with contact lens-assocd. giant papillary conjunctivitis received either loteprednol or the loteprednol vehicle (placebo), one drop, four times daily for 6 wk. Papillae, itching, contact lens intolerance, other signs and symptoms of giant papillary conjunctivitis (0-to-3 or 0-to-4 grade scales), and intraocular pressure were measured. The proportion of patients treated with loteprednol who at final visit demonstrated an improvement in papillae of at least one grade (78%, 85/109) was significantly greater than the proportion of those treated with placebo (51%, 56/110; P = .001). A treatment difference favoring loteprednol was seen with improvement in itching (95% vs 81%, 104/109 vs 89/110; P < .001) and lens intolerance (87% vs 77%, 95/109 vs 85/110; P = .053). Eight of 109 patients (7%, all taking loteprednol) had an intraocular pressure increase of 10 mm Hg or more on at least one visit during treatment. After discontinuation of loteprednol, intraocular pressure returned to normal levels. Both treatments were well tolerated, and no serious unexpected treatment-related medical events were reported. The rapid therapeutic response combined with the low incidence and transient nature of any intraocular pressure increase suggests that loteprednol is an appropriate treatment for giant papillary conjunctivitis.
 IT 82034-46-6, Loteprednol etabonate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis in humans)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 48 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 49 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1996:464563 CAPLUS
 DOCUMENT NUMBER: 124:325395
 TITLE: Cyclodextrins as suspending agents for pharmaceutical suspensions
 INVENTOR(S): Guy, Yaacov J.
 PATENT ASSIGNEE(S): Pharmos Corp., USA
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616659	A1	19960606	WO 1995-US15348	19951128
V: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US-5576311	A	19961119	US-1994-346954	19941130
CA 2206348	AA	19960606	CA 1995-2206348	19951128
AU 9642883	A1	19960619	AU 1996-42883	19951128
AU 715895	B2	20000210		
EP 794783	A1	19970917	EP 1995-941473	19951128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10510532	T2	19981013	JP 1995-518965	19951128
PRIORITY APPLN. INFO.: US 1994-346954 19941130				
WO 1995-US15348 19951128				


AB The present invention relates to stable aq. suspension of drugs suitable for therapeutic administration without requiring solubilization or complexation of those drugs. The suspensions are stabilized with cyclodextrin type suspending agents. Stabilized suspensions of corticosteroids which employ these suspending agents are useful for therapeutic treatment of the eye, ear, or nose.

IT 82034-46-6, Loteprednol etabonate
 RI: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (cyclodextrins as suspending agents for pharmaceutical suspensions)

RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 49 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 50 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1996:311689 CAPLUS
 DOCUMENT NUMBER: 124:325395
 TITLE: An aqueous nasal suspension comprising cyclodextrin
 INVENTOR(S): Kimura, Masako; Morita, Yasushi; Fukushi, Kunihiro
 PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 709099	A2	19960501	EP 1995-114715	19950919
EP 709099	A3	19960724		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AU 9532905	A1	19960418	AU 1995-32905	19950926
CA 2159288	AA	19960329	CA 1995-2159288	19950927
JP 08151332	A2	19960611	JP 1995-274743	19950927
PRIORITY APPLN. INFO.: JP 1994-233267 19940928				

AB This invention relates to an aq. nasal suspension comprising a cyclodextrin and hardly sol. drug whose one part by wt. requires 1000 or more parts by wt. of water to yield a homogeneous mixt. at 25.degree. under one atm. pressure and whose stability const. in relation to the cyclodextrin calcd. by soly. method is not greater than 1000. The aq. nasal suspension of this invention enhances the pharmacol. efficacy of the hardly sol. drug in water, improves its retention in nasal mucosa, and prolongs the action of the drug so that the frequency of administration can be decreased. Therefore, this nasal suspension can be used as a meritorious topical nasal prepn. assuring improved patient compliance. An anti-inflammatory nasal suspension contained loteprednol etabonate 0.5, .alpha.-cyclodextrin 5.0, NaCl 0.9, NaOAc 0.1, Na edetate 0.02, benzalkonium chlorides 0.005 g, HCl q.s. to pH 5.0, and sterilized pure water to 100 mL.

IT 82034-46-6, Loteprednol etabonate
 RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aq. nasal suspension comprising cyclodextrin for delivery of hardly sol. drugs)

RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 51 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1996:236149 CAPLUS
 DOCUMENT NUMBER: 124:331294
 TITLE: Development of soft drugs for ophthalmic use
 AUTHOR(S): Hoves, John F.
 CORPORATE SOURCE: Clinical Affairs, Pharmos Corporation, Alachua, FL, 32615, USA
 SOURCE: Ocular Therapeutics and Drug Delivery (1996), 363-74.
 Editor(s): Reddy, Indra K. Technomic: Lancaster, Pa.
 CODEN: 6ZQMAZ
 DOCUMENT TYPE: Conference: General Review
 LANGUAGE: English

AB A review with 28 refs. on the design of novel drugs for the eye using a soft drug approach. This design process starts with either a known inactive metabolite or a close analog. The metabolite is then chem. modified to achieve 2 characteristics: (1) restoration of therapeutic activity, and (2) a predictable 1-step biotransformation back to the inactive metabolite. The advantages of this approach are illustrated by loteprednol etabonate and adoprolole maleate that are currently in clin. development as ophthalmic therapeutic agents.

IT 82034-46-6, Loteprednol etabonate
 RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (development of soft drugs for ophthalmic use)

RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



19 ANSWER 52 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:973836 CAPLUS
 DOCUMENT NUMBER: 124:780
 TITLE: Topical preparations containing glucocorticosteroids and magnesium salts for treatment of inflammatory skin diseases
 INVENTOR(S): Diezel, Wolfgang
 PATENT ASSIGNEE(S): Vögepharm GmbH, Germany
 SOURCE: Ger. Offen., 4 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4413154	A1	19951019	DE 1994-4413154	19940415
DE 4413154	C2	19970528		

PRIORITY APPLN. INFO.: DE 1994-4413154 19940415


AB Topical prepn. contg. a combination of glucocorticosteroids and MgCl₂ or other Mg salts act against skin diseases such as psoriasis, atopic eczema, and allergic contact eczema by inhibiting phospholipase-A₂, which is involved in formation of LTb₄. Thus, a combination of 0.25% prednicarbate cream and 3.5% MgCl₂ cream was 77% effective in reducing croton oil-induced ear edema in mice.

IT 73771-04-7, Prednicarbate
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study); UNCLASSIFIED; THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical prepn. contg. glucocorticosteroids and magnesium salts for treatment of inflammatory skin diseases)


RN 73771-04-7 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



19 ANSWER 53 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



19 ANSWER 53 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:688950 CAPLUS
 DOCUMENT NUMBER: 123:93285
 TITLE: Suspension of loteprednol etabonate
 INVENTOR(S): Guy, Yaacov J.; Friedman, Doron
 PATENT ASSIGNEE(S): Pharmos Corp., USA
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: P1XXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9511669	A1	19950504	WO 1994-US12059	19941021
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SE, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US-5540930	A	19960730	US 1993-142743	19931025
CA 2174550	AA	19950504	CA 1994-2174550	19941021
AU 9479835	A1	19950522	AU 1994-79835	19941021
AU 697617	B2	19981015		
EP 730443	A1	19960911	EP 1994-930831	19941021
EP 730443	B1	20020515		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9407958	A	19961126	BR 1994-7958	19941021
HU 74882	A2	19970228	HU 1996-1081	19941021
JP 09504294	T2	19970428	JP 1994-512725	19941021
AT 217523	E	20020615	AT 1994-930831	19941021
IL 111402	A1	20001206	IL 1994-111402	19941025

PRIORITY APPLN. INFO.: US 1993-142743 A 19931025
 WO 1994-US12059 W 19941021

AB Ophthalmic or otolaryngol. anti-inflammatory compns. comprise a corticosteroid, a nonionic polymer in an aq. medium, and a nonionic surfactant. The suspensions may contain addnl. therapeutic agents, such as antibiotics, antiglaucoma, anticancer, non-steroidal anti-inflammatory, antiviral, and antifungal drugs. A water-insol. corticosteroid loteprednol etabonate 0.5% was incorporated into a vehicle contg. polyvinylpyrrolidone 0.6, glycerol 2.4, tyloxapol 0.3, di-Na edetate 0.0005, and benzalkonium chloride 0.001%, resp., to obtain a stable aq. ophthalmic suspension for the treatment of seasonal allergic conjunctivitis.

IT 82034-46-6, Loteprednol etabonate
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study); UNCLASSIFIED; THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (suspension compns. for anti-inflammatory corticosteroid drugs)

RN 82034-46-6 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11 β ,17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

19 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:615196 CAPLUS
 DOCUMENT NUMBER: 123:33510
 TITLE: Preparation of corticosteroid 17-alkylcarbonate-21-esters as antiinflammatories.
 INVENTOR(S): Stache, Ulrich; Alpermann, Hans-Georg; Duerckheimer, Walter; Bohn, Manfred
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 43 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 640616	A2	19950301	EP 1994-113048	19940822
EP 640616	A3	19950628		
EP 640616	B1	20021127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4328819	A1	19950302	DE 1993-4328819	19930827
AT 228530	E	20021215	AT 1994-113048	19940822
FI 9403902	A	19950228	FI 1994-3902	19940825
AU 9471474	A1	19950309	AU 1994-71474	19940825
AU 674980	B2	19970116		
HU 67959	A2	19950529	HU 1994-2451	19940825
HU 217620	B	20000328		
CN 1105368	A	19950719	CN 1994-115711	19940825
CN 1062562	B	20010228		
US 5608093	A	19970304	US 1994-294804	19940825
CA 2130943	AA	19950228	CA 1994-2130943	19940826
NO 9403174	A	19950228	NO 1994-3174	19940826
ZA 9406508	A	19950328	ZA 1994-6508	19940826
JP 07089982	A2	19950404	JP 1994-223963	19940826
IL 110798	A1	20001206	IL 1994-110798	19940828

PRIORITY APPLN. INFO.: DE 1993-4328819 A 19930827
 OTHER SOURCE(S): MARPAT 123:33510

AB Title compds. [I: A = CHOH, CHCl, CO, 9(11) double bond; Y = H, F, Cl; Z = H, F, Me; R1 = (substituted or anellated) aryl, heteroaryl; X = (unsatd.) (substituted) alkylene; m, n = 0, 1; R2 = alkyl, CH₂CH₂OMe; R3 = H, Me], were prepd. Thus, a mixt. of prednisolon-17-ethylcarbonate and PhCH₂CO₂H in pyridine was treated with conc. H₂SO₄ in pyridine and then with DCC to give prednisolon-17-ethylcarbonate-21-phenylacetate. This was 3 times stronger than prednicarbat in a screen using 12-O-tetradecanoylphorbol-13-acetate induced inflammation on rat ears.

IT 163846-14-8P 163846-15-9P 163846-16-0P
 163846-17-1P 163846-18-2P 163846-19-3P
 163846-20-6P 163846-21-7P 163846-22-8P
 163846-23-9P 163846-24-0P 163846-25-1P
 163846-26-2P 163846-27-3P 163846-28-4P
 163846-29-5P 163846-30-6P 163846-31-9P
 163846-32-0P 163846-33-1P 163846-34-2P
 163846-35-3P 163846-36-4P 163846-37-5P
 163846-38-6P 163846-40-0P 163846-41-1P
 163846-44-4P 163846-45-5P 163846-46-6P
 163846-47-7P 163846-48-8P 163846-49-9P
 163846-50-2P 163846-51-3P 163846-52-4P
 163846-53-5P 163846-54-6P 163846-55-7P
 163846-56-8P 163846-57-9P 163846-58-0P
 163846-59-1P 163846-60-4P 163846-61-5P

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


163846-62-6P 163846-63-7P 163846-64-8P
 163846-65-9P 163846-66-0P 163846-67-1P
 163846-68-2P 163846-69-3P 163846-70-5P
 163846-71-7P 163846-72-8P 163846-73-9P
 163846-74-0P 163846-75-1P 163846-76-2P
 163846-77-3P 163846-78-4P 163846-79-5P
 163846-80-6P 163846-81-7P 163846-82-0P
 163846-83-1P 163846-84-2P 163846-85-3P
 163846-86-4P 163846-87-5P 163846-88-6P
 163846-89-7P 163846-90-0P 163846-91-1P
 163846-92-2P 163846-93-3P 163846-94-4P
 163846-95-5P 163846-96-6P 163846-97-7P
 163846-98-8P 163846-99-9P 163847-00-5P
 163847-01-6P 163847-02-7P 163847-03-8P
 163847-04-9P 163847-05-0P 163847-06-1P
 163847-07-2P 163847-08-3P 163847-09-4P
 163847-10-7P 163847-11-8P 163847-12-9P
 163847-13-0P 163847-14-1P 163847-15-2P
 163850-02-1P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic Preparation); TMU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of corticosteroid 17-alkylcarbonate-21-esters as antiinflammatories)

RN 163846-14-8 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 21-(benzoyloxy)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-15-9 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(phenylacetyl)oxy]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-18-2 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 163846-19-3 CAPLUS


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-methoxybenzoyl)oxy]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-20-6 CAPLUS


L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-16-0 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-phenylpropyl)oxy]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-17-1 CAPLUS


CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(phenylacetyl)oxy]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-thienylacetyl)oxy]-, (11 β .)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-21-7 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-thienylacetyl)oxy]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-22-8 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-(2-thienyl)-2-propenyl)oxy]-, (11 β .)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.


L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-23-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[(2-furanylcarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-25-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(1-oxo-3-phenylpropyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-24-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[[3-(2-furanyl)-1-oxo-2-propenyl]oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 163846-26-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[1-methylethoxy]carbonyl]oxy]-21-[(phenoxyacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-27-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 163846-29-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[2-methoxyethoxy]carbonyl]oxy]-21-[[[1-oxo-3-phenyl-2-propenyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

RN 163846-30-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(phenylacetyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-28-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-17-[(pentyl)oxy]carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

RN 163846-31-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[1-methylethoxy]carbonyl]oxy]-21-[(phenylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-32-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-11-hydroxy-21-[(phenylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 163846-33-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-21-[(4-methylphenyl)acetyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-36-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

RN 163846-37-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-34-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(1-oxo-3-phenylpropyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-35-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(phenoxyacetyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 163846-38-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-21-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-40-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-41-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-6,16-dimethyl-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-44-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-chloro-17-[(ethoxycarbonyl)oxy]-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-45-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(2-thienylacetyl)oxy]-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-46-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-21-[(1H-indol-3-ylacetyl)oxy]-16-methyl-, (11.beta.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-47-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-48-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1H-indol-3-ylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-49-9 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17-[(ethoxycarbonyl)oxy]-21-[(phenylacetyl)oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-50-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6-fluoro-11-hydroxy-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-51-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 163846-52-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-53-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-6-methyl-21-[(phenylacetyl)oxy]-, (6.alpha.,11.beta.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-54-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-21-[(phenylacetyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.,16.beta.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-57-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy]-21-[(phenylacetyl)oxy]-, (11.beta.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-58-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[4-[4-bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-55-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[1-methylethoxy]carbonyl]oxy]-21-[(phenylacetyl)oxy]-, (11.beta.,16.alpha.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-56-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[2-methylpropoxy]carbonyl]oxy]-21-[(phenylacetyl)oxy]-, (11.beta.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-59-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(1,3-benzodioxol-5-ylcarbonyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-60-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(phenoxycarbonyl)oxy]-, (11.beta.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-61-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[(9H-fluoren-9-ylmethoxy)carbonyl]oxy-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 163846-62-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-, (11.beta.,21(E))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-65-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-6-methyl-, [6.alpha.,11.beta.,21(E))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 163846-66-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-16-methyl-, [11.beta.,16.alpha.,21(E))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-63-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-17-[(propoxycarbonyl)oxy]-, [11.beta.,21(E))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 163846-64-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-17-[(1-methylethoxy)carbonyl]oxy-, [11.beta.,21(E))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-67-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-16-methyl-, [11.beta.,16.beta.,21(E))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 163846-68-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-17-[(2-methylpropoxy)carbonyl]oxy-, [11.beta.,21(E))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-69-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-11-hydroxy-21-[[3-(4-methoxyphenyl)-1-oxo-2-propenyl]oxy]-, [11.beta.,21(E)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 163846-70-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-71-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[1-methylethoxy]carbonyl]oxy]-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 163846-72-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-73-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 163846-74-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[2-methylpropoxy]carbonyl]oxy]-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-75-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[3-[(1,1'-biphenyl)-4-yl]-1-oxo-2-propenyl]oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 163846-76-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[3-[(1,3-benzodioxol-5-yl)-1-oxo-2-propenyl]oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, [11.beta.,21(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-77-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-phenyl-2-propynyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-79-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorobenzoyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-78-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-phenyl-2,4-pentadienyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 163846-80-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-nitrobenzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-81-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(4-(acetylthio)benzoyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 163846-83-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-(methylthio)benzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-84-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-(phenylthio)benzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-82-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(2-(acetyloxy)benzoyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163846-85-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-4-phenylbutoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-86-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-pyridinylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-87-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21,21'-[2,6-pyridinediylbis(carbonyloxy)]bis[17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)-(11'.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-88-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-methylbenzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-89-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(3-methylbenzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-90-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(3-methylbenzoyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-91-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(3-methylbenzoyl)oxy]-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 163846-92-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(3-pyridinylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-93-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[[1-oxo-3-(3-pyridinyl)-2-propenyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 163846-94-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(3-thienylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163846-95-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(3-thienylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-97-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(5-chloro-2-thienyl)carbonyl]oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163846-96-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[(1-oxo-3-(2-thienyl)propoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163846-98-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[(3-furanylcarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163846-99-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(3-furanylcarbonyl)oxy]-11-hydroxy-17-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-01-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[3-(2-furanyl)-1-oxopropoxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-00-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(butoxycarbonyl)oxy]-21-[(3-furanylcarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163847-02-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(5-methyl-2-furanyl)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 163847-03-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1H-pyrrol-2-ylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-04-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(4-thiazolylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-05-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-21-[[[2-furanylmethoxy]carbonyl]oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163847-08-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[[[1-methyl-1H-indol-2-yl]carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-09-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(4-benzoylbenzoyl)oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163847-06-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1H-indol-3-ylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-07-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-methyl-1H-indol-3-yl)acetyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163847-10-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(5-methoxy-1H-indol-3-yl)acetyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 163847-11-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-naphthalenylacetyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163847-12-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(2-quinoxalinylnylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163847-13-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-isoquinolinylcarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 163958-62-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (11.beta.,21E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L9 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 163847-14-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[(1H-indol-3-yl)-1-oxo-2-propenyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 163847-15-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[4-(dimethylamino)benzoyl]oxy]-17-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 55 OF 63 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1995:609997 CAPLUS
 DOCUMENT NUMBER: 123:25928
 TITLE: Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats
 AUTHOR(S): Bodor, Nicholas; Wu, Whei-Mei; Murakami, Teruo; Engel, Steven
 CORPORATE SOURCE: College Pharmacy, Univ. Florida, Gainesville, FL, 32610, USA
 SOURCE: Pharmaceutical Research (1995), 12(6), 875-9
 CODEN: PHREB; ISSN: 0724-8741
 PUBLISHER: Plenum
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Pharmacokinetics, metab. and excretion of loteprednol etabonate (LE) were investigated in rats. The pharmacokinetic studies were performed by i.v. injections of LE (1-20 mg/kg). In the metab. and excretion studies, 0.5-10 mg/kg of LE were i.v. administered, bile and urine samples were collected for 6 h. The pharmacokinetic of LE showed a rapid, dose-dependent elimination with a total blood clearance (CL_{total}) of higher than 60 mL/min/kg. The metab. and excretion of LE also showed a marked dose-dependency. At 6 h after i.v. of LE (0.5-10 mg/kg), the total recoveries (LE and the metabolites, .DELTA.1-corticic acid etabonate (AE) and .DELTA.1-corticic acid (A), in bile and urine) were 99.35-26.72%. However, only about 2% of LE was excreted from the body through the urine. There were 0.93-2.12% and 0.66-0.26% of AE, and 75.67-19.69% and 20.74-2.77% of A excreted in the bile and urine, resp. The excretion of A was dose dependent, and significantly higher at the lower dose. Using the (1 of total excretion) vs. (log dose) plots, it could be predicted that almost all of the administered LE will be metabolized, and excreted as A when the systemic dose is lower than 0.25 mg/kg. The results indicate that LE absorbed systemically, after topical administration, can be rapidly transformed to the active metabolites, and eliminated from the body mainly through the bile and urine.

IT 82034-46-6, Loteprednol etabonate
 RL: BPR (Biological process); BSU (Biological study, unclassified);
 TMU (Therapeutic use); BIOL (Biological study); PROC (Process);
 USES (Uses)

(pharmacokinetics and metab. and excretion of loteprednol etabonate in rats)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 55 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

L9 ANSWER 56 OF 63 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1995:609996 CAPLUS
 DOCUMENT NUMBER: 123:1352
 TITLE: Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats - for safer treatment of gastrointestinal inflammation
 AUTHOR(S): Bodor, Nicholas; Murakami, Teruo; Wu, Whai-Mai
 CORPORATE SOURCE: College Pharmacy, Univ. Florida, Gainesville, FL, 32610, USA
 SOURCE: Pharmaceutical Research (1995), 12(6), 869-74
 CODEN: PHREB; ISSN: 0724-8741
 PUBLISHER: Plenum
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB As a safe anti-inflammatory corticosteroid, the utility of loteprednol etabonate (LE) for the treatment of gastrointestinal inflammation, via oral and rectal administration, was investigated in rats. In vivo, LE soln. and suspension were orally administered (20 mg/kg), and various LE preps. (soln., suspension and suppository) were applied in rectal loops (0.2 mg per loop). In vitro, various GI tissues were used to study the stability and partition of LE. After oral administration of LE soln., LE reached the upper GI tract effectively, but not the colon, due to absorption and/or decompn. In suspension, LE reached most of the GI tract (except rectum) in 8 h and showed little absorption. After rectal applications, LE remained intact in the rectal loop for more than five hours with a slow rate of disappearance, however, LE distributed in the rectal membrane to some extent. The concns. of LE and its inactive metabolites in plasma after both oral and rectal administrations were lower than the detection limit (0.1 µg/ml) at anytime during the expts. In vitro, LE in soln. was stable in stomach, but not in cecum, due to the hydrolysis by the cecal resident micro flora. In soln., LE distributed into the mucosal membranes efficiently (about 2.5.apprx.4.0 µm.g/g tissue). The results suggest that LE can be orally or rectally delivered in the GI tract for the topical treatment of the inflammatory bowel disease.

IT 82034-46-6, Loteprednol etabonate
 RI: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (loteprednol etabonate oral and rectal delivery for gastrointestinal inflammation treatment in rats)
 RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 56 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 57 OF 63 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1995:603909 CAPLUS
 DOCUMENT NUMBER: 123:17874
 TITLE: Mouthwashes containing steroids and antifungal agents for treatment of inflammatory conditions of the mouth
 INVENTOR(S): Eisen, Doree
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 5 pp. Cont.-in-part of U.S. 5,310,545.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5407663	A	19950418	US 1994-222277	19940404
US 5310545	A	19940510	US 1993-6287	19930115
PRIORITY APPLN. INFO.:			US 1991-683380	19910411
			US 1991-802646	19911209
			US 1992-963485	19921021
			US 1993-6287	19930115

AB Mouthwashes contg. steroids and antifungal agents are useful for treatment of inflammatory conditions of the mouth. Such therapy would allow direct contact of the medication with the diseased mucous membranes and would contact areas of the oral cavity that would not usually be reached with application of creams, gels, or ointments. Swishing for three to five minutes, then expectorating the aq. anti-inflammatory-contg., results in maintenance of contact of the active agents with the oral cavity surfaces for a longer time than would application of gels contg. those agents. A buffered soln. contg. benzalkonium chloride 0.02, and benzoic acid 0.1% in water was adjusted to pH = 4.5 with Na benzoate. Betamethasone dipropionate (I) and nystatin (II) were added to provide a compn. contg. 0.05% I, and 100,000 units/mL II. The compn. is swished around in the mouth for .gtoeq.3 min, then expectorated.

IT 73771-04-7, Prednicarbate
 RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mouthwashes contg. steroids and antifungal agents for treatment of inflammatory conditions of the mouth)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 57 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


L9 ANSWER 59 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:43082 CAPLUS
 DOCUMENT NUMBER: 122:205429
 TITLE: Loteprednol etabonate: A novel ocular steroid with improved safety profile
 AUTHOR(S): Neumann, Ron; Howes, John F.
 CORPORATE SOURCE: Pharmos Ltd., Kiryat Weizmann, Rehovot, 76326, Israel
 SOURCE: International Congress Series (1994), 1068 (Advances in Ocular Immunology), 245-8
 CODEN: EXMD4; ISSN: 0531-5131

DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Loteprednol etabonate is shown to be novel ocular steroid with high affinity for the glucocorticoid receptor and a unique ocular pharmacokinetics profile due its esterase-sensitive structure. Loteprednol etabonate is effective in models of ocular inflammation in animals and it has been highly effective in human ocular allergic diseases. Moreover, loteprednol etabonate exhibits the lowest propensity to elevate intraocular pressure among the currently used ocular steroids.

IT 82034-46-6, Loteprednol etabonate
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (loteprednol etabonate as novel ocular steroid with improved toxicity profile in humans and lab. animals)

RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 58 OF 63 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1995:558418 CAPLUS
 DOCUMENT NUMBER: 122:298823
 TITLE: Effect of cyclodextrins on the degradation of cortisone acetate, estradiol benzoate and prednicarbate in aqueous solution
 AUTHOR(S): Loftsson, T.; Jonsdottir, B.; Baldvinsdottir, J.; Fridriksdottir, H.
 CORPORATE SOURCE: University of Iceland, Iceland
 SOURCE: S.T.P. Pharma Sciences (1994), 4(5), 354-8
 CODEN: STSSE5; ISSN: 1157-1489

DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The degrdn. of 3 steroid esters, i.e., cortisone acetate, 17.beta.-estradiol 3-benzoate and prednicarbate, was studied in aq. buffer solns. A small amt. of maltosyl-dimaltosyl .beta.-cyclodextrin was used to solubilize 17.beta.-estradiol 3-benzoate in the aq. buffer solns. Its pH/degrdn. rate profile was of a typical V-shape with a min. at pH 3.7 and, at this pH and 80.degree., the shelf-life of the drug was 7.3 days. Cortisone acetate and prednicarbate were studied in pure aq. buffer solns. Both drugs had an U-shaped pH/degrdn. rate profile with a notable solvent catalysis and max. stability at pH about 3.5. The shelf-life of cortisone acetate at this pH and 70.degree. was calcd. to be about one day, and that of prednicarbate only about 5 h. Cyclodextrins, esp. randomly methylated .beta.-cyclodextrin, had a stabilizing effect on both drugs.

IT 73771-04-7, Prednicarbate
 RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (cyclodextrins effect on degrdn. of steroidal esters)

RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 60 OF 63 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1992:645750 CAPLUS
 DOCUMENT NUMBER: 117:245750
 TITLE: Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate
 AUTHOR(S): Bodor, Nicholas; Loftsson, Thorsteinn; Wu, Whei Mei
 CORPORATE SOURCE: Coll. Pharm., Univ. Florida, Gainesville, FL, 32606, USA
 SOURCE: Pharmaceutical Research (1992), 9(10), 1275-8
 CODEN: PHREB; ISSN: 0724-8741

DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The soft corticosteroid, loteprednol etabonate (I), was designed based on the "inactive metabolite approach." Accordingly, I should be metabolized by hydrolysis to the corresponding inactive corticene acid deriv., II. The in vitro and in vivo metab. of I indeed yielded mainly this inactive metabolite, which is more hydrophilic and thus readily eliminated from the body. Relatively high levels of I were found in tissues after i.v. administration of the drug in rats. The permeability of I through hairless mouse skin was comparable to what has been found for related "hard" steroids, without significant metab. taking place in the skin.

IT 82034-46-6, Loteprednol etabonate
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (pharmacokinetics of)

RN 82034-46-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 133991-63-6
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (pharmacokinetics of, as metabolite of loteprednol etabonate)

RN 133991-63-6 CAPLUS
 CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy)-11-hydroxy-3-oxo-, (11.beta.,17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 60 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 61 OF 63 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1992:612787 CAPLUS
 DOCUMENT NUMBER: 117:212787
 TITLE: Preparation and formulation of (bis(phosphono)butylaminocarbonyloxy)estratriene and analogs for treatment of bone disease
 INVENTOR(S): Saari, Walfred S.; Rodan, Gideon A.; Fisher, Thorsten E.; Anderson, Paul S.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 496520	A1	19920729	EP 1992-300291	19920114
R: CH, DE, FR, GB, IT, LI, NL				
CA 2059421	AA	19920723	CA 1992-2059421	19920115
JP 04352795	A2	19921207	JP 1992-8786	19920122
JP 07035395	B4	19950419		
US 5183815	A	19930202	US 1992-839741	19920219
			US 1991-644178	19910122

PRIORITY APPLN. INFO.: MARPAT 117:212787
 OTHER SOURCE(S):
 AB Comps. ABC [A = residue of a hydroxy-contg. steroidal hormone having human bone resorption-antagonist activity or bone formation-stimulatory activity; C = residue of an amino- or hydroxyalkyl-1,1-bis(phosphonate) having human bone affinity; B = covalent linkage connecting A through the hydroxyl moiety and C through the amino or hydroxyl moiety, which linkage can hydrolyze in the human body in the vicinity of bone to release steroidal hormone A] were prepd. for treatment of bone disorders (no data). Thus, [(Me2CHO)2P(O)(O)2CH2R (I; R = H), was condensed with CH2:CHCN and the product hydrogenated to give I [R = (CH2)3NH2], which was condensed with 3-benzoyloxy-17.β.-chlorocarbonyloxyestra-1,3,5(10)-triene (prepn. given) to give, after deprotection, title compd. II.
 IT 73771-04-7DP, derivs. linked to bisphosphonate moieties
 RI: THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, for treatment of bone disease)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyloxy)-11-hydroxy-21-(1-oxopropoxy)-, (11.β.)- (9CI)- (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 61 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:194683 CAPLUS
 DOCUMENT NUMBER: 116:194683
 TITLE: Preparation of 17-substituted corticoid 17-alkyl carbonates for treatment of dermatoses
 INVENTOR(S): Stache, Ulrich; Duerckheimer, Walter; Alpermann, Hans Georg; Petri, Walter
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 48 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 470617	A2	19920212	EP 1991-113338	19910808
EP 470617	A3	19920401		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 4025342	A1	19920213	DE 1990-4025342	19900810
FI 9103775	A	19920211	FI 1991-3775	19910808
HU 59155	A2	19920428	HU 1991-2643	19910808
HU 211994	B	19960129		
CZ 279875	B6	19950712	CZ 1991-2461	19910808
IL 99135	A1	19951208	IL 1991-99135	19910808
RU 2060997	C1	19960527	RU 1991-5001317	19910808
NO 9103115	A	19920211	NO 1991-3115	19910809
CA 2048841	AA	19920211	CA 1991-2048841	19910809
AU 9182560	A1	19920213	AU 1991-82560	19910809
AU 646066	B2	19940203		
ZA 9106291	A	19920429	ZA 1991-6291	19910809
JP 06041187	A2	19940215	JP 1991-223670	19910809
US 5362721	A	19941108	US 1993-15041	19930208
LV 10459	B	19950820	LV 1993-302	19930507
LT 3374	B	19950825	LT 1993-709	19930625
PRIORITY APPLN. INFO.: DE 1990-4025342			US 1991-742334	19910808

OTHER SOURCE(S): MARPAT 116:194683
 AB Title compds. [I; A = CH(OH), CH2, CO, Y, Z = H, F, Cl; R1 = F, Cl, Br, iodo, acyloxy, alkoxy, carbonyloxy, alkylsulfonic acid, etc.; R2 = alkyl, methoxyalkyl; R3 = H, Me] were prepd. Thus, prednisolone 17-isopropyl carbonate was stirred with pyridine/Ac2O to give prednisolone 17-isopropyl carbonate 21-acetate. The latter inhibited croton oil-induced ear edema in rats with IC50 = 0.1 mg/mL.
 IT 140452-34-2P 140452-35-3P 140452-36-4P
 140452-37-5P 140452-38-6P 140452-39-7P
 140452-40-0P 140452-41-1P 140452-42-2P
 140452-43-3P 140452-44-4P 140452-45-5P
 140452-46-6P 140452-47-7P 140452-48-8P
 140452-49-9P 140452-50-2P 140452-51-3P
 140452-52-4P 140452-53-5P 140452-54-6P
 140452-55-7P 140452-56-8P 140452-57-9P
 140452-58-0P 140452-59-1P 140452-60-4P
 140452-61-5P 140452-62-6P 140452-63-7P
 140452-64-8P 140452-65-9P 140452-66-0P
 140452-67-1P 140452-68-2P 140452-69-3P
 140452-70-6P 140452-71-7P 140452-72-8P
 140452-73-9P 140452-74-0P 140452-75-1P
 140452-76-2P 140452-77-3P 140452-78-4P
 140452-79-5P 140452-80-6P 140452-81-9P

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


140452-82-0P 140452-83-1P 140452-84-2P
 140452-85-3P 140452-86-4P 140452-87-5P
 140452-88-6P 140452-89-7P 140452-90-0P
 140452-91-1P 140452-92-2P 140452-93-3P
 140452-94-4P 140452-95-5P 140452-96-6P
 140452-97-7P 140452-98-8P 140452-99-9P
 140453-00-5P 140453-01-6P 140453-02-7P
 140453-03-8P 140453-04-9P 140453-05-0P
 140453-06-1P 140453-07-2P 140453-08-3P
 140453-09-4P 140453-10-7P 140453-11-8P
 140453-12-9P 140453-13-0P 140453-14-1P
 140453-15-2P 140453-16-3P 140453-17-4P
 140453-18-5P 140453-19-6P 140453-20-9P
 140453-21-0P 140453-22-1P 140453-23-2P
 140453-24-3P 140453-25-4P 140453-26-5P
 140453-27-6P 140453-28-7P 140453-29-8P
 140453-30-1P 140453-31-2P 140453-32-3P
 140453-33-4P 140453-34-5P 140453-35-6P
 140453-36-7P 140453-37-8P 140453-38-9P
 140453-39-0P 140453-40-3P 140453-41-4P
 140453-42-5P 140453-43-6P 140453-44-7P
 140453-45-8P 140453-46-9P 140453-47-0P
 140453-48-1P 140453-49-2P 140453-50-5P
 140453-51-6P 140453-52-7P 140453-53-8P
 140453-54-9P 140453-55-0P 140453-56-1P
 140453-57-2P 140453-58-3P 140453-59-4P
 140453-60-7P 140453-61-8P 140453-62-9P
 140453-63-0P 140453-64-1P 140453-65-2P
 140453-66-3P 140453-67-4P 140453-68-5P
 140453-69-6P 140453-70-9P 140453-71-0P
 140453-72-1P 140453-73-2P 140453-74-3P
 140453-75-4P 140453-76-5P 140453-77-6P
 140453-78-7P 140453-79-8P 140453-80-1P
 140454-09-7P 140454-10-0P 140454-11-1P
 140454-12-2P 140454-13-3P 140454-14-4P
 140454-15-5P 140454-16-6P 140454-17-7P
 140454-18-8P 140454-19-9P 140454-20-2P
 140454-21-3P 140454-22-4P 140454-23-5P
 140454-24-6P 140454-25-7P 140454-26-8P
 140454-27-9P 140454-28-0P 140454-29-1P
 140454-30-4P 140454-31-5P 140454-32-6P
 140454-33-7P 140454-34-8P 140454-35-9P
 140454-36-0P 140454-37-1P 140454-38-2P
 140452-57-3P 140475-76-9P 140475-77-0P
 140475-78-1P 140475-79-2P 140475-80-5P
 140475-81-6P 140475-82-7P 140475-83-8P
 140475-84-9P 140475-85-0P 140475-86-1P
 140475-87-2P 140475-88-3P 140475-89-4P
 140475-90-7P 140475-91-8P 140475-92-9P
 140475-93-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as local antiinflammatory for treatment of dermatosis)


RN 140452-34-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-[[[(2-methylpropoxy)carbonyloxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140452-37-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyloxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-38-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(2-methoxyethoxy)carbonyloxy]-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-39-7 CAPLUS


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.



RN 140452-35-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(2-methylpropoxy)carbonyloxy]-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-36-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(1-methylethoxy)carbonyloxy]-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-[[[(1-methylethoxy)carbonyloxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-40-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-17-[[[(2,2-dimethylpropoxy)carbonyloxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-41-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyloxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-42-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(1-methylethoxy)carbonyloxy]-21-(1-oxobutoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.



RN 140452-43-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(1-oxopentyl)oxy]-, (11.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-44-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(1-oxohexyl)oxy]-, (11.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140452-47-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-48-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(3-cyclopentyl-1-oxopropoxy)-11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-49-9 CAPLUS

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140452-45-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(2-methyl-1-oxopropoxy)-, (11.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-46-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropoxy)-11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(methoxycarbonyl)oxy]-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-50-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-51-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(propoxycarbonyl)oxy]-, (11.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140452-52-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[1-methylethoxy]carbonyl]oxy]-21-[[methylsulfonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-53-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[1-methylethoxy]carbonyl]oxy]-21-[[phenylsulfonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140452-57-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[2-methylpropoxy]carbonyl]oxy]-21-[[1-oxopentyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-58-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[2-methylpropoxy]carbonyl]oxy]-21-[[1-oxohexyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 140452-54-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[1-methylethoxy]carbonyl]oxy]-11-hydroxy-17-[[[1-methylethoxy]carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-55-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[1-methylethoxy]carbonyl]oxy]-21-[[[4-methylphenyl]sulfonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-56-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[2-methylpropoxy]carbonyl]oxy]-21-[[1-oxobutoxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 140452-59-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[[2-methyl-1-oxopropoxy]-17-[[[2-methylpropoxy]carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-60-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[2,2-dimethyl-1-oxopropoxy]-11-hydroxy-17-[[[2-methylpropoxy]carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-61-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[cyclopropyl]carbonyl]oxy]-11-hydroxy-17-[[[2-methylpropoxy]carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140452-62-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(3-cyclopentyl-1-oxopropoxy)-(2-methylpropoxy)carbonyl]oxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140452-64-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[2-methylpropoxy)carbonyl]oxy]-21-[(propoxycarbonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-63-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[(methoxycarbonyl)oxy]-17-[[2-methylpropoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-65-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[2-methylpropoxy)carbonyl]oxy]-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140452-66-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[2-methylpropoxy)carbonyl]oxy]-21-[(phenylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140452-69-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-21-[(1-oxobutoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-67-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[4-chlorophenyl)sulfonyl]oxy]-11-hydroxy-17-[[2-methylpropoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-70-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-21-[(1-oxopentyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-68-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-[[4-methylphenyl)sulfonyl]oxy]-17-[[2-methylpropoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)



RN 140452-71-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-21-[(1-oxopentyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
hydroxy-21-[(1-oxohexyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-72-8 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyloxy]-11-hydroxy-21-[(1-oxohexyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-73-9 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropoxy)-17-[(2,2-dimethylpropoxy)carbonyloxy]-11-hydroxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140452-76-2 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyloxy]-11-hydroxy-21-[(methylsulfonyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-77-3 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyloxy]-17-[(2,2-dimethylpropoxy)carbonyloxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140452-74-0 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-17-[(2,2-dimethylpropoxy)carbonyloxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-75-1 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyloxy]-21-[(ethoxycarbonyl)oxy]-11-hydroxy-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140452-78-4 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-21-(1-oxobutoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-79-5 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-21-[(1-oxopentyl)oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140452-80-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[(2-methoxyethoxy)carbonyl]oxy]-21-(2-methyl-1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140452-82-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-11-hydroxy-17-[(2-methoxyethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-81-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-11-hydroxy-17-[(2-methoxyethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-83-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(methylsulfonyl)oxy]-11-hydroxy-17-[(2-methoxyethoxy)carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140452-84-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140452-87-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-21-(2-methyl-1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-85-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-21-(1-oxobutoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-88-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-86-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(1-methylethoxy)carbonyl]oxy]-21-[(1-oxopentyl)oxy]-, (11.beta.,16.alpha.)-


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140452-89-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140452-91-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-90-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-21-[(methoxycarbonyl)oxy]-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140452-92-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140452-93-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(methylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[[[4-methylphenyl)sulfonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-96-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-94-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[4-chlorophenyl)sulfonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140452-97-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-95-5 CAPLUS


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140452-98-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxobutoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140453-00-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-21-[(1-oxohexyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140452-99-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-21-[(1-oxopentyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-01-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-21-(2-methyl-1-oxopropoxy)-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140453-02-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 140453-04-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-05-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-21-[(methoxycarbonyl)oxy]-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-03-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-06-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-07-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-21-[(propoxycarbonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-08-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyl]oxy]-21-[(methylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140453-11-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-21-[[[4-methylphenyl]sulfonyl]oxy]-17-[[[2-methylpropoxy]carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-12-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetoxy)-17-[[[2,2-dimethylpropoxy]carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-13-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[[2,2-dimethylpropoxy]carbonyl]oxy]-9-

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-09-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[2-methylpropoxy]carbonyl]oxy]-21-[(phenylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140453-10-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[4-chlorophenyl]sulfonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-17-[[[2-methylpropoxy]carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 fluoro-11-hydroxy-16-methyl-21-(1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-14-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[[2,2-dimethylpropoxy]carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-21-(1-oxobutoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-15-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[[2,2-dimethylpropoxy]carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-21-(2-methyl-1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-16-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-17-[[2,2-dimethylpropoxy]carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-17-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[2,2-dimethylpropoxy]carbonyl]oxy]-21-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-18-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[2,2-dimethylpropoxy]carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-21-[(methylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-19-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyl]oxy]-17-[[2,2-dimethylpropoxy]carbonyl]oxy]-9-fluoro-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140453-20-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy]-16-methyl-21-(1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-21-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy]-16-methyl-21-(1-oxobutoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 140453-22-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy]-16-methyl-21-(2-methyl-1-oxopropoxy)-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-23-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-24-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-9-fluoro-11-hydroxy-17-[[2-methoxyethoxy]carbonyl]oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-25-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-9-fluoro-11-hydroxy-17-[(2-methoxyethoxy)carbonyl]oxy-16-methyl-, (11.alpha.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140453-27-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[(1-methylethoxy)carbonyl]oxy-21-(1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-26-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-[(1-methylethoxy)carbonyl]oxy-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-28-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[(1-methylethoxy)carbonyl]oxy-21-(1-oxobutoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-29-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[(1-methylethoxy)carbonyl]oxy-21-(2-methyl-1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140453-31-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-11-hydroxy-6-methyl-17-[(1-methylethoxy)carbonyl]oxy-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-30-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-11-hydroxy-6-methyl-17-[(1-methylethoxy)carbonyl]oxy-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-32-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-17-[(1-methylethoxy)carbonyl]oxy-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-33-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[(methylsulfonyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-34-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-11-hydroxy-6-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-35-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-36-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-37-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxobutoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-38-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-[(1-oxopentyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-39-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-21-(2-methyl-1-oxopropoxy)-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-40-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-11-hydroxy-6-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-41-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-11-hydroxy-6-methyl-17-[[2-methylpropoxy]carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-42-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(3-cyclopentyl-1-oxopropoxy)-11-hydroxy-6-methyl-17-[[2-methylpropoxy]carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-45-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[2-methylpropoxy]carbonyl]oxy]-21-[(methanesulfonyl)oxy]-, (6.alpha.,11.beta.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-46-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[4-chlorophenyl]sulfonyl]oxy]-11-hydroxy-6-methyl-17-[[2-methylpropoxy]carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-43-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-17-[[2-methylpropoxy]carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-44-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-17-[[2-methylpropoxy]carbonyl]oxy]-21-[(propoxycarbonyl)oxy]-, (6.alpha.,11.beta.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-47-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-6-methyl-21-[[4-methylphenyl]sulfonyl]oxy]-17-[[2-methylpropoxy]carbonyl]oxy]-, (6.alpha.,11.beta.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-48-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[2,2-dimethylpropoxy]carbonyl]oxy]-11-hydroxy-6-methyl-21-[(1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-49-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-21-(2-methyl-1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140453-51-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-50-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-52-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-21-[(ethoxycarbonyl)oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-53-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-21-[(methylsulfonyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140453-55-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-54-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-56-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-6-methyl-21-(1-oxopropoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-57-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-6-methyl-21-(1-oxobutoxy)-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140453-59-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-58-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-60-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-6-methyl-21-[(methylsulfonyl)oxy]-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-61-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-(1-oxopropoxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140453-63-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-(2-methyl-1-oxopropoxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140453-62-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-(1-oxobutoxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-64-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-65-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-66-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-67-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-68-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxopropoxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-69-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-(1-oxobutoxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-70-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-21-[(1-oxopentyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-71-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-21-(2-methyl-1-oxopropoxy)-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-72-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-73-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[(2-methylpropoxy)carbonyloxy]-21-[(methylsulfonyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-74-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-17-[(2,2-dimethylpropoxy)carbonyloxy]-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-75-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(2,2-dimethylpropoxy)carbonyloxy]-21-[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-76-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(4-chlorophenyl)sulfonyloxy]-17-[(2,2-dimethylpropoxy)carbonyloxy]-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-77-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-78-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-16-methyl-21-(1-oxobutoxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140453-79-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-16-methyl-21-(1-oxobutoxy)-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140453-80-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(cyclopropylcarbonyl)oxy]-6,9-difluoro-11-hydroxy-17-[(2-methoxyethoxy)carbonyloxy]-16-methyl-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140454-09-7 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-(acetyloxy)-17-(((2-methylpropoxy)carbonyl)oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-10-0 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17-(((2-methylpropoxy)carbonyl)oxy)-21-(1-oxopropoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140454-14-4 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-((2,2-dimethyl-1-oxopropoxy)-17-(((2-methylpropoxy)carbonyl)oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-15-5 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-((cyclopropylcarbonyl)oxy)-17-(((2-methylpropoxy)carbonyl)oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-16-6 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-(3-cyclopentyl-1-oxopropoxy)-17-(((2-methylpropoxy)carbonyl)oxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 140454-11-1 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17-(((2-methylpropoxy)carbonyl)oxy)-21-(1-oxobutoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-12-2 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17-(((2-methylpropoxy)carbonyl)oxy)-21-((1-oxopentyl)oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-13-3 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-(2-methyl-1-oxopropoxy)-17-(((2-methylpropoxy)carbonyl)oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.




RN 140454-17-7 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-((ethoxycarbonyl)oxy)-17-(((2-methylpropoxy)carbonyl)oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-18-8 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-(((4-chlorophenyl)sulfonyl)oxy)-17-(((2-methylpropoxy)carbonyl)oxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 140454-19-9 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-(acetyloxy)-17-[[[(1-methylethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-20-2 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17-[[[(1-methylethoxy)carbonyl]oxy]-21-(1-oxopropoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-21-3 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17-[[[(1-methylethoxy)carbonyl]oxy]-21-(1-oxobutoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140454-22-4 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17-[[[(1-methylethoxy)carbonyl]oxy]-21-(2-methyl-1-oxopropoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-23-5 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-[(cyclopropylcarbonyl]oxy]-17-[[[(1-methylethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140454-24-6 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-(3-cyclopentyl-1-oxopropoxy)-17-[[[(1-methylethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-25-7 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-[(ethoxycarbonyl]oxy)-17-[[[(1-methylethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-26-8 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-17-[[[(1-methylethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 [[[(1-methylethoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 140454-27-9 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-(acetyloxy)-17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-28-0 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]-21-(1-oxopropoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-29-1 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-[(cyclopropylcarbonyl]oxy]-17-[[[(2,2-dimethylpropoxy)carbonyl]oxy]- (9CI) (CA INDEX NAME)


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
dimethylpropoxy)carbonyloxy)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-30-4 CAPLUS
CN Pregna-1,4-diene-3,11,20-trione, 17-[[[(2,2-dimethylpropoxy)carbonyloxy]-21-[(ethoxycarbonyl)oxy]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-31-5 CAPLUS
CN Pregna-1,4-diene-3,11,20-trione, 21-[[[(4-chlorophenyl)sulfonyloxy]-17-[[[(2,2-dimethylpropoxy)carbonyloxy]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140454-32-6 CAPLUS
CN Pregna-1,4-diene-3,11,20-trione, 21-(acetyloxy)-17-[[[(2-methoxyethoxy)carbonyloxy]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-33-7 CAPLUS
CN Pregna-1,4-diene-3,11,20-trione, 17-[[[(2-methoxyethoxy)carbonyloxy]]-21-(1-oxopropoxy)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140454-34-8 CAPLUS
CN Pregna-1,4-diene-3,11,20-trione, 21-[[[(cyclopropylcarbonyloxy)]-17-[[[(2-methoxyethoxy)carbonyloxy]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-35-9 CAPLUS
CN Pregna-1,4-diene-3,11,20-trione, 21-[[[(4-chlorophenyl)sulfonyloxy]]-17-[[[(2-methoxyethoxy)carbonyloxy]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140454-36-0 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 21-chloro-11-hydroxy-17-[[[(2-methylpropoxy)carbonyloxy]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140454-37-1 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 21-bromo-11-hydroxy-17-[[[(2-methylpropoxy)carbonyloxy]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140454-38-2 CAPLUS


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN Pregna-1,4-diene-3,20-dione, 11-hydroxy-21-iodo-17-[[[2-methylpropoxy]carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140462-57-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-21-[[1-oxohexyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-76-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(ethoxycarbonyl)oxy]-11-hydroxy-17-[[[2-methylpropoxy]carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140475-77-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[4-chlorophenyl)sulfonyl]oxy]-11-hydroxy-17-[[[2-methoxyethoxy]carbonyl]oxy]-, (11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-78-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-21-[[1-oxopropoxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 140475-79-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[(3-cyclopentyl-1-oxopropoxy)-9-fluoro-11-hydroxy-16-methyl-17-[[[1-methylethoxy]carbonyl]oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140475-80-5 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-17-[[[2-methoxyethoxy]carbonyl]oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-81-6 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-17-[[[2-


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)
 methoxyethoxy]carbonyl]oxy]-16-methyl-21-[(methylsulfonyl)oxy]-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140475-82-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[4-chlorophenyl)sulfonyl]oxy]-9-fluoro-11-hydroxy-17-[[[2-methoxyethoxy]carbonyl]oxy]-16-methyl-, (11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-83-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-17-[[[2,2-dimethylpropoxy]carbonyl]oxy]-11-hydroxy-6-methyl-, (6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140475-84-9 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-6-methyl-, (6.alpha.,11.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-85-0 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140475-86-1 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[[[(1-oxopentyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-87-2 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-17-[[[(1-methylethoxy)carbonyl]oxy]-21-[[[(methylsulfonyl)oxy]-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140475-88-3 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-89-4 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-6,9-difluoro-11-hydroxy-16-methyl-17-[[[(2-methylpropoxy)carbonyl]oxy]-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140475-90-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(ethoxycarbonyl)oxy]-6,9-difluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-91-8 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 21-[[[(4-chlorophenyl)sulfonyl]oxy]-6,9-difluoro-11-hydroxy-17-[[[(2-methoxyethoxy)carbonyl]oxy]-16-methyl-, (6.alpha.,11.beta.,16.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 140475-92-9 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17-[(1-methylethoxy)carbonyloxy]-21-[(1-oxopentyl)oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 140475-93-0 CAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 21-(2,2-dimethyl-1-oxopropoxy)-17-[[[1-methylethoxy]carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 62 OF 63 CAPLUS COPYRIGHT 2003 ACS (Continued)



L9 ANSWER 63 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1983:656 CAPLUS
 DOCUMENT NUMBER: 98:656
 TITLE: Experimental animal studies on topical and systemic activity of prednisolone-17-ethylcarbonate-21-propionate
 AUTHOR(S): Alpermann, H. G.; Sandow, J.; Vogel, H. G.
 CORPORATE SOURCE: Hoechst A.-G., Frankfurt/Main, 6230/80, Fed. Rep. Ger.
 SOURCE: Arzneimittel-Forschung (1982), 32(6), 633-8
 CODEN: ARZNAD; ISSN: 0004-4172
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 AB Topical administration of prednisolone 17-ethylcarbonate 21-propionate (I) [73771-04-7] to rats produced local antiinflammatory effects which were similar to those of topically applied desoxymethasone, however the systemic effects of topically applied I (stimulation of adrenal gland) were less pronounced than those of the ref. compd. In rats with induced edema, s.c. administered I had a weaker antiinflammatory effect than the s.c. administered ref. compd.
 IT 73771-04-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiinflammatory activity of, in topical and systemic administration)
 RN 73771-04-7 CAPLUS
 CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d ibib ab fqhit 1-15

L12 ANSWER 1 OF 15 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER:

137:69177 MARPAT

TITLE:

Compositions comprising cyclodextrins and NO-releasing drugs

INVENTOR(S):

Naggi, Annamaria; Torri, Gian Giacomo; Trespidi, Laura

PATENT ASSIGNEE(S):

Nicox S.A., Fr.

SOURCE:

Eur. Pat. Appl., 48 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1219306	A1	20020703	EP 2000-403719	20001229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002053188	A1	20020711	WO 2001-EP15340	20011227
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

EP 2000-403719 20001229


AB

The present invention relates to compn. comprising cyclodextrins and a NO-releasing drug of formula A-X-L-NON (A = radical deriving from a drug; X = divalent radical connecting A with the NO-releasing group L-NON; L = O, S, NH; n = 1, 2). Cyclodextrins (CDs) are selected from .alpha.-CD, .beta.-CD, .gamma.-CD, dimethyl-.alpha.-CD, dimethyl-.beta.-CD, dimethyl-.gamma.-CD, etc., and the drug is selected from NSAIDs, analgesics, antibacterials, antivirals, steroids, antineoplastics, .beta.-adrenergic agonists and blockers, antihyperlipoproteinemias, and bone resorption inhibitors. For example, three compns. contg. 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (I) was were prepd.: F1 contained 1.470 g of .alpha.-CD and 0.500 g of I mixed in water and then dried; F2 contained 1.470 g of .alpha.-CD and 0.500 g of I mixed in ethanol/water and then dried; and F3 contained 2.000 g of dimethyl-.beta.-CD and 0.500 g of I mixed in water and then dried; F0 represents the comparative formula contg. I alone. Inhibition of contraction of aortic rings obtained was 54% for F1, 59% for F2, 61% for F3, and 19% for F0.

MSTR 3A

L12 ANSWER 1 OF 15 MARPAT COPYRIGHT 2003 ACS

(Continued)



G17 = 66

O-C(O)-G19-H

MPL: claim 9

NTE: as NO-releasing derivatives

NTE: additional double bond and oxo formation also claimed

REFERENCE COUNT: 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 15 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER:

133:10057 MARPAT

TITLE:

Synthesis, activity and formulations of steroidal compounds for treatment of oxidative stress and/or endothelial dysfunction

INVENTOR(S):

Del Soldato, Piero

PATENT ASSIGNEE(S):

Nicox S.A., Fr.

SOURCE:

FCT Int. Appl., 102 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061604	A2	20001019	WO 2000-EP3238	20000411
WO 2000061604	A3	20010315		
M: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1311922	B1	20020320	IT 1999-M1751	19990413
BR 200009696	A	20020108	BR 2000-9696	20000411
EP 1169337	A2	20020109	EP 2000-917075	20000411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002542162	T2	20021210	JP 2000-611546	20000411
NO 2001004925	A	20011213	NO 2001-4925	20011010


PRIORITY APPLN. INFO.:

IT 1999-M1751 19990413


AB

Synthesis, activity and formulations of steroidal compds. for treatment of oxidative stress and/or endothelial dysfunction or their salts is disclosed. The precursors are such as to meet the pharmacol. tests reported in the description.

MSTR 1



G1 = 15-6 16-8



L12 ANSWER 2 OF 15 MARPAT COPYRIGHT 2003 ACS

(Continued)

G22 = 69

G23

G23 = 74

C(O)-G24-Me

MPL: claim 1

NTE: or salts

L12 ANSWER 3 OF 15 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 133:187953 MARPAT
 TITLE: Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
 INVENTOR(S): Garvey, David S.; Worcel, Manuel
 PATENT ASSIGNEE(S): Nitromed, Inc., USA
 SOURCE: PCT Int. Appl., 85 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000049993	A2	20000831	WO 2000-US4507	20000223
WO 2000049993	A3	20001130		


W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000037039 A5 20000914 AU 2000-37039 20000223
 PRIORITY APPLN. INFO.: US 1999-256171 19990224
 WO 2000-US4507 20000223

AB The present invention relates to nitrosated and/or nitrosylated steroids and to methods for the treatment of cardiovascular diseases and disorders, particularly the prophylactic and/or therapeutic treatment of restenosis, by administering nitrosated and/or nitrosylated steroids that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiolo. conditions. The methods for the treatment of cardiovascular diseases and disorders may further comprise administering at least one compd. that donates, transfers, or releases nitric oxide and/or elevate endogenous nitric oxide or endothelium-derived relaxing factor in vivo and/or is a substrate for nitric oxide synthase. Dexamethasone and prednisolone 21-nitrates were prepd. and were superior relative to the parent steroid in inhibiting the proliferation of vascular smooth muscle cells.

MUTR 1A

L12 ANSWER 3 OF 15 MARPAT COPYRIGHT 2003 ACS (Continued)



G18 = 0
 G21 = 71

G18-C(O)-G22

G22 = 74

G17

MPL: claim 1
 NTE: substitution is restricted
 NTE: additional double bond and oxo formation also claimed

L12 ANSWER 4 OF 15 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 132:308545 MARPAT
 TITLE: Preparation of soft steroids having anti-inflammatory activity
 INVENTOR(S): Bodor, Nicholas S.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 47 pp., Cont. of U.S. Ser. No. 626,535, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4996335	A	19910226	US 1985-807034	19851209
ZA 8104440	A	19821027	ZA 1981-4440	19810630
CA 1174667	A1	19840918	CA 1981-381293	19810708
SU 1318169	A3	19870615	SU 1981-3306552	19810709
JP 58206561	A2	19831201	JP 1982-101940	19820614
JP 2587034	B2	19970305		
AT 8402656	A	19850715	AT 1984-2656	19840820
AT 379817	B	19860310		
WO 8903390	A1	19890420	WO 1987-US2590	19871013
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
EP 334853	A1	19891004	EP 1987-907186	19871013
EP 334853	B1	19930609		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 90355	E	19930615	AT 1987-907186	19871013

PRIORITY APPLN. INFO.:
 US 1980-168453 19800710
 US 1981-265785 19810521
 US 1982-418458 19820915
 US 1984-626535 19840629
 AT 1981-3070 19810710
 CA 1982-381293 19820908
 EP 1987-907186 19871013
 WO 1987-US2590 19871013

AB The title steroids [I: R1 = alkyl, hydroxyalkyl, haloalkyl, CH2CO2R6, CH2CONR7R8, CHR9YR11, CHR10O2CR6, (un)substituted Ph, CH2Ph; R2 = (un)substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, Ph, CH2Ph; R3 = H, alpha- or .beta.-OH, -O2COR2, -Me, :CH2; R4 = H, F, Cl; R5 = H, F, Cl, Me; R6 = (un)substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl; R7, R8 = H, alkyl, cycloalkyl, Ph, CH2Ph; NR7R8 = satd. monocyclic amine; R9 = H, alkyl, Ph; R10 = H, alkyl, Ph, haloalkyl; R11 = alkyl; RPR11 = alkylene; X = O, S; Y = O, S, SO, SO2] are prepd. as antiinflammatory agents. Thus, oxidn. of hydrocortisone with NaIO4 gave cortienic acid (II, R1 = R2 = H), which was treated with Me chloroformate, converted to the Na salt and esterified using CH2ClI to give II (R1 = CH2Cl, R2 = MeO2C). At 1 mg/cotton pellet II (R1 = CH2Cl, R2 = EtO2C) inhibited granulation tissue in rats by 68%.

MUTR 1

L12 ANSWER 4 OF 15 MARPAT COPYRIGHT 2003 ACS (Continued)



DER: and salts
 MPL: claim 1
 NTE: substitution is restricted
 NTE: additional ring formation also claimed
 NTE: also incorporates structures III, IV, and VIII

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 15 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 128:294939 MARPAT
 TITLE: Preparation of nitrate esters of corticoid compounds and pharmaceutical applications thereof
 INVENTOR(S): Del Soldato, Piero
 PATENT ASSIGNEE(S): Nicox S.A., Fr.; Del Soldato, Piero
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9815568	A2	19980416	WO 1997-EP5426	19971002
WO 9815568	A3	19980618		
W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LA, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9747803	A1	19980505	AU 1997-47803	19971002
AU 719250	B2	20000504		
EP 929565	A2	19990721	EP 1997-910409	19971002
EP 929565	B1	20020529		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, SI, LT, FI, RO				
BR 9711586	A	19980824	BR 1997-11586	19971002
CN 1253563	A	20000517	CN 1997-180284	19971002
JP 2001501637	T2	20010206	JP 1998-517154	19971002
AT 218142	E	20020615	AT 1997-910409	19971002
RU 2186781	C2	20020810	RU 1999-108661	19971002
ES 2177952	T3	20021216	ES 1997-910409	19971002
KR 2000048911	A	20000725	KR 1999-702942	19990403
			IT 1996-MI2048	19961004
			WO 1997-EP5426	19971002

PRIORITY APPLN. INFO.:

AB The title compds. of the general formula B-X1-NO2 or their esters or salts, where B has structure I where there may be substituents in place of the H in the CH group or two hydrogens H2 in the CH2 group shown in the general formula; R and R1 are equal or different one from the other and may be hydrogen or linear or branched alkyls having from 1 to 4 carbon atoms, preferably R = R1 = CH3; B being a corticosteroid residue; R2 is -(CO-L)x-(X)y- where x and y are integers equal or different one from the other and equal to 0 or 1; where L is a bivalent connecting group; X is equal to X2 where X2 = O, NH, NR3 where R3 is a linear or branched alkyl having from 1 to 10 C atoms; or equal to X3 where X3 is equal to OH, CH3, Cl, N(CH2CH3)2, SCH2F, SH; X1 is a bivalent connecting bridge YO where Y is a C1-C20 alkylene were prepd. Thus, hydrocortisone was treated with 4-chlorobutanoyl chloride followed by treatment with AgNO2 to give the nitro deriv. II. II had a 62% antiarthritic activity in rats at 10 mg/kg, but did not affect cardiovascular parameters.

MSTR 1

L12 ANSWER 5 OF 15 MARPAT COPYRIGHT 2003 ACS (Continued)



G9 = 259

G10 = 259

G11 = 284

G12 = 284

DER: or esters or salts
 MPL: claim 1
 NTE: additional ring fusion also claimed


L12 ANSWER 6 OF 15 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 127:358991 MARPAT
 TITLE: Novel steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
 INVENTOR(S): Tjoeng, Foe S.; Currie, Mark G.; Zupc, Mark E.
 PATENT ASSIGNEE(S): G.D. Searle & Co., USA; Tjoeng, Foe S.; Currie, Mark G.; Zupc, Mark E.
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741144	A1	19971106	WO 1997-US6373	19970428
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5837698	A	19981117	US 1996-643018	19960502
AU 9729227	A1	19971119	AU 1997-29227	19970428
EP 900233	A1	19990310	EP 1997-923417	19970428
EP 900233	B1	20001129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000509072	T2	20000718	JP 1997-538946	19970428
AT 197799	E	20001215	AT 1997-923417	19970428
ES 2152670	T3	20010201	ES 1997-923417	19970428
			US 1996-643018	19960502
			WO 1997-US6373	19970428

PRIORITY APPLN. INFO.:


AB The present invention relates to a compd. having the formula A-B-C (A = hydroxyl contg. steroidal hormone; C = nitrite or nitrate contg. compd.; B = alkyl, alkenyl, alkynyl) were prepd. for use as smooth muscle relaxants, anti-inflammatory and vasodilation agents. Thus, nitrate ester I was prepd. by esterification of 9.alpha.-fluoro-16.beta.-methylprednisolone-17,21-dipropionate and isosorbide-5-nitrate with succinic anhydride. I was tested for its ability to block the induction of the proinflammatory agent PGE2 in human fetal fibroblast cells.

MSTR 1



G4 = 87

L12 ANSWER 6 OF 15 MARPAT COPYRIGHT 2003 ACS (Continued)



G11 = C(O)

G20 = alkoxy<(1-10)>

DER: and pharmaceutically acceptable esters and prodrugs

MPL: claim 5

NTE: substitution is restricted

L12 ANSWER 7 OF 15 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740836	A1	19971106	WO 1997-056374	19970428
V:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5985862	A	19991116	US-1996-642128	19960502
CA 2252876	AA	19971106	CA 1997-2252876	19970428
AU 9727325	A1	19971119	AU 1997-27325	19970428
EP 912185	A1	19990506	EP 1997-921224	19970428
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 2000509388	T2	20000725	JP 1997-538947	19970428
PRIORITY APPLN. INFO.:			US 1996-642128	19960502
			WO 1997-056374	19970428


AB Steroid nitrate esters I [R1 = H, OH, SH, ONO2, halogen, alkyl, acyl, acyloxy, heterocyclyl, alkoxy, silyloxy; R2 = ONO2; R3 = R4 = H, OH, ONO2, alkyl, acyl, alkenyl, alkoxy; R3R4 = OC(R1)R12O; R11 = R12 = H, alkyl; R1R12 = alicyclic; R5 = H, halogen; R6 = H, OH, oxo; Q = Q1 = H, Cl, F, alkyl; X = straight chain alkane, S; R7-10 = H; R7R8 = R9R10 = bond] were prepd for use in treating undesired smooth muscle contractions and inflammatory diseases. Thus, nitrate ester II was prepd. by nitration of 9.alpha.-fluoro-16.alpha.-methylprednisolone with fuming nitric acid and acetic anhydride. II was tested for its ability to block the induction of the proinflammatory agent PGE2 and assayed for smooth muscle relaxant activity using the rat aortic ring assay.

MSTR 1

L12 ANSWER 7 OF 15 MARPAT COPYRIGHT 2003 ACS (Continued)



G4 = 87



G11 = C(O)

G20 = alkoxy<(1-4)>

DER: and pharmaceutically-acceptable esters and prodrugs

MPL: claim 1

NTE: substitution is restricted

L12 ANSWER 8 OF 15 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721721	A1	19970619	WO 1996-0519219	19961206
V:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5707984	A	19980113	US 1995-569812	19951208
CA 2239910	AA	19970619	CA 1996-2239910	19961206
AU 9712772	A1	19970703	AU 1997-12772	19961206
EP 873351	A1	19981028	EP 1996-943559	19961206
EP 873351	B1	20000802		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 2000501732	T2	20000215	JP 1997-522081	19961206
AT 195128	E	20000815	AT 1996-943559	19961206
ES 2150152	T3	20001116	ES 1996-943559	19961206
PRIORITY APPLN. INFO.:			US 1995-569812	19951208
			WO 1996-0519219	19961206

AB Nitrite/nitrate steroid esters I [X1 = C(CH3)2, CH(CH3)2; X2X3 = C(R5)CH, CH(R5)CH2; Q = P = H, halogen, alkyl; R1 = H, OH, ONO, ONO2, halogen, sulfonyl, alkylthio, acyloxy, alkoxy, silyloxy, alkyl, alkenyl, alkynyl; R2 = H, OH, ONO, ONO2, alkoxy; R3 = R4 = H, OH, ONO, ONO2, alkyl, alkenyl, alkynyl, alkoxy; R5 = H, halogen; R6 = H, OH, oxo] were prepd. for use as antiinflammatory agents and smooth muscle relaxants. Thus, prednisolone-21-acetate with amyl nitrite in acetic acid, and, when tested for smooth muscle relaxant activity, II gave an EC50 value of 0.02 .mu.M compared to >100 .mu.M for prednisolone.


MSTR 1

L12 ANSWER 8 OF 15 MARPAT COPYRIGHT 2003 ACS (Continued)



G2 = C(O)

G4 = 87



G11 = C(O)

G20 = alkoxy<(1-10)>

DER: and pharmaceutically acceptable esters and prodrugs

MPL: claim 1

NTE: substitution is restricted

L12 ANSWER 9 OF 15 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER: 123:33510 MARPAT
 TITLE: Preparation of corticosteroid 17-alkylcarbonate-21-esters as antiinflammatories.
 INVENTOR(S): Stache, Ulrich; Alpermann, Hans-Georg; Duerckheimer, Walter; Bohn, Manfred
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 43 pp.
 CODEN: EPXKXW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 640616	A2	19950301	EP 1994-113048	19940822
EP 640616	A3	19950628		
EP 640616	B1	20021127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4328819	A1	19950302	DE 1993-4328819	19930827
AT 228530	E	20021215	AT 1994-113048	19940822
FI 9403902	A	19950228	FI 1994-3902	19940825
AU 9471474	A1	19950309	AU 1994-71474	19940825
AU 674980	B2	19970116		
HU 67959	A2	19950529	HU 1994-2451	19940825
HU 217620	B	20000328		
CN 1105368	A	19950719	CN 1994-115711	19940825
CN 1062562	B	20010228		
US 5608093	A	19970304	US 1994-294804	19940825
CA 2130943	AA	19950228	CA 1994-2130943	19940826
NO 9403174	A	19950228	NO 1994-3174	19940826
ZA 9406508	A	19950328	ZA 1994-6508	19940826
JP 07089982	A2	19950404	JP 1994-223963	19940826
IL 110798	A1	20001206	IL 1994-110798	19940828
			DE 1993-4328819	19930827

PRIORITY APPLN. INFO.:

AB Title compds. [I: A = CHOH, CHCl, CO, 9(11) double bond; Y = H, F, Cl; 2 = H, F, Me; R1 = (substituted or unsaturated) aryl, heteroaryl; X = (unsatd.) (substituted) alkylene; n, n = 0, 1; R2 = alkyl, CH2CH2OMe; R3 = H, Me], were prep'd. Thus, a mixt. of prednisolon-17-ethylcarbonate and PhCH2CO2H in pyridine was treated with conc. H2SO4 in pyridine and then with DCC to give prednisolon-17-ethylcarbonate-21-phenylacetate. This was 3 times stronger than prednicarbat in a screen using 12-O-tetradecanoylphorbol-13-acetate induced inflammation on rat ears.

MSTR 1

L12 ANSWER 9 OF 15 MARPAT COPYRIGHT 2003 ACS (Continued)



MPL: claim 1

L12 ANSWER 10 OF 15 MARPAT COPYRIGHT 2003 ACS


ACCESSION NUMBER: 122:161384 MARPAT
 TITLE: Preparation of peptidylglucocorticoids as antiinflammatories.
 INVENTOR(S): Zentel, Hans Joachim; Toepert, Michael; Laurent, Henry; Brumby, Thomas; Esperling, Peter
 PATENT ASSIGNEE(S): Schering A.-G., Germany
 SOURCE: Ger. Offen., 9 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4311987	A1	19941013	DE 1993-4311987	19930407
WO 9422898	A1	19941013	WO 1994-EP937	19940324
R: AU, CA, CZ, FI, HU, JP, KP, NO, NZ, RU, SK, UA, US				
W: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2158643	AA	19941013	CA 1994-2158643	19940324
AU 9465048	A1	19941024	AU 1994-65048	19940324
AU 696090	B2	19980903		
EP 693080	A1	19960124	EP 1994-912531	19940324
EP 693080	B1	19980422		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08508727	T2	19960917	JP 1994-521644	19940324
AT 165366	E	19980515	AT 1994-912531	19940324
ES 2118399	T3	19980916	ES 1994-912531	19940324
US 5616573	A	19970401	US 1995-530352	19951006
			DE 1993-4311987	19930407
			WO 1994-EP937	19940324

PRIORITY APPLN. INFO.:


AB R-Val-OGC [OGC = residue of an antiinflammatory 21-hydroxycorticoid; R = H, (HO-, amino-, oxo-, and/or halo-substituted) (O-, SO2-, and/or NH-interrupted)hydrocarbonyl], were prep'd. Thus, 6.alpha.-methylprednisolon-17-propionate was coupled with BOC-Val-OH using dimethylaminopyridine/DCC in CH2Cl2 to give 96% 6.alpha.-methylprednisolon-17-propionate-21-[N-(tert-butoxycarbonyl)valinate] (BOC-Val-OMP). This was deprotected with CF3CO2H (80%) and the resulting salt was coupled with BOC-Ala-Ala-Pro-OH using hydroxybenzotriazole/DCC/N-methylmorpholine in CH2Cl2 to give BOC-Ala-Ala-Pro-Val-OMP. The latter as a 0.3% (wt./vol.) prep'n. gave 81% inhibition of croton oil-induced edema in rat ears, vs. 67% inhibition for 6.alpha.-methylprednisolon-17-propionate-21-acetate. Title compds. are cleaved to the active form by leukocyte elastase, minimizing concn. of active compds. in noninflamed areas.

MSTR 1



G1 = 29

L12 ANSWER 10 OF 15 MARPAT COPYRIGHT 2003 ACS (Continued)



G11 = 38

G12 = alkoxy<(1-3)>

MPL: claims

L12 ANSWER 11 OF 15 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 117:212787 MARPAT
 TITLE: Preparation and formulation of
 [bis(phosphono)butylaminocarbonyloxy]estratriene and
 analogs for treatment of bone disease
 INVENTOR(S): Saari, Walfred S.; Rodan, Gideon A.; Fisher, Thorsten
 E.; Anderson, Paul S.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 496520	A1	19920729	EP 1992-300291	19920114
CA 2059421	AA	19920723	CA 1992-2059421	19920115
JP 04352795	A2	19921207	JP 1992-8786	19920122
JP 07035395	B4	19950419		
US 5183815	A	19930202	US 1992-839741	19920219
			US 1991-644178	19910122

PRIORITY APPLN. INFO.:
 AB Compd. ABC [A = residue of a hydroxy-contg. steroidal hormone having human bone resorption-antagonist activity or bone formation-stimulatory activity; C = residue of an amino- or hydroxyalkyl-1,1-bis(phosphonate) having human bone affinity; B = covalent linkage connecting A through the hydroxyl moiety and C through the amino or hydroxyl moiety, which linkage can hydrolyze in the human body in the vicinity of bone to release steroidal hormone A] were prepd. for treatment of bone disorders (no data). Thus, [(Me₂CHO)2P(O)(O)2CHR (I; R = H), was condensed with CH₂:CHCN and the product hydrogenated to give I [R = (CH₂)₃NH₂], which was condensed with 3-benzyloxy-17.β-chlorocarbonyloxyestra-1,3,5(10)-triene (prepn. given) to give, after deprotection, title compd. II.

MSR 1A

G1—G3—G2

G1 = 225




G3 = 4-1 5-3

L12 ANSWER 12 OF 15 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 116:194683 MARPAT
 TITLE: Preparation of 17-substituted corticoid 17-alkyl
 carbonates for treatment of dermatoses
 INVENTOR(S): Stache, Ulrich; Duerckheimer, Walter; Alpermann, Hans
 Georg; Petri, Walter
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 48 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 470617	A2	19920212	EP 1991-113338	19910808
EP 470617	A3	19920401		
DE 4025342	A1	19920213	DE 1990-4025342	19900810
FI 9103775	A	19920211	FI 1991-3775	19910808
HU 59155	A2	19920428	HU 1991-2643	19910808
HU 211994	B	19960129		
CZ 279875	B6	19950712	CZ 1991-2461	19910808
IL 59135	A1	19951208	IL 1991-99135	19910808
RU 2060997	C1	19960527	RU 1991-5001317	19910808
NO 9103115	A	19920211	NO 1991-3115	19910809
CA 2048841	AA	19920211	CA 1991-2048841	19910809
AU 9182560	A1	19920213	AU 1991-82560	19910809
AU 646066	B2	19940203		
ZA 9106291	A	19920429	ZA 1991-6291	19910809
JP 06041187	A2	19940215	JP 1991-223670	19910809
US 5362721	A	19941108	US 1993-15041	19930208
LV 10459	B	19950820	LV 1993-302	19930507
LT 3374	B	19950825	LT 1993-709	19930625

PRIORITY APPLN. INFO.:
 AB Title compds. (I; A = CH(OH), CH₂, CO; Y, Z = H, F, Cl; R₁ = F, Cl, Br, iodo, acyloxy, alkoxycarbonyloxy, alkylsulfonic acid, etc.; R₂ = alkyl, methoxyalkyl; R₃ = H, Me) were prepd. Thus, prednisolone 17-isopropyl carbonate was stirred with pyridine/Ac₂O to give prednisolone 17-isopropyl carbonate 21-acetate. The latter inhibited croton oil-induced ear edema in rats with IC₅₀ = 0.1 mg/mL.

MSR 1



G1 = 26

L12 ANSWER 11 OF 15 MARPAT COPYRIGHT 2003 ACS (Continued)



G4 = 0
 G5 = 0
 DER: and pharmaceutically acceptable salts or esters
 MPL: claim 1

L12 ANSWER 12 OF 15 MARPAT COPYRIGHT 2003 ACS (Continued)



MPL: claim 1

L12 ANSWER 13 OF 15 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9015816	A1	19901227	WO 1990-US2673	19900517
W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, RO, SD, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 9056403	A1	19910108	AU 1990-56403	19900517
EP 477195	A1	19920401	EP 1990-907622	19900517
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 04506066	T2	19921022	JP 1990-507619	19900517
US 1989-366935 19890616				
US 1990-483044 19900216				
WO-1990-US2673-19900517				

PRIORITY APPLN. INFO.:

L12 ANSWER 13 OF 15 MARPAT COPYRIGHT 2003 ACS

(Continued)



G13 = alkoxy<(1-6)>
MPL: claim 6

AB A combination of suramin or suramin-type compds., known angiostatic steroids, and DELTA-9(11)-etianic esters (I; R10 = .alpha.-Ra, .beta.-Rb where Rb = Me and RaR5 = 2,3-substituted (CH2)3CH, Rb = Me and RaR5 = CH:CHCOCH, etc.; R6 = .alpha.-Rc, .beta.-Rd where one of Rc, Rd = H and the other = H, F, Cl, Br, Me; R7 = .alpha.-Re, .beta.-Rf where one of Re, Rf = H and the other = H, Me; R16 = CH2 or (.alpha.-Rg, .beta.-Rh) where one of Rg, Rh = H and the other = H, Me, OH, F; R17 = C1-20 alkyl, C1-10 fluoroalkyl, C1-6 alkoxy, alkylaminoalkyl, cycloalkylalkyl, etc.; X = O, S; R21 = (substituted) C1-10 alkyl (prepn. given) are used for treatment of neovascular diseases such as cancer, diabetes, and arthritis (no data). Thus, oxidn. of 6.alpha.-fluoro-17,21-dihydroxy-16.alpha.-methyl-pregna-4,9(11)-diene-3,20-dione with HIO4 in refluxing aq. THF gave 6.alpha.-fluoro-17.alpha.-hydroxy-16.alpha.-methylandrosta-4,9(11)-dien-3-one-17.beta.-carboxylic acid (II). Acetylation of this with Ac2O/Et3N and methylation of the resulting 17-acetate with diazomethane in THF gave II Me ester 17-acetate.

MSTR 4B

L12 ANSWER 14 OF 15 MARPAT COPYRIGHT 2003 ACS

ACCESSION NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 285285	A2	19881005	EP 1988-302275	19880316
EP 285285	A3	19901205		
EP 285285	B1	19940608		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4957910	A	19900918	US 1988-165300	19880308
CA 1317224	A1	19930504	CA 1988-561210	19880311
DK 8801430	A	19880918	DK 1988-1430	19880316
ZA 8801856	A	19890426	ZA 1988-1856	19880316
AT 106729	E	19940615	AT 1988-302275	19880316
AU 8813216	A1	19880915	AU 1988-13216	19880317
AU 619174	B2	19920123		
JP 63301823	A2	19881208	JP 1988-64674	19880317
GB 1987-6313 19870317				
EP 1988-302275 19880316				

PRIORITY APPLN. INFO.:

AB Steroid surfactants, preferably bile acids, are drugs for the treatment and prevention of viral infections, such as by the human immunodeficiency virus (HIV). Bile acid salts (250 mg/L) inactivated HIV in human T-cell line (CEM) cultures, in vitro. Sublingual tablets comprised bile salts 500, glucose 75, and Mg stearate 2 mg.

MSTR 1A



G27 = 93

G35 = 93

G35 = alkoxy-carbonyl<(1-4)>
MPL: claim 12

L12 ANSWER 14 OF 15 MARPAT COPYRIGHT 2003 ACS

(Continued)


NTE: additional steroid ring modifications is allowed

L12 ANSWER 15 OF 15 MARPAT COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 109:93441 MARPAT
 TITLE: Conversion of prednisolone-21-alkyl carbonate to the
 17-alkyl carbonate analog
 INVENTOR(S): Martin, Wolfgang
 PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 3 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3637806	A1	19880519	DE 1986-3637806	19861106
EP 266719	A1	19880511	EP 1987-116074	19871102
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
HU 45545	A2	19880728	HU 1987-4943	19871104
DK 8705818	A	19880507	DK 1987-5818	19871105
AU 8780806	A1	19880512	AU 1987-80806	19871105
JP 63132897	A2	19880604	JP 1987-278453	19871105
ZA 8708305	A	19880629	ZA 1987-8305	19871105
PRIORITY APPLN. INFO.:			DE 1986-3637806	19861106

AB The title conversion is carried out using lithium dialkyl cuprates. A THF
 soln. of 5.8 g prednisolone-21-Et carbonate was treated with freshly prep.
 LiMe₂Cu at -30.degree. to give 67% of the 17-Et carbonate isomer.

MPTR 1



MPL: disclosure

=> d his

(FILE 'HOME' ENTERED AT 11:44:38 ON 05 MAR 2003)

FILE 'REGISTRY' ENTERED AT 11:45:06 ON 05 MAR 2003

L1 STRUCTURE UPLOADED
L2 24 S L1
L3 496 S L1 FULL
L4 STRUCTURE UPLOADED
L5 2 S L4 FULL SUB=L3

FILE 'USPATFULL' ENTERED AT 11:50:37 ON 05 MAR 2003

L6 0 S L5
L7 34 S L3

FILE 'CAPLUS' ENTERED AT 11:57:20 ON 05 MAR 2003

L8 2 S L5
L9 63 S L3/THU

FILE 'MARPAT' ENTERED AT 12:05:49 ON 05 MAR 2003

L10 2 S L3
L11 17 S L3 FULL
L12 15 S L11/COM

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
119.10	805.29

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-9.30	-51.62

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 12:08:59 ON 05 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAR 2003 HIGHEST RN 496834-05-0

DICTIONARY FILE UPDATES: 3 MAR 2003 HIGHEST RN 496834-05-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties